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ABSTRACT 
Chronic kidney disease (CKD) is a major public health issue, which is associated with 
significant cardiovascular risk. Increased arterial stiffness is believed to be a key pathway 
leading to this excessive cardiovascular burden. In this thesis, the use of allopurinol, a 
xanthine oxidase inhibitor, was found to be associated with lower arterial stiffness amongst a 
cohort of high-risk, CKD patients. A systematic review and meta-analysis of the 
cardiovascular effects of mineralocorticoid receptor antagonists demonstrated a consistent 
blood pressure lowering effect but highlighted the risk of hyperkalaemia and shortage of 
conclusive evidence of their use on other cardiovascular outcomes in patients with CKD. A 
pilot randomised controlled trial was conducted aiming to examine the effect of a low-dose 
mineralocorticoid receptor antagonist, spironolactone, on arterial stiffness in patients with 
stage 3 CKD in primary care. The study was terminated early due to low recruitment rate. 
Qualitative studies embedded within the trial found that patients with CKD in the community 
were generally unaware of their diagnosis and had misconceptions and negative views on the 
disease terminology. Perceiving that the research topic was relevant to patients’ personal 
health was identified as a significant prerequisite for their participation in CKD research in 
primary care. 
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CHAPTER 1 INTRODUCTION 
 
According to the latest Global Burden of Disease Study, chronic kidney disease (CKD) 
represents one of the top 20 leading cause of global loss of life (1). It is recognised as a 
growing and important public health issue, which affects up to 14% of the population of 
the developed world (2-5). While patients with CKD undoubtedly have heightened risk of 
progressing to end-stage renal disease (ESRD), their risk of cardiovascular (CV) morbidity 
and mortality are in fact far greater (6). Nonetheless, as patients with CKD are often 
asymptomatic in the early or moderate stage, the majority are unaware of their CKD 
diagnosis (7). In addition, there is also limited understanding regarding their illness 
perception and their attitudes towards CKD research participation, especially in primary 
care.  
 
 Definition of Chronic Kidney Disease 1.1
In 2001, as data from the 3
rd
 US National Health and Nutrition Examination Survey 
(NHANES) highlighted the high prevalence of patients with elevated serum creatinine, it 
was suggested that tackling the issue with under-diagnosis and under-treatment of this 
particular population were crucial to curb the rising epidemic of ESRD and reduce its CV 
disease burden (8). However, for decades, there was a lack of a unifying term or clear 
definition and classification to describe the states of reduced kidney function not requiring 
renal replacement therapy (RRT) (9), which invariably resulted in lost opportunities for 
prevention (10).  
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Hence, in 2002, the National Kidney Foundation’s (NKF) Kidney Disease Outcomes 
Quality Initiative (KDOQI) guidelines proposed for the first time a working definition and 
five-stage classification system of CKD, irrespective of the underlying cause (11). It 
defined CKD as ‘either kidney damage or decreased kidney function (estimated glomerular 
filtration rate [eGFR] < 60 ml/min/1.73m
2
) for three or more months’ (11). The kidney 
damage is ascertained by persistent urine albumin:creatinine ratio (uACR) of greater than 
30 mg/g or abnormalities in urine sediment, blood and urine chemistry measurements, 
kidney biopsy or imaging results. As decreasing eGFR was known to be related to 
increasing prevalence of CKD associated complications, the guidelines also introduced the 
five-stage classification of CKD, based upon GFR levels (Table 1-1). After several minor 
modifications, this CKD definition and classification were later endorsed and adopted by 
the Kidney Disease Improving Global Outcomes (KDIGO) in 2005 and 2007 (12, 13).  
 
Table 1-1: Kidney Dialysis Outcomes Quality Initiative (KDOQI) Guidelines and Kidney 
Disease Improving Global Outcomes (KDIGO): Definition and Stages of Chronic Kidney 
Disease (12-14). 
Stage Description GFR 
(mL/min/1.73m
2
) 
KDIGO modifications 
1 Kidney damage with normal or increased 
GFR 
≥ 90 1-5T if kidney 
transplant recipient 
2 Kidney damage with mild decreased 
GFR 
60-89 
3 Moderate decreased GFR 30-59 
4 Severe decreased GFR 15-29 
5 Kidney failure <15 (or dialysis) 5D if receiving dialysis 
Abbreviation: GFR, glomerular filtration rate 
Note: Chronic kidney disease is defined as either kidney damage or GFR <60ml/min/1.73m
2
 for ≥3 months. 
Kidney damage is defined as pathologic abnormalities or markers of damage, including abnormalities in 
blood or urine tests (i.e.: abnormal urine sediment or presence of urine albumin: creatinine ratio > 30 mg/g 
in two of three spot urine specimens) or imaging studies or presence of kidney transplant.  
 
By 2011, mounting evidence demonstrated the independent association between elevated 
albuminuria with renal, CV and survival outcomes in the meta-analyses (2, 15-17), which 
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prompted KDIGO to further modify the CKD classification system. It incorporated 
albuminuria stages, subdivided stage 3 into 3a and 3b and emphasized clinical diagnosis 
(18) (Table 1-2).   
 
Table 1-2: The Kidney Disease Improving Global Outcomes (KDIGO) classification of 
CKD prognosis by GFR and albuminuria categories (adapted from reference) (18). 
 
Persistent albuminuria 
 
A1 A2 A3 
Normal/mildly 
increased 
Moderately 
increased 
Severely 
increased 
<30 mg/g 30-300  mg/g >300 mg/g 
GFR categories 
(ml/min/1.73m
2
) 
G1 ≥90 Low Moderate High 
G2 60-89 Low Moderate High 
G3a 45-59 Moderate High Very high 
G3b 30-44 High Very high Very high 
G4 15-29 Very high Very high Very high 
G5 <15 Very high Very high Very high 
*The description of low, moderate, high and very high denotes risk of progression of renal disease. 
 
Following these landmark publications, this influential concept of CKD was widely 
accepted and soon led to an explosion of both clinical and research interest in this 
prevalent condition in the past two decades (19). Despite its critics, these clear and simple 
guidelines are instrumental in improving communications between physicians regarding 
patients with reduced kidney function, influence implementation of clinical practice 
guidelines and public health strategies and last but not the least, offer a vital structure for 
CKD research studies worldwide.  
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 Measuring and Estimating Glomerular Filtration Rate 1.2
As excretion of waste metabolic products and achieving fluid and electrolytes balance via 
filtration represents the key function of kidneys, the GFR is generally considered the best 
overall index of kidney function (20). Accurate measurement of GFR is fundamental in 
establishing CKD diagnosis and guiding treatments. Direct measurement of GFR (mGFR) 
is achieved by assessing plasma and urinary clearance of exogenous filtration markers, for 
instance, inulin, iothalamate, iohexol, EDTA (ethylenediaminetetraacetic acid) or DTPA 
(diethylene triamine pentaacetic acid) (20, 21). However, despite being the ‘gold-standard’ 
methods, reports have shown that there were significant inter-test variations within the 
same measuring method as well as considerable disparities in mGFR readings amongst 
different methods (22). Furthermore, such techniques are often cumbersome, labour-
intensive and not feasible for day-to-day practice (20), which led to the search of more 
accessible methods of estimating GFR using endogenous filtration markers (i.e.: 
creatinine, cystatin C). Interestingly, a recent observational study also suggested that 
mGFR was not better in predicting morbidity and mortality outcomes in CKD population 
compared to creatinine- or cystatin C- based eGFR (22).  
 
Serum creatinine is mainly the metabolic product of creatine and phosphocreatine from the 
skeletal muscle. Since the development of Cockcroft-Gault formula to predict creatinine 
clearance in 1976 (23), our knowledge and understanding in estimating GFR based on the 
endogenous filtration markers have come a long way. Pioneered by the Modification of 
Diet in Renal Disease (MDRD) study group, Levey et al first published a six-variable GFR 
estimating equation which improved on the over-estimation of GFR associated with 
Cockcroft-Gault formula (24). In 2006, the MDRD eGFR formula was further simplified 
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into a four-variable equation, incorporating age, gender, race (African American or 
otherwise) and serum creatinine calibrated to an assay traceable to isotope-dilution mass 
spectrometry (25). Though it is not without its limitations, this equation became and 
remains one of the most widely used equations to calculate eGFR as it provides a 
reasonably accurate GFR estimation in patients with CKD. Preceded by the landmark 
KDOQI guidelines on the clear, multi-layered definition of the CKD based upon eGFR 
and coupled with the global introduction of automated reporting of eGFR (26-28), this 
pragmatic method of estimating GFR has drastically increased the global awareness and 
recognition of CKD, influenced clinical practices and public health strategies as well as 
transformed the landscape of CKD research.  
 
Recently, the Chronic Kidney Disease Epidemiology Collaboration group (CKD-EPI) 
further advanced GFR estimation by introducing the CKD-EPI creatinine equation in 2009 
(29). Though the CKD-EPI creatinine equation was reported to be more accurate than that 
of the MDRD in the initial publication (percentage of estimated GFR within 30% of 
measured GFR using CKD-EPI or MDRD equations was 84.1% and 80.6%, respectively) 
(29), a following systematic review found that both equation had their strengths and 
weakness depending on the GFR ranges (30). The CKD-EPI equation appeared to perform 
better at higher GFRs whilst the reverse was true for the MDRD equation (30). This 
improved accuracy of estimating GFR at higher range of the CKD-EPI equation has been 
shown to significantly reduce the prevalence of CKD and better predict the risk of ESRD 
and mortality, in comparison to the MDRD equation (2).  These findings undoubtedly have 
implications in planning public health strategies and formulating epidemiology research.  
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In addition to serum creatinine, serum cystatin C, a cysteine proteinase inhibitor which is 
produced at a constant rate by nucleated cells (31), is another extensively-researched 
endogenous filtration marker. A meta-analysis concluded that serum cystatin C was 
superior to serum creatinine as a marker of GFR (32), which led to the development of two 
additional estimating equations based upon cystatin alone (CKD-EPI eGFRcystatin C) and in 
combination with creatinine (CKD-EPI eGFRcreatinine-cystatin C) (33). The combined 
creatinine-cystatin C equation was shown to perform best amongst the three equations and 
further improved on the correct reclassification of a significant proportions of those with 
creatinine-based eGFR of 45-59 ml/min/1.73m
2
 to having GFR of 60 ml/min/1.73m
2
 or 
above (33). 
 
In view of the advances made on the eGFR front in the past decade, the National Institute 
for Health and Care Excellence (NICE) has recently updated its guidelines on CKD, 
suggesting clinical laboratories to adopt the CKD-EPI equation when reporting eGFR (34). 
Furthermore, the guidelines also recommend physicians to consider measuring cystatin-C 
and using the cystatin C- based eGFR equation at initial diagnosis to rule out CKD in 
people with sustained creatinine-based eGFR of 45-59 ml/min/1.73m
2
 for at least 90 days 
but without proteinuria or other markers of kidney disease (34). 
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Table 1-3: Equations used to estimate glomerular filtration rate  
Cockcroft-Gault estimated 
Creatinine Clearance equation 
(23) 
 
(140-Age) × weight × 0.85 [if female] ÷ (72 x Scr) 
 
6-variable MDRD study eGFR 
equation (24) 
161.5 × Scr
−0.999
 × age
−0.176
 × 1.180 [if black] × 0.762 [if female]  
× BUN
−0.176
  × Albumin
+0.318 
  
4-variable MDRD study eGFR 
equation (25) 
175 × Scr
−1.154
 × age
−0.203
 × 1.212 [if black] × 0.742 [if female] 
CKD-EPI creatinine eGFR 
equation (29) 
141 × min(Scr /κ, 1)
α 
× max(Scr /κ, 1)
-1.269
 × 0.993
Age
 × 1.018 [if female]  
× 1.159 [if black] 
 
κ is 0.7 for females and 0.9 for males, α is -0.329 for females and -0.411 for 
males, min indicates the minimum of SCr /k or 1, and max indicates the 
maximum of SCr /k or 1. 
 
CKD-EPI cystatin C eGFR 
equation (33) 
133 × min(Scys /0.8,1)
-0.499
 × max(Scys /0.8,1)
-1.328
 × 0.996
 Age
  
× 0.932 [if female] 
 
CKD-EPI creatinine-cystatin C 
eGFR equation (33) 
135 × min(Scr /κ, 1)
α 
× max(Scr /κ, 1)
-0.601
 × min(Scys /0.8, 1)
-0.375
 × 
max(Scys /0.8, 1)
-0.711
 × 0.995
 Age
 × 0.969 [if female] × 1.08 [if black] 
 
κ is 0.7 for females and 0.9 for males, α is −0.248 for females and −0.207 for 
males, min indicates the minimum of Scr /κ or 1, and max indicates the maximum 
of Scr /κ or 1. 
 
Abbreviations: BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; MDRD: modification of diet in 
renal disease; Scr: serum creatinine; Scys: serum cystatin C 
N/B: Age given in years, weight given in kilograms, serum creatinine and blood urea nitrogen given in mg/dL, albumin 
given in g/dl, creatinine levels in µmol/L can be converted to mg/dL by dividing them by 88.4. 
  
 
 Epidemiology of Chronic Kidney Disease 1.3
There is significant variation in the reported estimated prevalence of CKD to date, both 
among and within the countries (35, 36). In the most recent U.S. Renal Data System 
Annual Report, the prevalence of CKD was estimated to be 13% (5). In comparison, the 
NEOERICA project estimated an overall prevalence of stage 3-5 CKD of 8.5% in 2007 in 
the United Kingdom (37), whilst a recent CKD primary care Quality and Outcomes 
Framework (QOF) registers 2013/14 reported an average prevalence of 4% (38). 
Interestingly, another UK-based epidemiological study, using two eGFRs, measured at 
least seven days apart, reported an even lower estimate of 3.5%, which highlighted the 
issues with misclassification of the diagnosis in primary care (35). Despite this variation, 
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studies have shown consistent increase of CKD prevalence over the years (39). Globally, 
while the mortality from lower respiratory infections, diarrhoeal disease, CV diseases, 
cancers and chronic respiratory diseases is falling, this is off-set by the rising numbers of 
deaths related to diabetes mellitus (DM) and CKD (1). In fact, CKD has risen from the 36
th
 
leading cause of global loss of life in 1990 to the 19
th
 in 2013 (1).  
 
In general, the increasing prevalence of DM, hypertension and most importantly, the 
ageing population are thought to be the key driving forces behind the ‘CKD epidemic’ (4). 
The prevalence of CKD increases exponentially with increasing age. While the median 
prevalence of CKD amongst population aged 30 years or older was estimated at 7%, the 
figures increased sharply to almost 36% in patients aged 64 years or older (36). 
Additionally, there is also a significant increase in the preponderance of older patients as 
the eGFR declines: the percentage of patients aged 70 years or above with eGFRs >60, 45-
59, 30-44 and <30 ml/min/1.73m
2
 was reported to be 16%, 50%, 81% and 77%, 
respectively, according to the data from the NEOERICA study (37). Notably, despite the 
incidence of CKD among 20-64 year-olds remaining stable at around 0.5% in the past few 
years, the raising trend of CKD incidence among those above the age of 65 years has 
shown no sign of abating, with a more than twofold increase between 2000 and 2008 (5).  
 
Patients with CKD, especially those with ESRD on dialysis, are known to be associated 
with significant morbidity and mortality (5). However, patients with ESRD only comprise 
a mere 2% of the total CKD population in the U.K. (40). While the healthcare cost for each 
patient with ESRD is substantial, the direct and indirect healthcare needs of the large CKD 
population should not be under-estimated. In 2012, the U.S Renal Data System reported 
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Medicare expenditure of almost $45 billion for the CKD population, rising significantly 
from the expenditure figure of $29 billion in 2008 (5). This considerable healthcare cost of 
CKD represents more than 1.5 times of their total expenditure on ESRD program in the 
U.S. (5). In contrast, the total cost of CKD to the English NHS in 2009-2010 was 
estimated to be at £1.45 billion, with more than half of the budget being spent on 2% of the 
CKD population who require dialysis (40). 
 
 Cardiovascular Disease in Chronic Kidney Disease 1.4
Although the risk to progressing to ESRD requiring dialysis was one of the key concerns 
for patients with CKD, for those with early or moderate stage CKD, their competing risk 
of death was far greater. In fact, in a study of 3,047 patients with stage 3 CKD, the 10-year 
cumulative incidence of ESRD was a mere 0.04 in comparison to their mortality rate of 
0.51 (6). This significant increase in mortality amongst the CKD population appeared to be 
heavily driven by their excessive CV burden (41). Compared with their age- and gender-
matched counterparts, patients with CKD in England were found to have 7,000 excess 
strokes and 12,000 excess myocardial infarctions per year (40). This excess CV event 
alone was reported to have incurred an estimated direct healthcare cost of £174-178 
million in UK in 2009-10 (40).  
 
1.4.1 Chronic Kidney Disease and Cardiovascular Outcomes 
Thus far, numerous large population-based longitudinal studies have consistently 
demonstrated the independent relationship between the presence of CKD and increased 
CV events (41-45). The pivotal epidemiological study by Go et al in 2004 first 
demonstrated the significant reversed graded association between eGFR and CV events as 
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well as mortality (41). After adjusting for various comorbidities, patients with eGFR 45-
59, 30-44, 15-30 and <15 ml/min/1.73m
2
 were associated with a hazard ratio for CV 
events of 1.4, 2.0, 2.8 and 3.4, respectively (41). The data from ARIC study also reported 
this independent graded increased risk of de novo atherosclerotic CV disease and recurrent 
atherosclerotic CV disease with each 10 ml/min/1.73m
2
 decline of eGFR (42). Such 
findings were equally noted amongst those above the age of 65 years (46). Several meta-
analyses have since provided confirmation on such findings (2, 16, 17). Even after 
adjusted for traditional CV risk factor and albuminuria, compared to those with eGFR of 
95 ml/min/1.73m
2
, patients with eGFR of 60, 45 and 15 ml/min/1.73m
2
 had hazard ratios 
of all-cause mortality of 1.03, 1.38 and 3.11 (47) and hazard ratio of CV mortality of 1.11, 
1.73 and 3.08, respectively, (17).  
 
Importantly, besides being a strong risk factor, CKD is also a crucial adverse prognostic 
marker for those with established CV disease (48, 49). Among patients with chronic heart 
failure, mortality risk increased with decreasing eGFR (48). In fact, baseline renal function 
was found to be a stronger predictor of mortality than left ventricular (LV) ejection 
fraction in patients with severe heart failure (50). Likewise, such association between renal 
function and mortality was also noted in patients with acute coronary syndrome (51, 52), 
intracerebral haemorrhage (53), established vascular disease (54) and chronic stable 
coronary artery disease (55). 
 
It is therefore crucial to improve our understanding of the underlying mechanisms 
contributing to this heightened CV burden in the CKD population and explore the potential 
therapeutic agents which might help in tempering the adverse CV outcomes. 
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1.4.2 Factors Contributing to Increased Cardiovascular Burden in Chronic Kidney 
Disease 
Patients with CKD are known to have a high burden of traditional CV risk factors (41, 47). 
There is significantly greater prevalence of DM, hypertension, dyslipidaemia as well as 
prior CV disease (i.e.: coronary heart disease, stroke, peripheral arterial disease and heart 
failure) in the CKD population compared to the general population (41). Cross-sectional 
data from the NHANES showed that almost 80% of patients with CKD stages 3 to 5 CKD 
had two or more CV risk factors compared to 33% of those without CKD (47). Of note, the 
NHANES data also highlighted the suboptimal management of CV risk factors amongst 
CKD patients and suggested that this might have contributed to their increased CV 
morbidity and mortality (47). Another large U.S. cohort study of the more than 130,000 
elderly participants also revealed that patients with moderate renal impairment (serum 
creatinine= 221-345 µmol/L) were less likely to undergo thrombolytic therapy, 
angiography, angioplasty or receive cardio-protective medications (i.e.: aspirin, β-
blockers) during hospitalisation for myocardial infarction as compared to those with serum 
creatinine below 132 µmol/L (56). Nonetheless, a more recent, albeit smaller study 
examining the use of secondary CV prevention medications in 6,913 participants reported 
different findings. The use of anti-platelet agents was found to be similar across different 
eGFR groups (57). In fact, when compared to those with eGFR ≥ 60 ml/min/1.73m2, 
patients with eGFR < 45 ml/min/1.73m
2
 were 1.14, 1.20 and 1.10 times more likely to 
receive angiotensin-converting enzyme inhibitors (ACEi) or angiotensin II receptor 
blockers (ARB), β-blockers and statins, respectively (57).  
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Irrespective of the varying findings on the standard of CV risk management in CKD 
population, it is becoming increasingly apparent that the CV disease in CKD differs from 
those of the general population (58, 59). While the Framingham risk score, based upon 
age, gender, DM, systolic blood pressure (BP), smoking status and cholesterol profiles, is 
widely used to estimate individual patient risk of CV disease in the general population, it 
has been shown to significantly under-estimate CV events in patients with CKD at 5 and 
10 years (60). This finding therefore suggested that those traditional risk factors probably 
have a different risk relationship with CV disease in patients with CKD compared to the 
general population or that there are other ‘non-traditional’ risk factors which are unique to 
the CKD which have not been accounted for (61). Some of these widely-studied, ‘non-
traditional’ CV risk factors pertinent to the CKD population include, but not limited to, 
albuminuria, anaemia, mineral bone disorder, activation of the renin-angiotensin-
aldosterone system (RAAS), increased oxidative stress and inflammation (58, 59, 61, 62). 
The high prevalence of such traditional and non-traditional risk factors is thought to 
contribute to the various abnormal CV phenotypes seen in the CKD population (49).  
 
 Abnormal Cardiovascular Phenotypes in Chronic Kidney Disease 1.5
The cardiac abnormalities in the CKD are typified by concentric LV hypertrophy (LVH) 
and LV dilatation with proportional hypertrophy (61, 63). In fact, nearly 40% of patients 
with CKD were found to have evidence of LVH (64). Regional, global, longitudinal or 
diastolic LV dysfunction as well as myocardial fibrosis were also some of the other 
features of cardiomyopathy associated with CKD (63). Notably, many of these cardiac and 
vascular abnormalities are evident even in patients with early CKD (65, 66) despite 
satisfactory blood pressure (BP) control (67). Indeed, a study of 40 patients with early or 
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moderate stage CKD clearly demonstrated subclinical abnormalities of LV myocardial 
deformation on detailed cardiac magnetic resonance imaging, despite apparently preserved 
conventional echocardiographic measures of systolic function (68).   
 
With regards to vascular abnormalities, there are two distinct but overlapping pathological 
phenotypes associated with CKD: atherosclerosis and arteriosclerosis (69). Atherosclerosis 
is primarily an intimal disease characterised by patchy distribution of fibro-atheromatous 
plaques, leading to vascular occlusion. In contrast, arteriosclerosis is a diffuse disease of 
the arterial medial layer associated with increased collagen content, vascular calcification, 
hypertrophy and hyperplasia of vascular smooth muscle cells, resulting in thickening and 
hardening of the arteries (58). Accelerated atherosclerosis is common among patients with 
CKD leading to the increased prevalence of coronary artery disease, stroke and peripheral 
arterial disease (61). Though such vasculo-occlusive events remain one of the important 
causes of death among the CKD population, a greater proportion of CV deaths in CKD are 
in fact attributable to sudden cardiac death, arrhythmia and congestive heart failure (5). 
Hence, other pathological changes, for instance, arteriosclerosis, endothelial dysfunction 
and cardiomyopathy are therefore thought to play an essential role in contributing to the 
heightened CV events in patients with CKD (61).  
 
Elastic arteries are important to buffer the pressure oscillations resulting from the 
intermittent ventricular ejection (70). They provide a ‘cushioning function’ to supply 
steady blood flow to peripheral organs and tissues (70). During systole, the stroke volume 
generated by the LV is partially forwarded to the peripheral tissues (71). The elasticity of 
the proximal aorta allows part of the systolic pressure generated by the heart to be 
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transformed into elastic force and the distended vessel accommodates the rest of the stroke 
volume (71). During diastole, the recoiled aorta will then propelled these ‘reserved’ 
volume of blood forward to facilitate continuous blood flow to the peripheral tissues (71). 
As the artery compliance decreases, the energy requires to expand the artery increases. 
Hence, reduction or loss of arterial distensibility does not only augment arterial systolic 
and pulse pressure, increase arterial circumferential stress, but it also exposes the 
myocardial, cerebral and renal microvasculature to excessive fluctuations in flow and 
pressure (72).  
 
In the general population, increasing arterial stiffness has long been known to be 
associated with advancing age (73). This age-related arterial stiffening is coupled with 
increased ventricular systolic stiffness even in the absence of hypertrophy (74). Such 
premature ageing or stiffening of the aorta was well-documented amongst patients with 
ESRD (75, 76). However, these changes are not solely confined to those with advanced 
CKD. Mourad et al first described the positive correlation between creatinine clearance 
(CrCl) and carotid compliance after adjustment for age, gender and BP (65). Subsequently, 
others had further demonstrated a stepwise increase in arterial stiffness with the declining 
CrCl, eGFR and advancing CKD stages (77-79). In a multivariate analysis of 95 patients 
with mild to moderate CKD, Briet et al  also highlighted the independent relationship 
between GFR and arterial stiffness (80). Though several recent studies did not find such 
consistent, direct correlation between levels of arterial stiffness and severity of CKD (81-
83), most agreed that overall, CKD population is associated with increased arterial 
stiffness compared to their counterparts. Importantly, Edwards et al observed that the 
reduction of aortic distensibility and increment of ventricular systolic and diastolic 
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stiffness, resembling those of heart failure with preserved ejection fraction, occurred as 
early as stage 2 CKD (67). This characteristic cardiac remodelling in CKD was postulated 
to be part of the mechanisms in maintaining the arterial-ventricular coupling and cardiac 
performance in the presence of ever increasing afterload pressure related to arterial 
stiffness (67). Thus, the prevalent increase of arterial stiffness in the CKD population is 
believed to be a key, early mechanistic pathway that leads to LV hypertrophy, myocardial 
fibrosis, systolic as well as diastolic cardiac dysfunction and culminating in excessive CV 
morbidity and mortality (58).  
 
1.5.1 Measurements of Arterial Stiffness 
Devices such as Complior (Alam Medical, Vincennes, France), Sphygmocor (AtCor 
Medical, Sydney, Australia), PulsePen (Diatechne, Milan, Italy), PulseTrace 
(Micromedical, Chatham Maritime, UK), Arteriograph (TensioMed Kft., Budapest, 
Hungary) and Vicorder (Skidmore Medical, Bristol, UK) allow simple and direct 
measurement of pulse wave velocity (PWV) (84), which facilitate studying arterial 
stiffness in various high CV risk populations. 
 
Proposed by Bramwell and Hill in 1922 (85), the propagative model of the circulatory 
system illustrated that the velocity of pulse wave correlates inversely with the distensibility 
of the artery (85, 86). Since then, others have also highlighted the important influence of 
reflected waves on aortic pressure wave forms (87-89). As there is a gradual reduction of 
arterial elasticity, from proximal to distal, along the arterial tree, this unique feature 
therefore enables the generation of wave reflection to amplify the propagating pressure 
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wave, resulting in the ‘amplification phenomenon’, whereby the peripheral pressure wave 
becomes greater that than of central’s (86).   
 
Based upon these concepts, PWV represents a non-invasive, most widely-used, validated 
and the gold-standard method of arterial stiffness measurement (84, 90). Other available 
methods to calculate arterial stiffness also include using vascular echotracking techniques, 
magnetic resonance imaging or applanation tonometry to calculate pressure-diameter 
relationship or indirectly estimate arterial stiffness via diastolic pressure decay modelling 
or aortic characteristic impedance (84). Though it can be measured at various sites, 
carotid-femoral PWV (cfPWV), which corresponds to aortic stiffness, is of the most 
clinical relevance amongst all as it has been demonstrated to be an independent predictor 
of adverse CV outcomes in a wide range of  populations (86).  For both studies detailed in 
this thesis (RIISC and STOP-CKD), the Vicorder was the device used for measuring 
cfPWV (see section 4.3.5.2) 
 
1.5.2 Implications of Increased Arterial Stiffness 
Arterial stiffness as measured by cfPWV has significant prognostic value across different 
populations. It has been shown to be an independent determinant of CV events, CV 
mortality and all-cause mortality in the general and elderly population (91-96) as well as in 
patients with hypertension (97-100), DM or glucose intolerance (101), CKD (102) and 
ESRD (103-106). In fact, in several studies, arterial stiffness demonstrated stronger 
prognostic value than other traditional risk factors, including systolic BP (SBP) (92, 94, 
101). A meta-analysis of 17 longitudinal studies, including diverse populations, concluded 
that each 1 m/s increase of arterial stiffness measured by cfPWV, correlated to an increase 
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adjusted risk of approximately 15% in total CV events, CV mortality or all-cause mortality 
(107). Interestingly, this predictive ability of arterial stiffness in total CV events and CV 
mortality was found to be significantly greater amongst patients with higher baselines CV 
risk, including the ESRD population, as compared to the general population (107).  
 
However, the data on the predictive value of arterial stiffness in progression to ESRD 
amongst the CKD population is conflicting. While Taal et al and Ford et al demonstrated 
an independent association between arterial stiffness and the rate of renal function decline 
or progression to ESRD (108-110), others did not (111, 112). 
 
1.5.3 Therapeutic Approaches to Reduce Arterial Stiffness 
Over the years, numerous mechanisms of increased arterial stiffness in CKD have been 
postulated. In addition to the effect of ageing and increased prevalence of traditional CV 
risk factors, other reasons which were believed to contribute to alteration of extracellular 
matrix or endothelial dysfunction and hence resulted in acceleration of arteriosclerosis in 
CKD population includes formation of advanced glycation end-products (AGE) (113), 
activation of RAAS (114, 115), increased oxidative stress (116), vascular calcification 
(117, 118) and chronic inflammation (58). Although the mechanisms leading to arterial 
stiffening in CKD appear to be multifactorial, complex and most likely inter-linked, 
identification of some of these key pathways may provide opportunities to develop 
therapeutic targets in attenuating this unfavourable vascular remodelling. 
  
In the general population, aerobic-endurance exercise (119-121), low salt diet (122), 
moderate alcohol consumption (123, 124), consumption of n-3 fatty acid (125) or 
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isoflavones (126) as well as increased dietary intake of phytoestrogen (127) had been 
implicated in improving arterial compliance. Thus far, with regards to the pharmacological 
approaches, antihypertensive agents including ACEi, ARB, calcium channel blockers and 
mineralocorticoid receptor antagonists (MRAs) as well as AGE cross-links breakers such 
as aminoguanidine, have shown promising effects on arterial stiffness reduction in various 
populations (128). 
 
Nonetheless, research data on such approaches focusing on the CKD population remain 
scarce. Two small-scale studies involving patients with ESRD suggested that sevelamer, a 
non-calcium-based phosphate binder which lowers gastro-intestinal phosphate absorption, 
improves, or at least attenuates the progression aortic stiffness (129, 130). Another study 
of 21 patients with secondary hyperparathyroidism on dialysis demonstrated reduction of 
cfPWV after 12 months of cinacalcet treatment (131). However, a study of 120 non-
diabetic patients with stage 3 CKD did not provide evidence that sevelamer carbonate 
improves LV mass, LV function or arterial stiffness (132). With regards to the effect of 
statins on arterial stiffness, a double-blinded study involving 37 patients with serum 
creatinine levels > 120 µmol/L reported that atorvastatin prevented the progression of 
aortic stiffening when compared with placebo (133). Though a systematic review 
published in 2010 showed conflicting results in regards to the effect of statins on arterial 
stiffness, several recent studies in hypertensive patients demonstrated consistent beneficial 
effects as those seen in the CKD cohort (134-136). 
 
Amongst all of the antihypertensive agents, the effect on arterial stiffness reduction by 
RAAS pathway inhibitors appeared to be independent of BP (137, 138). The use of ACEi 
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was associated with LV mass reduction (139) and favourable survival in patients with 
ESRD (138). A double-blinded, placebo-controlled study has also explored the use of low-
dose spironolactone (a non-selective MRA) in patients with stage 2-3 CKD (140). 
Encouragingly, patients receiving spironolactone were found to have significant 
improvements in arterial stiffness and LV mass after 40 weeks of treatment (140).  
 
This thesis aims to examine the potential effect of two pharmacological agents: xanthine 
oxidase inhibitor and MRA, on arterial stiffness. Further discussions of the possible 
mechanisms by which these two pharmacological agents affect CV surrogate markers and 
CV outcomes are detailed in section 1.7.  
 
 Cardiovascular Risk Management in Chronic Kidney Disease 1.6
Despite the heightened CV risk in patients with CKD, there is often a lack of information 
to guide management (141), and over-reliance on post-hoc or subgroup analyses of studies 
in the general population, which might be prone to bias (142). Applying treatment 
strategies verified in the general population to patients with CKD is a highly debatable 
approach for several reasons, including the unique CV pathophysiology and risk profile as 
discussed (143). This issue with the paucity of evidence is epitomised by the uncertainty in 
BP management, which is considered the core of the CV management in CKD. Thus far, 
though observational studies have established that elevated BP is associated with increased 
risk of renal disease progression (144-146), the optimal BP range for patients with CKD 
remains less certain, especially for those with minimal albuminuria (147, 148).  
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Two decades ago, the MDRD study demonstrated that a tighter mean arterial pressure 
(MAP) slowed the renal progression in CKD population with proteinuria > 1g/ day (149). 
Likewise, although intensive BP control showed no benefit on renal progression in the 
overall cohort of AASK study, it hinted at a probable beneficial effect amongst those with 
the baseline proteinuria > 220 mg/g (150). Together with the observation studies, these 
trials therefore formed the basis of the several nephrology guidelines, recommending a 
tighter BP target of <130/80 mmHg for the CKD population with proteinuria, until the 
present (151-153). Nonetheless, on closer inspection, the conclusion from both the RCTs 
was in fact drawn from a subgroup analysis, as the overall intention-to-treat analysis of the 
RCT revealed no significant benefit between the groups. Even within the subgroup 
analysis of the MDRD study, the benefit seen with intensive BP control was solely driven 
by the 54 patients with proteinuria > 3g/day at baseline (151). A recent systematic review 
of 11 RCTs concluded that although intensive BP control did appear to reduce the risk of 
renal progression and ESRD, it was only amongst those with proteinuria (147). Such 
strategies in fact failed to demonstrate any convincing, beneficial effect on CV events or 
mortality. Additionally, there were substantial variations regarding the definition of 
‘intensive BP-lowering strategies’ across the included studies (i.e.: MAP < 92 mmHg, BP 
<120/80 mmHg, diastolic BP [DBP] < 75 mmHg, etc.), which made implementing such 
conclusions to practice particularly tricky (147). This is further complicated by the finding 
of a J-shape relationship between SBP and poorer outcomes in CKD population, as several 
studies have observed the significant increased stroke risk, CV or all-cause mortality  
amongst those with SBP < 120 mmHg compared to their counterparts (154-156).  
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While the optimal BP target to reduce CV burden for patients with CKD remains a 
debatable issue, there is growing consensus on the beneficial role of RAAS blockade in 
CKD, which appeared to be independent of its effects on BP and albuminuria reductions 
(152, 153). Aside from being a regulator of fluid and electrolytes balance and a potent 
mediator of BP via arterial vasoconstriction, RAAS have also been implicated in its role in 
the up-regulation of chronic inflammation and fibrosis (157, 158). A patient-level meta-
analysis published in 2003 reported that the use of ACEi was associated with better renal 
outcomes even after adjustment for BP and urine protein excretion in CKD population 
(153). Though, another similar meta-analysis published 2 years after appeared to be less 
convinced of their benefit on kidney disease progression (159), a more recent pooled 
analysis by Balamuthusamy et al revealed that in comparison with placebo, RAAS  
blockade reduced risk of myocardial infarction, heart failure and total CV outcomes in 
CKD patients (160).  
 
With regards to the use of statins, the most recent meta-analysis concluded that statin 
therapy reduces CV morbidity and mortality as well as all-cause mortality in patients with 
all stages of CKD, though the observed beneficial effects appear to be less among patients 
with advanced CKD or ESRD (161).  
 
Thus far, the only evidence-based pharmacological agents available in attenuating adverse 
outcomes in CKD population therefore appeared to be limited to BP control, especially 
using RAAS blockade, and lowering LDL-cholesterol with statin-based therapy. With this 
backdrop, NICE recently updated its guidelines on early identification and management of 
CKD in primary and secondary care in 2014. In terms of CV management, it recommends 
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a tight BP target of 130/80 mmHg or less for those with DM or uACR > 70 mg/mmol, but 
a BP target of <140/90 mmHg, in parallel with the general population, for the non-
diabetic, CKD population without significant albuminuria. In addition, the guidelines also 
encourage the use of ACEi or ARB. Though it suggests the use of low-dose statins for 
primary and secondary CV prevention, there is no specific guidance regarding the 
assessment of their CV risk and the threshold of starting statin treatment primary 
prevention remains unclear. As in line with the non-CKD population, the guidelines 
suggest offering antiplatelet medications to patients with CKD for secondary prevention of 
CV disease, but highlight the associated increased risk of bleeding (34).  
 
1.6.1 Quality and Outcomes Framework in Chronic Kidney Disease Management 
In response to the high prevalence of CKD and its significant association with increased 
morbidity and mortality, the Department of Health first introduced CKD as part of the 
Quality and Outcomes Framework (QOF) in 2006. The QOF is essentially an ‘annual 
reward and incentive programme detailing general practice achievement results’, intended 
to benefit both patients and the National Health Service (NHS) (162). It measures practice 
achievement against a wide range of ‘evidence-based’ clinical indicators. The CKD 
domain of QOF from 2006 till 2015 included five clinical indicators (see Table 1-3). Since 
its introduction, the UK observed an drastic reduction of incidence of ‘late-presenters’, 
defined as patients with progression of CKD entering services as acute emergencies, from 
31% to 19% in the past few years (163). 
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Table 1-4: The Quality and Outcomes Framework (QOF) domain 2014/15 in Chronic 
Kidney Disease 
Indicator Points Achievement 
threshold 
Records 
CKD001. The contractor establishes and maintains a register of patients 
age 18 or over with CKD (US National Kidney Foundation: Stage 3 to 5 
CKD) 
6  
Ongoing management 
CKD002. The percentage of patients on the CKD register in whom the last 
blood pressure reading (measured in the preceding 12 months) is 140/85 
mmHg or less 
11 41-81% 
CKD003. The percentage of patients on the CKD register with 
hypertension and proteinuria who are currently treated with an ACEi or 
ARB 
9 45-80% 
CKD004. The percentage of patients on the CKD register whose notes 
have a record of a urine albumin:creatinine ratio (or protein:creatinine 
ratio) test in the preceding 12 months 
6 45-80% 
 
Nonetheless, the latter three indicators (CKD002, CKD003, CKD004) have since been 
removed from the 2015/16 QOF document  (164). According to the General Practitioners 
(GP) Committee and executive lead on QOF, such drastic changes were intended to reduce 
the focus on box-ticking and enable GPs to treat patients according to their clinical needs 
(165). This decision also perhaps reflected the quandary highlighted by Fink et al that 
despite clear evidence showing the association between CKD and poor outcomes, fervent 
desire by all parties (i.e.: policy makers, healthcare professionals, patients, etc.) to improve 
the outcomes, there is astonishingly little good-quality, compelling evidence to make 
strong recommendations in guiding the management of such heterogeneous groups of 
patients (166).  
 
1.6.2 Quality and Quantity of Research Evidence in Chronic Kidney Disease 
Indeed, a previous editor of two prestigious medical journals expressively conveyed his 
concerns regarding the decline of basic research in nephrology several years ago (167). In 
 24 
 
addition, the deficiencies of translational research were also thought to be contributing to 
the majority of the day-to-day practical dilemmas encountered in nephrology (168).  
 
Due to their well-documented advantages, randomised controlled trials (RCTs) represent 
the gold standard for testing hypotheses in medical research (169, 170). Nonetheless, renal 
medicine has a poor track record for producing good quality, large-scale RCTs. In an 
evaluation of the number and quality of RCTs, nephrology was found to have published 
fewer than 12 other medical specialties (169). The proportion of all nephrology citations 
that were RCTs was only 1%. Another analysis of the journal citations from 1998 to 2010, 
disappointingly echoed similar findings (171). Among nine sub-specialities of internal 
medicine, nephrology journals remained to have the lowest impact factor (171). Indeed, a 
recent authoritative and comprehensive systematic review looking at studies right up to 
November 2011, struggled to find large, high quality RCTs from which to make strong 
recommendations on screening and monitoring early stage CKD (166). In particular, they 
found that evidence of outcomes in CKD patients was scant and often derived from post 
hoc analyses of subgroups of patients enrolled in trials. Few trials reported or 
systematically collected information about adverse events suggesting the possibility of 
selective reporting and publication bias (166).  
 
Strippoli et al first highlighted the pervasive issues of unclear allocation concealment, lack 
of blinding of outcome assessors and failure to perform intention-to-treat-analysis in RCT 
reporting in nephrology more than a decade ago (169). A recent study by Deo et al 
regrettably continued to report similar findings (172). Disappointingly, more than a quarter 
of the RCTs were found to have failed to describe their primary outcome and the majority 
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were criticised to be poor in handling and reporting data lost to analysis (172). Studies in 
patients with CKD in the past have often produced negative or neutral results, which might 
be attributable to several pivotal methodological flaws (173). The issues with missing 
primary outcome designation and conflicting results amongst RCTs in nephrology may be 
in part, fuelled by the lack of consensus regarding the various definition of renal-endpoints 
(i.e.: doubling of creatinine, decline of eGFR > 25%, requiring dialysis, etc) as well as 
over-reliance of its use in short-term studies (174). Often, the studies were also 
underpowered as a consequence of ‘over-optimistic’ assumptions about event rates and the 
impact of therapeutic interventions. These factors clearly need to be taken into account 
when planning future trials as information gleaned from good quality, rigorously 
conducted pilot studies is essential when designing large, adequately powered hard-
endpoint studies (175). 
 
 Potential Pharmacological Agents for Cardiovascular Intervention 1.7
Several potential therapeutic agents aiming at reducing traditional or non-traditional risk 
factors have been under research for CV intervention in CKD. This thesis will be focusing 
on two of these therapeutic agents: (1) Xanthine oxidase inhibitor and (2) MRA. 
 
1.7.1 Xanthine Oxidase Inhibitors 
Uric acid is the oxidation end-product of purine metabolism. Renal elimination of uric acid 
accounts for the majority (75%) of its disposal, whilst the rest was via gastro-intestinal 
route (176). Uric acid has been shown to have positive association with several 
inflammatory markers (177), stimulate the inflammatory pathway (178), impair nitric 
oxide generation (179), promote vascular smooth muscle cells proliferation and upregulate 
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the pro-thrombotic effects mediated by platelet activation (180), all of which contribute to 
the pathogenesis of hypertension, endothelial dysfunction and hence, vascular disease and 
stiffening. There is an abundance of data showing the association between hyperuricaemia 
and increased arterial stiffness (181, 182), CV events and mortality in the general 
population, even in physiological range (183-191).  A recently published study using 
Mendelian Randomisation further strengthened the evidence of the causal relationship 
between hyperuricaemia and adverse CV outcomes, especially sudden cardiac death (192). 
Additionally, raised uric acid level has also been found to be an independent risk factor for 
developing CKD in a meta-analysis containing more than 190,000 participants  (193). 
 
Hyperuricaemia is highly prevalent in the CKD population (194). In a study of 223 
patients with Immunoglobulin A (IgA) nephropathy, hyperuricaemia was independently 
associated with progression of kidney disease, defined by increment of creatinine > 20 % 
(195). In the post-hoc analysis of MDRD study, hyperuricaemia was also reported as an 
independent risk factor for both CV and all-cause mortality in patients with stage 3-4 CKD 
(196). Nonetheless, despite accumulating evidence demonstrating associations between 
hyperuricaemia with adverse outcomes, a recent meta-analysis demonstrated no 
association between changes in serum uric acid level and risk of CV events or all-cause 
mortality (197).  
 
While the role of elevated uric acid level simply as a risk marker rather than a modifiable 
CV risk factor remains contentious, studies exploring the use of the xanthine oxidase 
inhibitors (i.e.: allopurinol and febuxostat) in reducing vascular dysfunction have yielded 
encouraging results (198-201). Xanthine oxidase inhibitors are uric acid lowering agents 
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widely used as treatments for chronic gout. They inhibit the formation of uric acid from 
xanthine and hypoxanthine reducing serum uric acid levels and preventing crystallization. . 
In addition to their uric acid lowering effect, importantly, xanthine oxidase inhibitors have 
long been shown to have direct free radical scavenging action (202). Indeed, the 
mechanism through which allopurinol improved endothelial function was thought not to be 
related to uric acid lowering, but to its ability to reduce vascular oxidative stress in patients 
with chronic heart failure (203).  Xanthine oxidase is one of the enzymatic systems 
involves in the production of reactive oxygen species (ROS) (204). Over-production of 
ROS, which exceeds the defence mechanisms of anti-oxidants, is believed to result in 
oxidation of essential biological macromolecules (i.e.: deoxyribonucleic acid [DNA], 
protein, membranes, etc.). Additionally, as superoxide radicals readily inactivate 
endothelial NO, thereby impairing vaso-relaxation, there is an accumulating body of 
evidence demonstrating that oxidative stress contributes significantly to endothelial 
dysfunction in cardiovascular disease (205), which conceivably contributes to increased 
arterial stiffness and CV disease (58, 204). . In animal models, xanthine oxidase inhibitors 
were found to reduce vascular free radical production (206, 207), improve blood pressure 
and endothelial function (208-210) as well as prevent hypertension-induced left ventricular 
and renal hypertrophy (211, 212). Among patients with CKD, the use of allopurinol has 
thus far been demonstrated to be associated with improvements in surrogate markers for 
CV disease including endothelial function (198, 199) and LVH (198). Furthermore, in an 
RCT of 113 patients with eGFR < 60 ml/min/1.73m
2
, the use of allopurinol has also been 
found to be associated with improved inflammatory markers, reduced hospitalisations, and 
significantly lower risk of CV events over the 2-year follow-up period (200, 201).  
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Nonetheless, the potential beneficial effect of allopurinol in retarding renal disease 
progression is not clear. Limited by substantial heterogeneity of baselines characteristics 
across the eight included studies, a meta-analysis published in 2014 was unable to make 
clear conclusion regarding the effect of allopurinol on renal outcomes in patients with 
CKD (213). Interestingly, a post-hoc data analysis of an RCT by Goicoechea et al 
demonstrated not only persistent favourable outcomes on CV events, but also on renal 
progression amongst the group originally assigned with allopurinol treatment, despite 
significant number of treatment cross-overs during the five additional years of follow-up 
(200). 
 
Although these results are encouraging, the general consensus is that a blanket clinical use 
of xanthine oxidase inhibitors in patients with CKD based on the existing body of evidence 
is still very premature. In our striving towards reducing the disease burden in the CKD 
population, xanthine oxidase inhibitors warrant further investigation.  
 
1.7.2 Mineralocorticoid Receptor Antagonists 
Aldosterone is a mineralocorticoid which is one of the key effectors of the 
RAAS. Traditionally, it is known for its function on kidneys and colon epithelium in 
regulating Na
+
 reabsorption and K
+
 secretion, which forms part of the feedback loop in 
RAAS and BP control (214) (Figure 1-3). This classic action of aldosterone is dependent 
on the transcription and translation of the genes, resulting in the synthesis of protein 
stimulating transport, and is therefore termed the ‘genomic’ action.   
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Figure 1-1: Genomic actions of aldosterone and its associated feedback loops. 
 
Beyond these classical actions of aldosterone, there has been growing interest and shift of 
focus onto its wider arrays of non-genomic effects in the recent years (215). Unlike the 
genomic actions which have a latent period of 30-60 minutes, the non-genomic actions of 
aldosterone were rapid (latency < 15 minutes) and not solely confined to kidneys or colon 
(216). Extensive expression of mineralocorticoid receptors has been identified in the heart, 
endothelial cells, vascular smooth muscle cells as well as in kidney mesangial cells. These 
non-genomic actions of aldosterone have therefore gained particular interest in the field of 
cardiology and are believed to be a crucial mediator in pathological remodelling of both 
the CV and renal systems (214, 217).  
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Thus far, there is a substantial body of evidence demonstrating the role of aldosterone in 
numerous CV effects, including endothelial dysfunction, transmural arterial inflammation 
and ultimately, myocardial and vascular hypertrophy and fibrosis/stiffening independent of 
BP control (218-221). In vitro, aldosterone was reported to enhance epidermal growth 
factor receptor, (222), stimulate collagen abundance in human aortic smooth muscle cell in 
the presence of reactive oxygen species (223), induce osteopontin gene expression of the 
endothelial cells (224), up-regulate chemoattractant proteins and facilitate the 
transmigration of monocytes to the sub-endothelium (225, 226), all of which are 
implicated in vascular dysfunction and invariably leads to increase arterial stiffening 
Experimental research in animal models also demonstrated its role in promoting oxidative 
stress, inflammation, sclerotic and fibrotic changes in both the kidneys and CV systems 
(217). Furthermore, Di Zhang et al reported cross-talk between angiotensin II and 
aldosterone signalling in cardiac remodelling, hence concluded that their effects on CV 
system are additive (218). In human beings, a high aldosterone level was associated with 
higher LV mass, increased arterial stiffness, endothelial dysfunction and insulin resistance 
(227). Many of these deleterious effects of aldosterone were also found to be independent 
of BP or angiotensin II actions (217). Use of MRAs, which inhibits the action of 
aldosterone, appears to attenuate these detrimental effects (217). 
 
Thus far, the RAAS remains a principal target for CV intervention, and inhibitors of this 
system (ACEis or ARBs) have been used widely in improving hypertension and 
proteinuria in patients with CKD (228-230). Nonetheless, the effect of RAAS blockade is 
not always efficient in normalising BP, proteinuria and CV risk. In fact, in a certain subset 
of patients, prolonged use of ACEIs and ARBs, regardless of dose and class (231-233), can 
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lead to ‘aldosterone breakthrough’(234). Though it is a well-recognised phenomenon, 
there is no clear consensus on the definition of ‘aldosterone breakthrough’. While it is 
generally regarded as elevation of post-treatment plasma aldosterone level from pre-
treatment baseline (235), some non-CKD studies defined it as aldosterone level above the 
normal range, which varies considerably across different laboratories and studies (231, 
232, 236, 237).  
 
Amongst patients with diabetic or IgA nephropathy, the incidence of aldosterone 
‘breakthrough’ is high and reported to be 28-53% (233, 238-240). Nonetheless, the current 
evidence regarding the clinical significance of the presence of ‘aldosterone breakthrough’ 
is conflicting, which is likely to be related to short study duration and methodological 
limitations (234). While some investigators have reported an association between 
‘aldosterone breakthrough’ with greater proteinuria (233, 238), others have not (239, 240). 
Similarly, while Schjoedt et al demonstrated association between ‘aldosterone 
breakthrough’ with renal progression in a small study of type 1 diabetic nephropathy 
(239), this finding was, however, not evident in a larger post-hoc analysis of a RCT (240). 
Nonetheless, amongst those with ‘aldosterone breakthrough’, Sato et al demonstrated that 
the use of low dose spironolactone significantly reduced albuminuria and LV mass index 
without change in BP after 24 weeks (238).  
 
Thus far, the beneficial CV effect of aldosterone blockade, in addition to standard 
treatment, is perhaps best evidenced by the heart failure studies. In the RALES and 
EPHESUS studies, that use of MRAs was proven to confer significant reduction in 
morbidity and mortality among patients with heart failure (241, 242). These landmark 
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findings were later confirmed in a meta-analysis (243). With regard to the CKD 
population, in addition to its role in reducing proteinuria (244-247), other studies have also 
suggested improvement of multiple surrogate markers of CV disease with the use of 
MRAs (247). Nevertheless, its role in long-term CV outcomes in patients with CKD 
remains uncertain.  
 
In a randomised, double-blinded, placebo-controlled trial of 112 patients with stage 2 or 3 
CKD in the secondary care setting, Edwards et al. demonstrated that the addition of  a 
MRA, spironolactone, 25 mg once daily to background ACEi or ARB treatment safely 
reduced LV mass (-14 ± 13 g versus +3 ± 11 g, p < 0.01) and decreased arterial stiffness 
(cfPWV: -0.8 ± 1.0 m/s versus -0.1 ± 0.9 m/s, p < 0.01), compared with placebo (140, 248, 
249). A trial to examine whether these desirable intermediate endpoints changes can be 
translated into long-term gains in terms of reduced CV morbidity and mortality in large 
CKD cohort is clearly warranted. 
 
 Qualitative Research in Chronic Kidney Disease 1.8
Although there is an increasing number of a quantitative research study exploring the 
effects of various pharmacological interventions in improving CKD outcomes, issues 
regarding patients’ illness experience and disease perceptions on CKD, especially in the 
early or moderate stage remain under-researched.  
 
In the NICE CKD 2014 guidelines, it was emphasized that patients with CKD should be 
informed of their diagnosis, involved in shared decision making and supported in self-
management (34). Nevertheless, a large recent UK study highlighted the issue of poor 
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awareness among patients with stage 3 CKD, whereby a staggering 41% of them were 
unaware of their CKD diagnosis (7).  As the majority of the patients often remain 
asymptomatic especially in the early or moderate stage, the combination of CKD being a 
silent condition and the issue of low diagnosis awareness among patients undoubtedly 
creates barriers in treatment delivery and potentially affects patients’ outcomes. Hence, 
there is a clear need for further research into early and moderate stage CKD to examine the 
issues underlying low CKD illness awareness, explore patients’ illness perceptions, 
identify patients’ perceived knowledge gap and improve understanding of the needs 
amongst this large, growing, distinct group of patients. In addition, this in-depth 
understanding of patients’ perceptions of CKD will also form the foundation for exploring 
the barriers to their participation in research studies. Such knowledge is not only 
paramount in informing future healthcare resource planning, but is also crucial in 
formulating future research questions and study design in CKD.  
 
 Illness Perceptions of Patients with Chronic Kidney Disease 1.9
In the past few decades, there have been a growing number of studies assessing illness 
experience and quality of life (QOL) in patients with kidney disease. Questionnaires or 
scoring systems, for example, Beck’s Depression Inventory (BDI), Medical Outcomes 
Study Short Form 36-Item Health Survey (SF-36), Kidney Disease Quality of Life 
(KDQOL) instrument and Karnofsky Performance Scale (KPS) have been used to quantify 
symptoms or disease burden. Much research has been focusing on patients with ESRD, 
whereby issues with depression, anxiety and sexual dysfunction are prevalent (250-253) 
and QOL is known to be markedly lower than the general population (254). Though the 
disease burden is generally less in patients with early or moderate stage CKD, its 
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significant negative impact on patients’ physical and mental QOL is nonetheless noticeable 
even in its early stages (255). This implies that in addition to disease burden, other factors 
clearly are in play affecting patients’ QOL and outcomes. Above all, patients’ perception 
of illness is believed to be one such crucial factors. Illness perception thus far has been 
shown to influence patients’ illness behaviour, coping strategies, psychosocial well-being 
and QOL in various chronic illnesses, including patients with ESRD (256-260).  
 
This awareness of the importance of the psychological aspects of the illness experience is 
clearly not novel. Engel’s call for an integrated biopsychosocial model which incorporated 
social, psychological and behavioural dimensions of illness to replace the biomedical 
model almost four decades ago, revolutionised the approach in understanding, researching 
and managing various diseases (261). The psychosocial reaction to illness was referred to 
‘a set of cognitive, emotional and behavioural responses induced by every sick person by 
all the illness-related information they received’ (262).  
 
1.9.1 Theoretical Models of Illness Perceptions 
Aiming to promote a more balanced scientific and humanistic approach towards patients’ 
care and ensuring physicians were equipped with the skills to deal with the patients’ 
psychological aspects, Lipowski formulated a theoretical framework proposing the four 
domains of ‘meaning of illness’ (challenge or threat, loss, gain or relief and punishment) 
and four main categories of ‘determinant of meaning’ (intrapersonal factor, interpersonal 
factor, illness-related factor as well as sociocultural and economic factors) (263).  
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Recently, increasing attention has been paid to exploring a more dynamic model of illness 
representation and health behaviours (264). Illness representations are patients’ beliefs and 
expectations about an illness or somatic symptom. First proposed in 1980, Leventhal et al 
conceptualised patients’ common-sense representations of health and illness via a self-
regulatory framework (260). This common-sense theoretical model of self-regulation 
enables the organisation of the multitude of information required when evaluating a certain 
health behaviour as well as incorporating coping actions and appraisal (265). Initially 
based upon a simple Fear-Drive reduction model (266), Leventhal et al assumed that fear 
(health threat) motivated actions or procedures to eliminate or reduce fear (health threat) 
and that these actions or procedures were then reinforced or learnt (267). However, the 
lack of interaction between fear levels and action plans in the initial health behavioural 
studies led to the development of the parallel process model. The parallel process model 
postulated that health threat generates cognitive as well as emotional representations of 
threat, both of which trigger parallel corresponding actions to manage the perceived threat 
(danger control) and emotional fear (fear control) (267). Building further upon the model, 
Leventhal et al theorised that patients act as common-sense scientists when constructing 
representations of health threat and categorised the knowledge of the health threat into five 
domains: identity, timeline, consequences, cause and control (268) (Figure 1-4). The 
meanings of each domain are detailed in Table 1-4 and each domains contain both abstract 
(semantic) and concrete (perceptual or experiential) information with a bi-directional link 
between the two (268). In addition, Cameron et al also theorised the rule of ‘symmetry’ 
which refers to the pressure to connect or anchor the abstract with the concrete and vice 
versa (268). With each addition and integration of new information, the illness 
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representation modulates, evolves and develops both in the cognitive and emotional sense 
in order to response to the change.  
 
 
Figure 1-2: The common-sense self-regulatory model of illness and health behaviour. 
Adapted from Cameron et al 2002 (268). 
 
 
Table 1-5: Five dimensions of illness representation and examples of abstract and concrete 
information in each dimensions (268).  
 Meaning Abstract Concrete  
Identity Label placed on the disease 
and the symptoms associated 
with it 
My blood pressure is high. My legs are swollen. 
Timeline Perceived duration/course of 
illness 
This cough will last for a 
few weeks. 
It seems this cough has 
lasted as long as this 
house. 
Consequences Beliefs about the severity of 
the illness and its expected 
outcomes or impacts on life 
functions 
This kidney problem will 
shorten my life. 
My kidney failed and I 
ended up on dialysis a year 
ago. 
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Cause Personal ideas about the 
cause(s) of the illness 
This illness is caused by a 
flu virus. 
My cousin passed on this 
nasty flu to me. 
Control Perceived management of the 
illness. Beliefs about the 
extent to which the disease is 
amenable to control or cure 
This chemotherapy is 
going to stop the cancer 
from spreading. 
The doctor showed me that 
my cancer has reduced by 
2cm in size since I started 
with this medication. 
 
1.9.1.1 Quantitative Studies of Illness Perception in Kidney Disease 
This illness representation framework later formed the basis of the Illness Perception 
Questionnaire (IPQ), revised Illness Perception Questionnaire (IPQ-R), brief Illness 
Perception Questionnaire (IPQ-B) and multi-perspective Illness Effects Questionnaire 
(IPQ-MP), all of which aim to quantify patients’ illness perception and have been used in 
various chronic medical conditions (259). Another widely used questionnaire is the Illness 
Effect Questionnaire (IEQ) developed by Greenberg and Peterson (269).  
 
To date, much research has utilised such questionnaires to quantitatively study illness 
perception in patients with ESRD. Amongst patients on maintenance haemodialysis, lower 
consequence perceptions were reported to predict non-adherence of fluid intake (270) 
while negative emotional perceptions and unawareness of the chronicity of the illness was 
associated with poorer diet and medication self-care behaviours (271). Importantly, Covic 
et al also found that patients’ QOL score was not associated with dialysis treatment 
duration, but with their illness perceptions (272).  The study reported that personal control 
and time-line component of illness perceptions correlated positively, while emotional 
response correlated negatively with the QOL (272). Similarly, Fowler et al also described 
the negative correlation between index of well-being with perceived consequences and 
emotional response (273).  
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The majority of these studies have demonstrated patients’ illness perception as a powerful 
tool in influencing coping mechanisms and predicting both psychological and clinical 
outcomes in patients with ESRD (274-278). Importantly, a recent systematic review of 
patients with ESRD summarised the association between negative perception of illness 
with increased mortality (259). Patients’ apparent interpretation of their illness is therefore 
as, if not more, crucial in predicting patients’ outcomes than co-morbidities or disease 
characteristics (277). However, its potential role as a modifiable prognostic factor is yet to 
be fully studied and utilised. 
 
Compared to the dialysis population, illness perception among the pre-dialysis CKD 
population remains an under-researched subject. Though patients on dialysis were found to 
perceive more illness consequences and consider that their treatment controls their illness 
more strongly than CKD patients in the pre-dialysis phase (279), perceived autonomy and 
self-esteem levels among patients with stage 4 CKD were nonetheless strongly influenced 
by their illness and treatment perceptions (280). Likewise, in another study of patients with 
stage 3b to stage 5 CKD, including those with ESRD, illness perceptions were shown to 
significantly influence the occurrence of anxiety or depression (281). 
 
1.9.1.2 Qualitative Studies of Illness Perception in Kidney Disease 
Though the use of a questionnaire to assess illness perception among patients with 
advanced CKD has been widely implemented, a study evaluating the validity of the IPQ-R 
in patients with different stages of CKD suggested that the questionnaire should be 
interpreted with care in earlier stages of CKD or if few symptoms are reported (264). In 
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addition, it highlighted the need to capture uncertainty regarding illness identity in this 
particular group of patients (264).   
 
An interview study conducted in Taiwanese patients with early stage CKD identified six 
emergent themes, which included experiencing early symptoms, self-interpreting the 
causes of having CKD, realising CKD is a long-term disease, believing CKD could be 
controlled by following doctors' orders, anticipating the consequences of having CKD, and 
adopting coping strategies to delay the progress of CKD (282). In contrast, CKD was 
perceived to be a silent, treacherous and terminal disease among patients participating in a 
preventive renal programme in Colombia (283). Patients in early stages of CKD often 
described fear of the need for dialysis or transplantation and were aware of the irreversible 
and serious nature of their condition (283). Interestingly, despite these concerns, these 
patients remained stoic and felt that they were able to continue to live ‘a normal life’ as 
they understood that the early stages of CKD are often asymptomatic (283). Using a 
modified version of Lipowski’s ‘meaning of illness’ schema, a mixed-method research 
examining CKD patients with or without dialysis and renal transplant recipients treated at 
a Northern England Renal Unit noted that most patients regarded their illness as a 
‘challenge’ in life that they could overcome or had to endure (284). The study categorised 
their meaning of illness into eight categories- challenge, value, enemy, punishment, 
strategy, weakness, relief and irreparable loss (284). Intriguingly, a lesser proportion of 
patients with CKD not requiring dialysis were noted to select ‘value’ and a greater 
proportion selected ‘loss’ as compared to those on dialysis or renal transplant recipients 
(284). Illness perceived as ‘value’ implied a view that “the experience will make one a 
stronger person” while illness perceived as ‘loss’ signified a view that “one’s disease is 
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getting worse or may die or lose the ability to function as before”. The main concerns of 
patients with CKD not requiring dialysis were found to be related to their prognosis or to 
their perceived lack of improvement (284). These apparent differences in views among 
patients with different stages of CKD identified in both quantitative and qualitative studies 
clearly warrant further exploration. 
 
An Australian focus group study of patients with all stages of CKD described the influence 
of healthcare service experience on patient’s illness perception and highlighted the issue 
with inadequate information, psychosocial and practical support (285). Another 
exploratory Canadian study of patients with mild to moderate CKD similarly reported 
searching for evidence, realising kidney disease is forever, managing the illness, self-
caring and the need for disease-specific information as the key themes (286). Though the 
findings from these studies may not necessarily be generalisable to the NHS experience, 
they do provide insights into the role that healthcare information plays in empowering 
patients with early stages of CKD.  
 
To date, though several research studies have been conducted to quantitatively and 
qualitatively evaluate this issue, the majority of these studies focused mainly on patients 
with advanced CKD receiving dialysis (287-289). Even when early or moderate stage 
CKD patients were included in the studies, their viewpoints were often combined with 
those with ESRD, risking overlooking or diluting their specific perspectives and needs 
(284, 285). Though the disease burden is undoubtedly much greater and the healthcare 
resource is considerably more intensive for each patient with ESRD, the overall impact of 
the much more prevalent early or moderate stage CKD should not be underestimated and 
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clearly requires further research. Crucially, as only one of the studies was conducted in the 
UK (284), the differences in culture and healthcare systems across the studies conducted in 
various countries meant that the findings might not be applicable or relevant to the UK 
CKD population. Additionally, despite the prevalence of CKD, research studies are often 
plagued by poor research participant recruitment. It is plausible that patients’ views on 
CKD related research and their willingness to participate in the studies are influence by 
their illness perceptions. There is therefore a pressing need for qualitative research to 
further explore CKD illness perceptions amongst patients with early to moderate stage 
CKD in the UK.  
 
 Patients’ Perception on Research in Chronic Kidney Disease 1.10
While 82% of the public believes it is important for the NHS to offer opportunities to 
participate in healthcare research according to a recent national poll in the UK, the 
majority of research studies continue to be mired by poor recruitment (290). In fact, a 
review of 114 multi-centre cohort trials funded by the UK Medical Research Council 
(MRC) or the Health Technology Assessment (HTA) Programme revealed that two in 
three trials failed to achieve their original sample sizes and half required an extension for 
the study due to poor recruitment rate (291). In addition to having significant impact on the 
timelines and financial resources of the studies, poor recruitment of research participants 
can also severely jeopardise the power and validity of the study, leading to false negative 
outcomes, or even resulting in early termination (292). In fact, in another recent study 
which examined nearly 7,000 CV studies registered on the registry of ClinicalTrial.gov 
over a period of 13 years, almost 11% of the studies were found to have terminated 
prematurely (293). Of these early-terminated trials, an astonishing 54% were primarily 
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attributed to low recruitment (293). There was therefore a general consensus to focus on 
increasing value and reducing waste in research in recent years (294-300).  
 
A review by the Cochrane Collaboration examined the effect of various strategies to 
improve recruitment to RCTs (301). Telephone reminders to non-responders; use of opt-
out, rather than opt-in procedures for contacting potential trial participants; and open 
designs appeared to be effective in increasing recruitment. However, the lack of blinding 
as a significant trade-off in open designs needs to be considered carefully as it undoubtedly 
increases risk of bias (301). Furthermore, financial incentives and short messaging service 
(SMS) message to potential participants also appear promising and warrant further 
evaluation while evidence for several other interventions, including use of video and 
certain types of change to consent procedure was otherwise inconclusive (301). The review 
therefore highlighted the clear need for further research into effective strategies in 
optimising recruitment in view of the current gap of knowledge. Indeed, an initiative 
entitled ‘trial forge’ was recently set up in order to improve the evidence base for trial 
decision making and increase trial efficiency (302).  
 
Patients’ opinions are invaluable in formulating the optimal strategies to improve 
recruitment, which is pertinent and applicable to individual study aims and designs. In 
brief, understanding patients’ perception, engaging patients in research design, identifying 
barriers to recruitment, exploring ways to overcome barriers are therefore paramount in 
facilitating research recruitment, with an ultimate aim for improving the quantity as well as 
the quality of the research evidence to guide CKD management. 
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 Summary and Scope of Thesis  1.11
CKD is a significant public health issue, which is associated with high CV risk and 
incurring substantial costs to the healthcare system. However, there is a disconcertingly 
lack of good quality research evidence in guiding the management of these patients. In 
addition, there also appears to be a misplaced focus of research activities in the secondary 
care while the majority of CKD patients are in fact managed in primary care by their GPs. 
Hence, there is a clear need to establish feasibility of conducting large-scale RCTs in CKD 
in primary care and identify barriers to such research participation, which are invaluable in 
facilitating future research designs.  
 
To date, several potential therapeutic options for modulating CV risk in CKD are on the 
horizon. Amongst them, xanthine oxidase inhibitors and MRAs have shown promising 
preliminary outcomes in studies thus far. Further research is clearly warranted to assess 
their use.  
 
Nonetheless, despite the medical advances in the diagnosis and management of patients 
with CKD in the past few decades, there are growing concerns regarding the low illness 
awareness amongst patients with early to moderate CKD in the community. Furthermore, 
there is also limited understanding regarding their illness perceptions and willingness to 
CKD research participation, which is fundamental to provide guidance for future CKD 
research and reduce barriers in research recruitment.  
 
This thesis therefore consists of four broad aims: 
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1. Explore the relationship between the use of allopurinol and arterial stiffness in 
CKD population in a cross-sectional study in secondary care; 
2. Systematically review the CV effects of MRAs in CKD in published literature; 
3. Examine the CV effect of low-dose spironolactone in CKD in primary care via a 
pilot RCT and ascertain the feasibility of such RCT in CKD in the primary care; 
4. Qualitatively study patients’ perception of CKD in primary care and explore the 
barriers to patients’ research participation in CKD study. 
 
 Structure of Thesis 1.12
This thesis began with an introduction which outlined the definition and epidemiology of 
CKD, CV disease burden in CKD, issues of lack of research evidence in guiding the 
management of CV risk in CKD and highlighted the two potential agents for CV 
intervention in CKD, i.e.: xanthine oxidase inhibitors and MRAs. The introduction also 
emphasized the need to incorporate qualitative studies to enrich the research evidence, 
described the data regarding illness awareness as well as illness perceptions in CKD and 
underlined the importance of gathering further qualitative information on patients’ 
perceptions on research participation in primary care in CKD. This will be followed by 
Chapter 2 which describes the methods and results of a cross-sectional study conducted to 
examine the association between the use allopurinol and arterial stiffness in CKD. 
Chapters 3, 4 and 5 focus on the CV effects of MRAs in CKD population. The methods 
and results of a systematic review and meta-analysis summarising the CV effects of MRAs 
is presented in Chapter 3 while Chapter 4 details the methodology of a feasibility RCT 
which aimed to examine the effect of low-dose spironolactone on arterial stiffness in CKD 
in primary care (The STOP-CKD study). Chapter 5 reports the quantitative outcomes of 
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the STOP-CKD study and describes the research recruitment issues encountered by the 
trial. As a mixed-method trial, the STOP-CKD study incorporated a qualitative interview 
component, which examined patients’ perceptions of CKD and explored the barriers to 
CKD research participation in primary care setting. The results from this qualitative study 
fed back into the issues highlighted by the RCT and are presented and discussed in 
Chapters 6 and 7. Lastly, the main findings of thesis are summarised and concluded in 
Chapter 8. 
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CHAPTER 2 ASSOCIATION OF ALLOPURINOL WITH 
ARTERIAL STIFFNESS REDUCTION IN CHRONIC 
KIDNEY DISEASE 
 
 Introduction 2.1
Asymptomatic hyperuricaemia is associated with increased CV and all-cause mortality in 
the general population (183-188) and in patients with CKD (194-196, 303-305). 
Hyperuricaemia is highly prevalent among CKD population (194). Thus far, the use of the 
xanthine oxidase inhibitor, allopurinol in patients with CKD have been shown to improve 
surrogate markers for CV disease including endothelial function (198, 199) and LVH 
(198). In addition, a single-blinded RCT of 113 patients with CKD has also demonstrated 
that allopurinol use was associated with a slower progression of renal dysfunction and a 
reduction in CV events (200, 201, 306).   
 
Arterial stiffness is thought to be a key initiating factor contributing to the elevated CV 
risk observed in patients with CKD (58). Carotid-femoral PWV is considered to be the 
current ‘gold-standard’ measurement of arterial stiffness (86). Although allopurinol has 
been shown to improve endothelial function, lower central aortic pressure and regress 
LVH in patients with CKD, its effects on cfPWV remain unclear (198). We therefore, 
examined the relationship between allopurinol use and cfPWV in patients with CKD 
recruited into the Renal Impairment In Secondary Care (RIISC) cohort study (307). 
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 Subjects and Methods 2.2
2.2.1 Ethics Statement 
The study was approved by the South Birmingham Local Research Ethics committee 
(reference: 10/H1207/6) and all participants gave informed and written consent. The study 
was conducted in accordance with the Declaration of Helsinki. (Clinical Trials 
Registration Number: NCT01722383; Date of Registration: November 11, 2012). 
 
2.2.2 Study Design and Participants 
The RIISC study is a prospective, observational cohort study of patients with CKD with 
evidence of, or at high risk of, renal disease progression. The inclusion and exclusion 
criteria have previously been reported in detail (307). In brief, patients were included if 
they had stage 3 CKD with a declining MDRD eGFR of ≥5 ml/min/year or ≥10 
ml/min/5years or a uACR ≥70 mg/mmol on three consecutive occasions, or stage 4 or 5 
CKD. GFR was estimated using the four-variable MDRD equation with serum creatinine 
recalibrated to be traceable to an isotope derived mass spectroscopy (IDMS) method  (24). 
Patients with established renal failure receiving dialysis treatment and patients receiving 
immunosuppressive medication were excluded from the study. From October 2010 to 
November 2012, 437 out-patients under regular follow-up were recruited from renal 
clinics at two large teaching hospitals in the United Kingdom.  
 
2.2.3 Baseline Measurements 
Baseline clinical information on participants’ demographics, renal diagnosis, diagnosis of 
DM, CV history, past medication history, family history, concomitant medication, 
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smoking and alcohol consumption history were recorded. Presence of CV disease was 
defined by history or other evidence of angina, previous myocardial infarction, previous 
stroke or transient ischaemic attack, peripheral vascular disease, a previous 
revascularisation procedure or heart failure. Presence of DM was defined as receiving 
treatment for DM or a confirmed clinical diagnosis of diet-controlled DM. Smoking 
history and pack years were determined by participant self-reporting. An allopurinol user 
was defined as a participant who was receiving any dosage of allopurinol on recruitment. 
We contacted the GPs of all allopurinol users to obtain further details on the reason for 
prescription, presence of side effect related to allopurinol in the initial three months of 
treatment and start date of allopurinol to determine the duration of exposure. 
 
Peripheral BP was measured in the dominant arm using a British Hypertension Society 
approved automated oscillometric sphygmomanometer (BPM-100, BpTRU
TM
), which 
obtained a series of six BP readings at 1-minute intervals after 5 minutes of rest (308). 
Mean BpTRU BP was derived from the average of the 2
nd
 to 6
th
 BP readings. Carotid-
femoral PWV was measured non-invasively using the Vicorder system (Skidmore 
Medical, Bristol, UK) as previously described by Pucci et al (309). This is an operator 
independent and highly reproducible technique with low within-subject variation (309). 
After 5 minutes of lying supine, cfPWV measurements were obtained in duplicate; the 
mean of two measurements was used in data analyses. Central pressure waveforms were 
derived and analysed using PWA as previously described (310). The central pressure 
waveform was analysed to determine the augmentation index (AIx) and central aortic 
pressures. AIx represents the difference between the second and first peaks of the central 
pressure waveform in systole, expressed as a percentage of the pulse pressure. Given the 
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known effects of heart rate, AIx was corrected to a heart rate of 75 beats per minute 
(AIx75) (311).  
 
Routine laboratory testing included blood haematological (Beckman Coulter Haematology 
Analyzer) and biochemical profiles as well as uACR (Roche Hitachi 702 Analyser). 
Additional samples were centrifuged and serum was aliquoted and stored at -80
0
C and 
subsequently batch analysed for high sensitivity C-reactive protein (hsCRP) using a 
commercially available assay (SpaPlus assay, Binding Site). Tissue AGE level was 
determined by skin autofluorescence (SAF) using a validated AGE Reader
TM
 (DiagnOptics 
BV, Groningen, The Netherlands). 
 
 Statistical Analysis 2.3
Statistical analysis was performed using SPSS version 19.0 (SPSS Inc, Chicago, IL). 
Numerical values were expressed as mean (standard deviation [SD]) for parametric data or 
median (interquartile range [IQR]) for non-parametric data. Normality of the distribution 
of data was assessed by visual inspection of histogram and normal probability plot (312). 
Non-parametric variables were log transformed prior to analysis to achieve normal 
distribution. If normal distribution was not achieved after transformation, non-parametric 
tests were used. Parametric continuous data were compared using student t-tests and non-
parametric using Mann-Whitney tests. Pearson or Spearman’s bivariate correlation 
analysis was used to examine the relationship between parametric and non-parametric 
numerical variables, respectively. Correlation coefficient factors were expressed as ‘r’ for 
Pearson correlation analyses and ‘rho’ for Spearman’s analysis. Categorical data were 
compared by χ2 tests. As age correlated strongly with arterial stiffness, we divided the 
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studied population into four age quartiles. Two-way analysis of variance (ANOVA) was 
performed to examine the interaction between age and the use of allopurinol as well as 
their individual effect on cfPWV. In addition, multiple linear regression was performed to 
explore the relationship between cfPWV and independent variables. Missing data was 
excluded by cases pairwise during analyses. Statistical significance was defined as a two-
tailed p value <0.05.  
 
 Results 2.4
2.4.1 Baseline Characteristics 
Four hundred and thirty-seven patients were recruited of whom 14 did not have cfPWV 
measured for technical reasons and were therefore excluded from the study. One patient 
who was receiving febuxostat, an alternative xanthine oxidase inhibitor, was also 
excluded. In total, 422 patients were included in the analyses. The numbers of individuals 
at each stage of study are detailed in Figure 2-1. The baseline demographic and 
biochemical characteristics of the study population are shown in Table 2-1. The mean age 
was 63 (SD: 16) years with 60% of male gender and 71% of white ethnicity. Use of 
antihypertensive agents was common and 67% were receiving either an ACEi or ARB. A 
small number (5%) were on both an ACEi and an ARB. There was a high prevalence of 
hyperuricaemia; 84% had a serum uric acid concentration greater than 360 μmol/L. The 
frequencies of different stages of CKD were: stage 1, 0.2%; stage 2, 1%; stage 3a, 5.3%; 
stage 3b, 23.1%; stage 4, 61.7%; stage 5, 8.7%. Seventy-seven patients (18%) were 
receiving regular allopurinol, 61% as a dose of 100 mg/day (range: 50-400 mg/day). 
Haemodynamic parameters are presented in Table 2-2.  
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Figure 2-1: Flow chart of participants included in the study 
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Table 2-1: Baseline demographic, clinical and biochemical characteristics of all 
participants and according to the usage of allopurinol. 
 
 All participants 
(n= 422) 
Allopurinol user       
(n=77) 
 
Non-allopurinol 
user (n=345) 
P Value Number 
missing 
data (%) 
Age (years) 63 ± 16 62 ± 15 64 ± 17 0.31 0 
Male  225 (60%) 59 (77%) 196 (57%) 0.001 0 
Ethnicity    0.006 1 (0.2) 
White 301 (71%) 67 (87%) 234 (67%)   
Asian 64 (15%) 4 (5%) 60 (17%)   
Afro-Caribbean 40 (10%) 3 (4%) 37 (11%)   
Body Mass Index (kg/m
2
) 29.8 ± 6.8 31.8 ± 6.4  29.3 ± 6.8 0.003 9 (2) 
Presence of Diabetes 
Mellitus 
152 (36%) 24 (31%) 128 (37%) 0.33 0 
Presence of CVD 142 (34%) 21 (27%) 121 (35%) 0.19 0 
Current smoker 58(14%) 4 (5%) 54 (16%) 0.02 0 
Ex-smoker 174 (41%) 35 (46%) 139 (40%) 0.41 0 
Smoking pack years *§§  2 (0-22) 0 (0-15) 2 (0-24) 0.25 13 (3) 
Number of antihypertensive 
agents 
2.4 ± 1.3 2.5 ± 1.0 2.4 ± 1.4 0.49 6 (1) 
Use of ACEI/ARB 281 (67%) 55 (71%) 227 (66%) 0.32 0 
Use of thiazide 24 (6%) 1 (1%) 23 (7%) 0.10 0 
Use of Antiplatelet agents 166 (39%) 37 (48%) 129 (37%) 0.08 0 
Use of Statin 247 (59%) 46 (60%) 201 (58%) 0.81 0 
Duration of allopurinol 
exposure (months) 
- 74 ± 54 - - 18 (23) 
Serum creatinine*§ 
(μmol/L) 
213 (169-263) 216 (174-270) 212 (167-263) 0.77 6 (1) 
eGFR*§ ( ml/min/1.73m
2
) 25 (19-31) 26 (21-33) 24 (19-31) 0.24 6 (1) 
Urine ACR*§ (mg/mmol) 35.0 (6.9-163.1) 40.1 (7.4-134.3) 33.8 (6.7- 166.7) 0.70 45 (11) 
Serum uric acid  (μmol/L) 479 ± 121 431 ± 123 489 ± 117 <0.001 8 (2) 
Cholesterol (mmol/L) 4.6 ± 1.2 4.5 ± 1.1 4.7 ± 1.2 0.33 5 (1) 
Corrected calcium 
(mmol/L) 
2.26 ± 0.14 2.25  ± 0.14 2.26 ± 0.14 0.82 10 (2) 
Phosphate*§ (mmol/L) 1.13 (0.99-1.28) 1.10 (1.00-1.23) 1.13 (0.98-1.30) 0.50 7 (1) 
hsCRP*§ (mg/L) 3.280 (1.228-
9.332) 
3.678 (1.215-
9.246) 
3.203 (1.257-
9.332) 
0.92 103 (24) 
SAF (a.u.) 3.0 ± 0.8 2.8 ± 0.7 3.1 ± 0.8 0.02 60 (14) 
 
Data are presented as frequency (percentage), mean ± standard deviation or *median (interquartile range).  
Parametric data was analysed using unpaired two-tailed t-test or Pearson’s χ2unless otherwise specified.  
§Log-transformed prior to analyses.  §§Analysed using Mann-Whiteney U test 
Abbreviations: ACR= albumin creatinine ratio; bpm= beats per minutes; CVD= cardiovascular disease; ACEI= angiotensin converting 
enzyme inhibitor; ARB=Angiotensin II receptor blocker; eGFR= estimate glomerular filtration rate, hsCRP= high sensitivity C-reactive 
protein; SAF= skin autofluorescence. 
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Table 2-2: Haemodynamic parameters of all participants and according to the usage of 
allopurinol. 
 
 All participants 
(n= 422) 
Allopurinol user 
(n=77) 
Non-allopurinol 
user 
(n=345) 
P Value Number 
missing 
data (%) 
Peripheral SBP 
(mmHg) 
129 ± 20 126 ± 22 129 ± 20 0.19 14 (3) 
Peripheral DBP 
(mmHg) 
76 ± 13 76 ± 12 75 ± 13 0.59 14(3) 
Peripheral PP (mmHg) 71 ± 18 67 ± 18 72 ± 17 0.02 16 (4) 
Central SBP (mmHg) 141 ± 20 136 ± 22 142 ± 20 0.02 16 (4) 
Central PP (mmHg) 65 ± 18 61 ± 18 66 ± 17 0.02 16 (4) 
AIx (%) 21 ± 9 20 ± 9 21 ± 9 0.45 12 (3) 
AIx75 (%) 21 ± 9 20 ± 8 21 ± 9 0.35 12 (3) 
Heart Rate (bpm) 69 ± 13 68 ± 15 69 ± 15 0.42 8 (2) 
cfPWV (m/s) 10.2 ± 2.4 9.5 ± 2.3 10.3 ± 2.4 0.006 0 
Abbreviations: AIx: augmentation index; AIx75= augmentation index adjusted to heart rate of 75bpm; bpm= beats per minute; DBP= 
diastolic blood pressure; SBP= systolic blood pressure; PP= pulse pressure; cfPWV= carotid-femoral pulse wave velocity 
 
2.4.2 Use of Allopurinol 
The demographic, clinical and biochemical characteristics of the cohort and a comparison 
between allopurinol users and non-allopurinol users is shown in Table 2-1. There was 
significantly higher proportion of patients of male gender and white ethnicity and a 
significantly lower proportion of patients who were current smokers among allopurinol 
users. Allopurinol users had a higher body mass index (BMI) than non-allopurinol users. 
There was otherwise no significant difference in age, prevalence of DM, prevalence of CV 
disease, percentage of ex-smokers, smoking pack years, total number of antihypertensive 
agents used and use of ACEi or ARB between the groups. Allopurinol users had 
significantly lower serum uric acid concentrations and lower SAF level compared to non-
allopurinol users. Other biochemical variables, including kidney function, albuminuria, 
lipid and bone profiles and hsCRP levels were not different between the groups. 
Allopurinol users had significantly lower peripheral and central pulse pressures (PP), 
central SBP and cfPWV (Table 2). There were no differences in heart rate, peripheral SBP, 
AIx and AIx75 between allopurinol and non-allopurinol users.  
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Among the 77 allopurinol users, details regarding allopurinol prescription were available 
from their primary care physician on 59 patients. Ninety four percent were commenced on 
allopurinol for gout and 6% for asymptomatic hyperuricaemia. Side effects were reported 
in 12% during the first 3 months of allopurinol treatment: 3 had acute gout, 2 had a skin 
rash, 1 had diarrhoea and 1 complained of increased thirst. The mean duration of 
allopurinol use at recruitment was 74 months (SD: 54 months). 
 
2.4.3 Use of Allopurinol and Pulse Wave Velocity 
Univariate correlations with cfPWV are shown in Table 2-3. Although BMI positively 
correlated with serum uric acid level (r=0.178, p<0.001), there was no significant 
correlation between BMI and cfPWV. Uric acid levels, kidney function and hsCRP also 
did not correlate with cfPWV. In participants who were not receiving ACEi or ARB 
(n=141), there was no correlation between uric acid and cfPWV (p=0.66). Six percent of 
participants were receiving a thiazide. Use of thiazide did not correlate with levels of uric 
acid (p=0.58) or cfPWV (p=0.66). 
 
Pulse wave velocity positively correlated with increasing age, white ethnicity, SAF, 
peripheral and central SBP and PP. Ex-smokers and smoking pack years had a significant 
positive correlation with cfPWV whilst current smoking did not. Use of allopurinol (mean 
difference: -0.8 m/s; 95% confidence interval [CI], -0.2 to -1.4 m/s, p=0.006), use of 
ACEi/ARB and Afro-Caribbean ethnicity were also associated with lower cfPWV. Neither 
the dose of allopurinol or duration of use of allopurinol had a significant correlation with 
cfPWV. Fifty-one percent (n=39) of the allopurinol users had a uric acid level below 416 
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µmol/L. Among allopurinol users, there was no difference in cfPWV between those with a 
uric acid below or above this threshold (p=0.92). 
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Table 2-3: Univariate analyses with carotid-femoral pulse wave velocity as the dependent 
outcome variable. 
 Correlation coefficient  
 
P value 
Demographics 
Age (years) 0.534 <0.001 
Gender (Male)  0.088 0.07 
Ethnicity   
White 0.105 0.03 
Asian 0.014 0.77 
Afro-Caribbean -0.105 0.03 
Body Mass Index (kg/m
2
) -0.057 0.25 
Presence of diabetes mellitus 0.082 0.09 
Presence of cardiovascular disease 0.044 0.37 
Current smoker 0.021 0.67 
Ex-smoker 0.198 <0.001 
Smoking Pack Years** 
 
0.244 <0.001 
Haemodynamics 
BpTRU Peripheral SBP (mmHg) 0.320 <0.001 
BpTRU Peripheral DBP (mmHg) -0.061 0.21 
Peripheral PP (mmHg) 0.454 <0.001 
Central SBP (mmHg) 0.440 <0.001 
Central PP (mmHg) 0.442 <0.001 
AIx (%) 0.024 0.63 
AIx75 (%) 
 
0.023 0.64 
Biochemical markers 
Serum creatinine* (μmol/L) 0.039 0.43 
eGFR ( ml/min/1.73m
2
)* -0.078 0.11 
Urine ACR (mg/mmol)* -0.042 0.40 
Serum uric acid  (μmol/L) -0.035 0.48 
Cholesterol (mmol/L) -0.080 0.11 
Corrected calcium (mmol/L) -0.001 0.98 
Phosphate (mmol/L)* 0.019 0.71 
hsCRP (mg/L)* 0.062 0.27 
SAF (a.u.) 
 
0.253 <0.001 
Medications 
Use of allopurinol -0.135 0.006 
Dose of allopurinol (mg) -0.185 0.11 
Duration of allopurinol exposure (months) -0.019 0.89 
Use of ACEI/ARB -0.163 0.001 
Use of thiazide 0.021 0.66 
 
Abbreviations: ACEI= angiotensin converting enzyme inhibitor; ACR= albumin creatinine ratio; AIx: augmentation index; AIx75= 
augmentation index adjusted to heart rate of 75bpm; ARB= angiotensin II receptor blocker; SBP= systolic blood pressure; DBP= 
diastolic blood pressure; PP= pulse pressure; SAF= skin autofluorescence. 
Parametric data was analysed using Pearson correlation unless otherwise specified. 
*Natural Log transformed prior to analyses. 
**Non-parametric data was analysed using Spearman’s bivariate correlation analysis.  
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Two-way ANOVA was used to explore the impact of age and use of allopurinol on 
cfPWV. Participants were divided into quartiles of age (19-50, 51-65, 66-76 and 77-92 
years). Pulse wave velocity increased with age and was significantly lower in non-
allopurinol users (Figure 2-2). There was no interaction between age and use of allopurinol 
(p=0.27). There were significant main effects for both age and use of allopurinol, with age 
having a large effect size (partial eta squared=0.201, p<0.001) and use of allopurinol 
having a small albeit significant effect size (partial eta squared=0.011, p=0.03). 
 
 
Figure 2-2: Differences in pulse wave velocity according to the use of allopurinol and age 
quartiles.  
 
A linear regression model was created with cfPWV as the dependent variable. Variables 
which correlated with cfPWV at a p value <0.1 were included in a standard regression 
model. As there was strong co-linearity among the BP measures, peripheral PP was 
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selected from these parameters for incorporation in the regression model as it had the 
strongest correlation (r=0.45, p<0.001) with cfPWV. Similarly, smoking pack years was 
selected to adjust for the relationship between smoking history and cfPWV in the 
regression model. Preliminary analyses were performed to ensure no violation of the 
assumptions of normality, linearity and multi-collinearity. Factors entered into the model 
were age, gender, ethnicity, smoking pack years, diagnosis of DM, SAF level, peripheral 
PP, use of ACEi/ARB and use of allopurinol. Age, peripheral PP and use of allopurinol 
were significant independent determinants of cfPWV (Table 2-4). In the regression model, 
the use of allopurinol was associated with a mean reduction of cfPWV of 0.63 m/s (95% 
CI, -0.09 to -1.17 m/s, p=0.02). The model explained 35% of the variance in cfPWV. 
Substituting peripheral SBP, central SBP or central PP, for peripheral PP and substituting 
smoking pack years for current or previous smoking status made no appreciable difference 
to the model. 
 
Table 2-4: Multiple regressions with carotid-femoral pulse wave velocity as the dependent 
outcome variable. 
  
 Mean change of PWV  95% CI P value 
Lower bound Upper bound 
Age (/5 years) 0.306 0.225 0.387 <0.001 
Gender (male) 0.423 -0.009 0.856 0.06 
White ethnicity 0.252 -0.296 0.800 0.4 
Afro-caribbean ethnicity 0.552 -0.245 1.350 0.2 
Smoking pack years  0.005 -0.006 0.015 0.4 
Presence of diabetes mellitus 0.163 -0.261 0.586 0.5 
SAF (/1 a.u.) -0.258 -0.559 0.043 0.09 
Peripheral PP (/5 mmHg) 0.186 0.121 0.251 <0.001 
Use of ACEI/ARB -0.136 -0.579 0.307 0.5 
Use of allopurinol -0.633 -1.174 -0.092 0.02 
 
Adjusted R2 for model= 0.348, p<0.001. 
Abbreviations: ACEI= angiotensin converting enzyme inhibitor; ARB= angiotensin II receptor blocker; CI= confidence interval; PP= 
pulse pressure, PWV= pulse wave velocity; SAF= skin autofluorescence. 
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 Discussion 2.5
This observational study in a prospectively recruited CKD cohort suggests that the use of 
allopurinol was associated with reduced arterial stiffness as measured by cfPWV, the 
current gold-standard measurement of arterial stiffness (86); this association was 
independent of age and BP. Arterial stiffness, which is a hallmark of CKD, is a well-
recognised, powerful prognostic marker of CV morbidity and mortality in both the general 
and CKD population (58, 103, 107). Increased arterial stiffness results in higher systolic 
pressures, greater pressure fluctuations and leads to ventricular-arterial uncoupling, 
myocardial hypertrophy and fibrosis. Alterations in the extracellular matrix and endothelial 
dysfunction promoted by chronic inflammation, increase oxidative stress and accumulation 
of advanced glycation end products, vascular calcification, and activation of RAAS have 
been postulated to contribute to increased arterial stiffness (58, 313).  
 
Allopurinol, a xanthine oxidase inhibitor, is commonly prescribed for patients with gout as 
a uric acid lowering agent. During the catalytic reaction that produces uric acid, xanthine 
oxidase generates ROS, which may contribute to the development of endothelial 
dysfunction, hypertension and vascular damage (314). Accumulating evidence from 
interventional studies indicates that allopurinol improves endothelial dysfunction (198, 
203), lowers LV mass (198), and may slow progression of CKD and lower CV risk (201). 
The results of this current study suggest that some of the beneficial effect of allopurinol 
may occur through reducing arterial stiffness.  
 
Even among allopurinol users, there was a high prevalence of hyperuricaemia. Although 
several large observational studies have reported a strong association between 
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hyperuricaemia and CV morbidity or mortality, the evidence for hyperuricaemia as a risk 
factor or risk marker of CVD is conflicting (315-323). Despite a significant association 
between allopurinol use and cfPWV, we found no significant direct association between 
serum uric acid levels and cfPWV. In a small group of patients with chronic heart failure, 
George et al demonstrated that the mechanism of improvement in endothelial function 
with allopurinol was attributable to reduced oxidative stress and not to uric acid reduction 
(203). CKD is known to be associated with increased oxidative stress and acute-phase 
inflammation, which may both contribute to increased CV risk (324). We found no 
significant difference in the levels of hsCRP between allopurinol users and non-allopurinol 
users, suggesting that inflammation was not a prominent mechanism in this association. 
Advanced glycation end-products (AGE) have a bi-directional relationship with oxidative 
stress, including studies showing that increased oxidative stress is associated with 
formation and accumulation of AGE (325-329). Level of tissue AGE as measured by SAF, 
which positively correlated with arterial stiffness, was found to be significantly lower in 
the allopurinol users when compared to non-allopurinol users, indicating that this 
biological pathway may be relevant to the link between allopurinol use and cfPWV 
described here. 
 
As arterial stiffness and BP are closely related, it is possible that the effect of allopurinol 
on arterial stiffness may be mediated through improved BP. A recent meta-analysis 
showed that allopurinol is associated with a small but significant reduction in BP (330). 
Several hypotheses have been postulated to explain this apparent association. The 
antioxidant effect of allopurinol was considered to play a major role in improving 
endothelial function and BP regulation (330). Nonetheless, there was no clear consensus 
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to-date regarding the effects of oral antioxidant on arterial BP. While some demonstrated 
BP lowering effect of antioxidant vitamins (331, 332), others did not (333-336) and one 
study showed paradoxical blunting of exercise training-induced improvement in 
endothelial function with antioxidant administration (337). In addition to its antioxidant 
property, there is emerging evidence that allopurinol can block the deleterious CV effect of 
angiotensin II (338-340). In this current study we found a significant difference in both 
peripheral and central BP between allopurinol users and non-allopurinol users, despite a 
comparable prevalence of ACEi/ARB use and total numbers of anti-hypertensive agents 
between groups. However, after adjustment in a multivariate analysis, the use of 
allopurinol remained significantly associated with arterial stiffness. This suggests an 
independent association between the use of allopurinol and lower vascular stiffness. This 
observation is supported by an RCT of 66 patients with mild to moderate hypertension 
which reported a favourable effect of allopurinol on aortic compliance, independent of 
ACEi or thiazide-based antihypertensive therapy (341).  
 
 Limitations 2.6
There were a number of limitations in this study. Due to the observational, cross-sectional 
nature of the study, the association between allopurinol use and lower arterial stiffness 
reported here does not prove causality.  
 
Although there were unequal distributions of gender, ethnic, BMI, current smoking status 
and differences in serum uric acid between the groups, these are unlikely to have resulted 
in bias. Male gender was associated with higher cfPWV, however despite a higher 
proportion of males amongst allopurinol users, use of allopurinol remained associated with 
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a lower cfPWV. In addition, people of African-Caribbean ethnicity had a lower cfPWV; 
most of the African-Caribbean participants were non-allopurinol users. The unequal 
distribution of gender and ethnicity between the groups was therefore unlikely to have 
resulted in bias against non-allopurinol use. As the number of non-white participants was 
small, we were unable to confidently examine the influence of allopurinol in different 
ethnic groups; this should be an area for future study. Although there were differences in 
BMI and serum uric acid level between the groups, there parameters did not have a 
significant bivariate association with cfPWV; hence, they were unlikely to confound the 
findings. Smoking history is known to have significant influence on arterial stiffness and 
there were a higher proportion of current smokers in the allopurinol non-user group. In 
addition, the comparatively lower peripheral and central pressures in the allopurinol user 
group might have contributed to lower cfPWV as BP is a strong determinant of arterial 
stiffness. However, after adjusted for haemodynamic parameters and smoking history in 
the regression model, use of allopurinol remained associated with lower cfPWV.  
 
Although all available confounding variables were included in this study, there may be 
other potential unknown confounders as the biology of vascular disease in CKD is 
complex. The measurement of hsCRP was performed only at single time-point rather than 
the two time-points two weeks apart recommended by the American Heart Association 
(342). We did not have measurements of endothelial dysfunction, which is closely linked 
to arterial stiffness and CKD (58). Finally, encouraging results have been reported on an 
effect of allopurinol in improving renal function in patients with asymptomatic 
hyperuricaemia (343) or delaying disease progression in patients with CKD (201, 344). 
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However, due to the cross-sectional nature of the data we were unable to examine this 
relationship.  
 
This cross-sectional study did not demonstrate statistically significant association between 
PWV and levels of renal function. Though majority of the studies to date have reported a 
direct linear, negative relationship between GFR and arterial stiffness (65, 77, 80), 
McIntyre et al similarly did not find eGFR as an independent determinant of arterial 
stiffness in the cross-sectional study of 1,717 patients with CKD stage 3 but concluded age 
and traditional CV risk factors as the strongest determinants (345). The unique inclusion 
criteria of RIISC study might provide much explanation to such finding. As stated in 
section 2.2.2., the RIISC study enrolled patients with CKD stage 3-5, however, those with 
CKD stage 3 would only be included if they were deemed to be at high risk of renal 
disease progression, which was defined as those with a declining MDRD eGFR of ≥5 
ml/min/year or ≥10 ml/min/5years or a uACR ≥70 mg/mmol on three consecutive 
occasions. As urinary albumin excretion has been shown to be independently associated 
with greater arterial stiffness (83), such unique selection of patients with CKD stage 3 
most possibly have affected and confounded the association between arterial stiffness and 
eGFR in this study population.  
 
 Conclusion 2.7
In summary, the data shown here suggests that allopurinol is independently associated with 
lower arterial stiffness in patients with progressive CKD. This adds to the accumulating 
evidence of the favourable effect of allopurinol on CV outcomes in a well-defined CKD 
cohort and indicates one mechanism by which this may occur. This study provides further 
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justification for a large definitive RCT examining the therapeutic potential of allopurinol 
to reduce CV risk in people with CKD. 
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CHAPTER 3 SYSTEMATIC REVIEW AND META-
ANALYSIS OF THE CARDIOVASCULAR EFFECTS 
OF MINERALOCORTICOID RECEPTOR 
ANTAGONISTS IN PATIENTS WITH CHRONIC 
KIDNEY DISEASE 
 
 Introduction 3.1
The importance of the RAAS in the progression of renal disease and in the development of 
CV disease amongst the CKD population is widely recognised (227, 346). The renal and 
CV benefits of inhibition of the RAAS have been demonstrated in multiple large trials of 
ACEi and ARB, largely attributed to the prevention of the multiple adverse effects of 
angiotensin II (347).  
 
Strong evidence suggests that ACEi and ARB drugs do not effectively inhibit aldosterone 
production in all patients and that aldosterone may also be a mediator of renal and CV 
damage in patients with CKD (227). Mineralocorticoid receptors (MR) are present in the 
brain, heart and blood vessels as well as the kidney, and there is evidence of aldosterone 
production within these tissues (348). Local MR activation by aldosterone causes 
numerous pathological effects on the CV system including endothelial injury, 
inflammation, oxidative stress and fibrosis in the heart and vasculature, as well as the 
development of hypertension and autonomic dysfunction (58, 348). This evidence has led 
to the suggestion that potentially someday all renal patients with be on an MRA as a “renal 
aspirin” (349).  
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However, there is still a reluctance to use these agents in patients with CKD particularly 
because of the risk of further deterioration in renal function and the risk of dangerous 
hyperkalaemia (347). Although the effects of MRA on proteinuria have been the subject of 
recent meta-analyses, the potential benefits of MRA on CV parameters and mortality in 
patients with CKD are not clear (245, 246). This systematic review therefore examined the 
actions of MRA on surrogate markers of CV disease as well as major patient level CV 
end-points in patients with CKD.  
 
 Methods 3.2
This systematic review and meta-analysis was performed in accordance with the PRISMA 
statement (350). The protocol and detailed methodology for this systematic review was 
registered with the International Prospective Register of Systematic Reviews 
(PROSPERO; CRD42013006795) (351). The following electronic databases and trial 
registers were searched from their conception to September 2013: MEDLINE, EMBASE, 
Trip Database, Cochrane Central Register of Controlled Trials (CENTRAL), Cochrane 
Renal Group specialised register, Current Controlled Trials and ClinicalTrials.gov. 
References of included articles and relevant review articles were hand-searched. Search 
terms including both medical subject headings (MeSH) and their derivatives: 
mineralocorticoid receptor antagonist, spironolactone, eplerenone, chronic kidney disease, 
and chronic renal failure. All searches were limited to human studies.  
 
3.2.1 Type of Studies 
All fully published RCTs examining the CV effects of both spironolactone and eplerenone 
in patients with CKD were included. Cohort studies, case series and case reports were 
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excluded from the review owing to the high potential for bias in these study designs. 
Crossover studies were included provided there was evidence of a washout period and/or 
exclusion of a carry-over effect. All analyses were repeated excluding crossover studies. 
There was no language restriction. 
 
3.2.2 Types of Participants 
Studies enrolling adult participants, with CKD stages 1-5, as defined by the KDOQI 
guidelines, including dialysis patients and kidney transplant recipients (352).  
 
3.2.3 Types of Interventions 
The review included studies of both non-selective (spironolactone) and selective 
(eplerenone) MRAs with or without concomitant use of ACEi and/or ARB given for at 
least 4 weeks. 
 
3.2.4 Types of Outcome Measures 
Data on the effects of MRA on the following outcome measures were examined: systolic 
and diastolic BP; parameters of arterial stiffness including PWV; endothelial function and 
oxidative stress; carotid intima-media thickness (CIMT); LV ejection function; LV mass; 
CV morbidity and mortality; hyperkalaemia (serum potassium> 5.5 mmol/L); decline in 
renal function and other adverse events including gynecomastia. 
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3.2.5 Data Collection 
The selection of relevant articles was performed in stages. The initial literature search, 
which broadly applied the inclusion criteria using the search strategy or search terms, was 
performed to identify any potentially relevant articles. Two reviewers (Dr Charles Ferro 
and the author) independently screened retrieved articles and discarded studies that did not 
meet the inclusion criteria. Studies and reviews that might include relevant data or 
information on trials were retained initially. Duplicates studies were removed. Both 
reviewers further reviewed the eligibility of the selected studies in abstract form, or if 
appropriate, in full text, independently by assessing if the inclusion criteria and outcome 
measures were met. The reasons for excluding studies were documented. The selected and 
excluded articles between the two reviewers were compared. Disagreements regarding 
article selection, data extraction and quality assessment were discussed between reviewers 
until consensus on inclusion was reached or by consultation with a third party (Dr Adnan 
Sharif).  
 
Further data extraction of the eligible studies was carried out by the two reviewers 
independently. Information regarding trial design, patients’ characteristics (age, 
comorbidities, CKD stages), intervention drugs, dosage, treatment duration, co-
intervention, follow-up duration, withdrawal rates and type of outcome measures were 
recorded on a standard collection form (see Appendix 3-1). Non-English articles were 
translated into English before data extraction. In the case of multiple publications of the 
same trial, with different data sets, all outcomes and results were grouped together and 
single data extraction was performed on the most complete dataset.   
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3.2.6 Study Quality 
The risk of bias assessment tool developed by Cochrane Renal Group (353) was applied to 
each study. The reviewers independently assessed the quality of each included study on 
selection bias (sequence generation, allocation concealment), detection bias (personnel and 
participant, outcome assessors), attrition bias (incomplete outcome data), reporting bias 
(selective outcome reporting) and other potential biases (Appendix 3-2). Disputes were 
settled by discussion with a third party (Dr Adnan Sharif).  
 
3.2.7 Statistical Assessment  
Meta-analysis was conducted to generate pooled estimates of the outcomes using RevMan 
5.2 software (©2012, The Cochrane Collaboration, UK). Data were pooled and a random 
effect model was used as summary effect measure. Relative risk ratio or weighted mean 
difference with accompanying 95% CI were used to report individual and summary effect 
measures for dichotomous or continuous data, respectively. χ2 tests for heterogeneity were 
performed to examine if the degrees of freedom were greater than the Cochran Q statistic, 
with α of above 0.05 as statistical significance. In addition, we also calculated the I2 
statistic to provide the estimated percentage of heterogeneity observed. I
2
 values of 25%, 
50% and 75% corresponded to low, medium and high levels of heterogeneity. Any 
heterogeneity was further explored. When appropriate, subgroups of different MRAs 
(selective or non-selective), comparator (active or placebo/standard treatment) and 
concomitant ACEi and/or ARB were analysed. A two-sided p-value of <0.05 was 
considered significant for all analyses. 
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 Results 3.3
3.3.1 Search Results 
A total of 2,823 articles were identified, of which 66 articles met the general inclusion 
criteria. Full-text assessment of these articles identified 29 eligible studies (31 articles) 
(140, 248, 249, 354-381) (Table 3-1), enrolling a total of 1,581 patient for qualitative 
synthesis and 28 eligible studies enrolling a total of 1,548 patient for meta-analysis (Figure 
3-1). 
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Figure 3-1: Study flow diagram of the systematic review and meta-analysis of the 
cardiovascular effects of mineralocorticoid antagonist in patients with chronic kidney 
disease 
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Table 3-1: Characteristics of the populations and interventions of the included trials 
 
Study Type of study Study population Intervention(s) Also on 
ACEi/ARB 
No. of 
patients 
Study 
duration 
(weeks) 
Outcomes measured 
(Underlined parameters 
represent primary outcome) 
Abolghasmi et 
al, 2011 (354) 
RCT, double-
blinded, 
parallel. 
 
CKD (eGFR 25-50 ml/min) 
with resistant hypertension 
Spironolactone 25- 50 mg/d vs. 
Placebo 
Yes 41 
 
12 BP, serum K
+
, creatinine, serum 
and urinary Na
+ 
Bianchi et al, 
2006 (355) 
RCT, open-
label, parallel. 
 
 
 
Non-diabetic CKD 
(eGFR 34-116 ml/min) and 
proteinuria (1.0-3.9 g/g 
creatinine) 
Spironolactone 25 mg/d 
 
 
Yes 165 52 BP, serum K
+
, creatinine, 
proteinuria, eGFR 
Boesby et al, 
2011 (356) 
RCT, open-
label, cross-
over. 
 
 
Non-diabetic CKD (CrCl 
24-195 ml/min) with 
proteinuria >500 mg/d or 
albuminuria >300mg/d 
Eplerenone 25-50 mg/d No 42 8 BP, serum K
+
, creatinine, 
albuminuria 
Boesby et al, 
2013 (357) 
RCT, open-
label, parallel. 
 
 
CKD stage 3-4 with BP 
>130/80 mmHg or use of 
anti-hypertensive. 
Eplerenone 25-50 mg/d No 54 24 cfPWV, AIx, ambulatory arterial 
stiffness index, BP, serum K
+
, 
creatinine, proteinuria, eGFR 
Chrysostomou 
et al, 2006 
(358) 
RCT, double-
blinded 
followed by 
open-label, 
parallel. 
 
 
 
CKD with creatinine < 200 
µmol/L but proteinuria > 
1.5g/d 
Ramipril 5mg/d vs. Ramipril 
5mg/d + Irbesartan 150mg/d vs. 
Ramipril 5mg/d + Spironolactone 
25mg/d vs. 
 Ramipril 5mg/d + Irbesartan 
150mg/d + Spironolactone 
25mg/d 
Yes 41 52 Proteinuria, BP, eGFR 
Edwards et al, 
2009, 2010, 
2012 (140, 
248, 249) 
 
RCT, double-
blinded, 
parallel. 
 
 
 
 
Non-diabetic CKD stage 2-
3 
Spironolactone 25mg/d Yes 112 40 24 hour ambulatory BP, cfPWV, 
PWA, LV mass, LV function, 
serum K
+
, creatinine, albuminuria, 
eGFR, N-terminal-pro-B-type 
natriuretic peptide, aminoterminal 
propeptide of type III procollagen 
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Study Type of study Study population Intervention(s) Also on 
ACEi/ARB 
No. of 
patients 
Study 
duration 
(weeks) 
Outcomes measured 
(Underlined parameters 
represent primary outcome) 
Epstein et al, 
2006 (359) 
RCT, double-
blinded, 
parallel. 
Type 2 DM with 
albuminuria (uACR ≥ 
50mg/g) and CrCl > 70 
ml/min 
Enalapril 20mg/d vs. Enalapril 
20mg/d + Eplerenone 50mg/d vs. 
Enalapril 20mg/d + Eplerenone 
100mg/d 
 
Yes 268 12 Albuminuria, incidence of 
hyperkalaemia, BP, eGFR 
Esteghamati et 
al, 2013 (360) 
RCT, open-
label, parallel. 
 
 
DM with uACR ≥ 30 mg/d 
and eGFR>30 
ml/min/1.73m
2 
Spironolactone 25mg/d + ARB 
vs.ACEi+ ARB 
Yes 136 78 BP, albuminuria, serum creatinine, 
K
+
, eGFR 
Furumatsu et 
al, 2008  (361) 
RCT, open-
label, parallel. 
 
 
 
 
 
Non-DM CKD with 
persistent proteinuria (>0.5 
g/d), serum creatinine <3.0 
mg/dl (or CrCl > 30 
ml/min), BP < 130/80 
mmHg 
Spironolactone 25mg/d + 
Enalapril 5mg + Losartan 50mg/d 
vs. Trichlormethiazide 1mg/d (if 
Cr<1.8 mg/dl) or Furosemide (if 
Cr<1.8 mg/dl + Enalapril 5mg + 
Losartan 50mg/d 
Yes 32 12 BP, serum K
+
, creatinine, PAI-1, 
PRA, AII, PAC, proteinuria and 
urinary Type IV collagen 
Guney et al, 
2009 (362) 
RCT, parallel. 
 
 
 
 
Non-DM CKD stage 1-3, 
BP <130/80 mmHg and 
persistent proteinuria (> 0.5 
mg/mg). 
Spironolactone 25mg/d; Yes 24 26 BP, serum K
+
, creatinine, PAC, 
proteinuria and urinary TGF-β1 
Hase et al, 
2013 (363) 
RCT, open-
label, parallel. 
 
 
 
T2DM with uACR ≥ 
100mg/g, 
*creatinine ≥ 2mg/dl 
excluded 
Spironolactone 25mg/d vs. 
Trichlormethiazide 2mg/d 
Yes 36 24 BP, serum K
+
, creatinine, 
albuminuria 
Joffe et al, 
2007 (364) 
RCT, double-
blinded, cross-
over. 
 
 
 
DM with albuminuria 
(uACR ≥ 30 mg/g) and 
Creatinine < 1.5 mg/dl 
Eplerenone 50mg/d vs. 
Hydrochlorothiazide 12.5mg/d + 
potassium 10mEq/d 
Yes 16 6 BP, serum K
+
, creatinine, 
proteinuria, adenosine-stimulated 
myocardial perfusion reserve, 
brachial artery reactivity, 
peripheral arterial tonometry 
Lizakowski et 
al, 2013 (365) 
RCT, double-
blinded, cross-
over. 
Non-DM CKD stage 1-3, 
proteinuria > 500mg/d 
 
Eplerenone 50mg/d + 
Telmisartan 80mg/d vs. 
Aliskerin 300mg/d + Telmisartan 
80mg/d vs.Telmisartan 160mg/d; 
Yes 18 8 24 hour ambulatory BP, serum K
+
, 
creatinine, eGFR, urinary TGF-β1, 
plasma concentration of prorenin 
and renin 
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Study Type of study Study population Intervention(s) Also on 
ACEi/ARB 
No. of 
patients 
Study 
duration 
(weeks) 
Outcomes measured 
(Underlined parameters 
represent primary outcome) 
Matsumoto et 
al, 2006 (366) 
RCT (2:1 ratio), 
parallel. 
 
 
 
DM nephropathy with UAE 
> 30 mg/g 
*creatinine > 1mg/dl 
excluded 
Spironolactone 50mg/d; 
Amlodipine 2.5mg/d 
No 33 12 BP, serum K
+
, creatinine, serum 
adiponectin, visfatin, TNF-α, 
plasma PAI-1, hsCRP, sCD40L, 
BNP 
Mehdi et al, 
2009 (367) 
RCT, double-
blinded, 
parallel. 
 
DM nephropathy with 
uACR ≥ 300mg/g and 
hypertensive. 
Spironolactone 25mg/d vs. 
Losartan 100mg/d vs. Placebo 
Yes 80 48 Ambulatory BP, serum K
+
, 
creatinine, albuminuria, HbA1c 
Meiracker, et 
al, 2006 (368) 
RCT, double-
blinded, 
parallel. 
 
DM with uACR > 
20mg/mmol and creatinine 
<265 µmol/L 
Spironolactone 25-50mg/d vs. 
Placebo 
Yes 59 52 BP, serum K
+
, creatinine, 
proteinuria, HbA1c 
Morales et al, 
2009 (369) 
RCT, open-
label, cross-
over. 
 
 
Obesity (BMI > 30 kg/m
2
) 
with proteinuria > 0.5g/d. 
Eplerenone 25 mg/d vs. 
Lisinopril 10 mg/d + Candesartan 
16mg/d vs.  
Lisinopril 20mg/d 
Yes 12 6 BP, serum K
+
, creatinine, 
proteinuria, plasma renin and 
aldosterone level 
 
Nielsen et al, 
2012 (370) 
RCT, double-
blind, cross-
over. 
 
 
Type 1 DM with 
microalbuminuria (30-300 
mg/d) 
Spironolactone 25 mg/d; 
Placebo 
Yes 21 8 24 hour BP, serum K
+
, creatinine, 
eGFR; albuminuria, markers of 
tubular damage (urinary LFABP, 
NGAL, KIM1) 
Nielsen et al, 
2013 (371) 
RCT, double-
blinded, cross-
over. 
 
 
Type 1 or type 2 DM with 
micro- or macroalbuminuria 
Spironolactone 25 mg/d; 
Placebo 
Yes 69 
 
8 Inflammatory markers, endothelial 
dysfunction (sE-selectin, s-ICMI, 
s-VCAMI, VWF, p-selectin, s-
thrombomodulin) and NT-proBNP 
Rossing et al, 
2005 (372) 
RCT, double-
blinded, cross-
over. 
 
 
Type 2 DM nephropathy 
with albuminuria > 300 
mg/d and GFR> 30 
ml/min/1.73m
2
 
Spironolactone 25 mg/d; 
Placebo 
Yes 21 8 24-hour ambulatory BP, serum 
K
+
, eGFR, albuminuria 
Saklayen et al, 
2008 (373) 
RCT, double-
blinded, cross-
over. 
DM nephropathy with 
creatinine < 2mg/dl and K
+ 
< 5.0 mEq/L 
Spironolactone 25-50 mg/d; 
Placebo 
Yes 30 12 24-hour ambulatory BP, serum 
K
+
, eGFR, proteinuria 
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Study Type of study Study population Intervention(s) Also on 
ACEi/ARB 
No. of 
patients 
Study 
duration 
(weeks) 
Outcomes measured 
(Underlined parameters 
represent primary outcome) 
        
Schjoedt et al, 
2005 (374) 
RCT, double-
blinded, cross-
over. 
Type 1 DM with  
albuminuria >300 mg/d and 
GFR > 30 ml/min/1.73m
2
 
and K
+ 
< 4.5 mmol/L 
 
Spironolactone 25 mg/d vs. 
Placebo 
Yes 22 8 24-hour ambulatory BP, serum 
K
+
, eGFR, HbA1c, albuminuria, 
plasma renin and aldosterone 
levels 
Taheri et al, 
2009 (375) 
RCT, double-
blinded, 
parallel. 
 
Haemodialysis with heart 
failure (NYHA III-IV) and 
EF ≤ 45% 
Spironolactone 25 mg thrice 
weekly post-dialysis vs. Placebo 
Yes 16 24 Serum K
+
, EF and LV mass 
Taheri et al, 
2012 (376) 
RCT, double-
blinded, 
parallel. 
 
CAPD with heart failure 
(NYHA III-IV and EF ≤ 
45%) with K
+
 < 5.5 mEq/l 
Spironolactone 25 mg alternate 
days vs. Placebo 
Yes 18 24 Serum K
+
 and EF 
Takebayashi 
et al, 2006 
(377) 
RCT (5:3 ratio), 
parallel 
 
 
Type 2 DM nephropathy 
with UAE > 30 mg/g 
creatinine. 
Spironolactone 50 mg/d; 
Amlodipine 2.5 mg/d 
No 40 12 Urinary 8-iso-prostaglandin F2α, 
urinary MCP-1 and albuminuria 
Tylicki et al, 
2008 (378) 
RCT, open-
label, cross-
over. 
 
Non-DM CKD, proteinuria 
> 0.3 g/d and GFR > 45 
ml/min 
Spironolactone 25 mg/d; 
None 
Yes 18 8 24-hour ambulatory BP, serum 
K
+
, creatinine, eGFR, proteinuria, 
PRA, urinary NAG, α1m, PIIINP 
Vukusich et 
al, 2010 (379) 
RCT, double-
blinded, parallel 
 
 
Non-DM HD with no 
residual renal functionand 
K
+ 
< 6 mEq/L 
Spironolactone 50 mg thrice 
weekly post-HD vs. Placebo 
No 66 104 BP, serum K
+
, CIMT 
Zheng et al, 
2011 (380) 
RCT, parallel. 
 
 
 
DM, albuminuria > 300 
mg/d and creatinine < 1.7 
mg/dl 
Spironolactone 20 mg/d + 
Benazepril 10mg/d vs. Benazepril 
10mg/d 
Yes 40 12 Serum K
+
, creatinine, proteinuria, 
Ziaee et al, 
2013 (381) 
RCT, parallel. Type 2 DM with 
microalbuminuria, 
creatinine < 2 mg/dl and K
+
 
< 5.5 mmol/l 
Spironolactone 25 mg/d + 
Enalapril 25 mg b.d. vs. 
Enalapril 25 mg b.d. 
Yes 51 12 BP, serum K
+
, creatinine, GFR, 
albuminuria, 
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Abbreviation: AII= angiotensin II; ACEi= angiotensin converting enzyme inhibitor; AIx= augmentation index; ARB= angiotensin II receptor blocker; α1m= α1-microglobulin; b.d.= twice daily; 
BMI= body mass index; BNP= B-type natriuretic protein; BP= blood pressure; CAPD= patients on continuous ambulatory peritoneal dialysis; cfPWV= carotid-femoral pulse wave velocity; 
CKD= chronic kidney disease; CMR= cardiovascular magnetic resonance; Cr= serum creatinine; CrCl = creatinine clearance; DM= diabetes mellitus; EF= ejection fraction; eGFR= estimated 
glomerular filtration rate; GN= glomerulonephritis; HbA1c = haemoglobin A1c; HD= patients on haemodialysis; hsCRP= high sensitivity c-reactive protein; K
+= potassium; KIM-1= kidney 
injury molecule 1; LFABP= liver-type datty-acid binding protein; LV= left ventricular; LVMI= left ventricular mass index; MCP-1=  monocyte chemoattractant protein 1; Na+= sodium; NAG = 
N-acetyl-β-D-glucosaminidase; NGAL= neutrophil gelatinase associated lipocalin; NT-proBNP= N-terminal-pro brain natriuretic peptide; NYHA= New York Heart association; PAC= plasma 
aldosterone concentration PAI-1= plasminogen activator inhibitor-1; PIIINP = amino-terminal propeptide of type III procollagen; PRA= plasma renin activity; pt= participants; PWA= pulse 
wave analysis; RCT= randomised controlled trial, SBP= systolic blood pressure; sE-selectin= soluble E-selectin; s-ICMI= soluble-intercellular adhesion molecule; s-VCAMI= soluble vascular 
cell adhesion molecule I; TNF-α = tumour necrosis factor alfa; uACR= urine albumin:creatinine ratio; UAE= urine albumin excretion; VWF= von Willebrand factor
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3.3.2 Trial Characteristics 
The characteristics of included studies are detailed in Table 3-1. Ten were crossover studies. 
One study examined patients on peritoneal dialysis (376), two studies examined patients on 
haemodialysis (375, 379) and the remaining studies examined patients with CKD. All but two 
of these studies (354, 356) excluded patients with advanced CKD (eGFR<30 ml/min/1.73m
2
). 
Even for the two studies which included patients with advance CKD, it was not clear how 
many patients with such level of renal function were actually recruited. This review did not 
identify any eligible study involving renal transplant recipients. Spironolactone was used in 
23 studies and eplerenone in six. Active comparator arms involving the use of additional 
antihypertensive agents were noted in 13 studies with the rest involving MRA treatment being 
compared against placebo or standard care. Concomitant use of ACEi and/or ARB was 
reported in 24 studies. Study duration ranged from 8 to 104 weeks and study population 
ranged from 12 to 268 participants. None of the studies were powered to detect hard primary 
outcomes. Proteinuria or albuminuria was the primary outcome in 17 of the studies with CV 
outcomes as secondary end-points. Risks of bias in the included studies are shown in 
Appendix 3-3. Most of the studies did not report enough information for adequate assessment 
of risk on most of the parameters assessed. 
 
3.3.3 Effects of Interventions 
3.3.3.1 End of treatment blood pressure 
Twenty-one studies reported data on BP suitable for analysis. Three protocols required the use 
of additional antihypertensive agents to be initiated during the study in order to achieve a BP 
<130/80 mmHg in both the intervention and control arms (359, 364, 378) and were therefore 
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excluded from the analyses leaving 18 RCTs with 1,129 patients. Spironolactone was used in 
16 studies and eplerenone in two.  
 
Overall, there was a significant reduction of SBP with MRA (-5.24, 95% CI: -8.65, -1.82 
mmHg, p=0.003; Figure 3-2) although there was high heterogeneity (χ2=90.03, p<0.001; 
I
2
=80%). Exclusion of the only study examining the effects of MRA in patients with CKD 
and resistant hypertension (354) resulted in a small change in treatment effect (-3.56, 95% CI: 
-5.30, -1.83 mmHg, p<0.001) but reduced the heterogeneity (χ2=20.74, p=0.2; I2=18%). 
Exclusion of crossover studies made little difference (-3.56, 95% CI: -5.85, -1.27 mmHg, 
p=0.002) with low-medium heterogeneity (χ2=18.61, p=0.1; I2=36%). Overall, MRA lowered 
SBP (-3.31, 95% CI: -4.78, -1.84 mmHg; p<0.001) versus placebo with low heterogeneity 
(χ2=8.06, p=0.6; I2=0%) but not when compared with another anti-hypertensive agent (-3.77, 
95% CI: -8.25, 0.71 mmHg, p=0.1) although this analysis had moderate heterogeneity 
(χ2=12.66, p=0.05; I2=53%). 
 
Spironolactone reduced SBP (-3.56, 95% CI: -5.61, -1.51 mmHg, p<0.001) with low 
heterogeneity (χ2=20.29, p=0.2; I2=26%); it was more effective than placebo (-3.23, 95% CI: -
5.19, -1.28 mmHg, p=0.001; I
2
=6%) and active comparators (-3.64, 95% CI: -6.36, -0.91 
mmHg, p=0.009; I
2
=38%). Analysis of the two studies using eplerenone suggested a SBP-
lowering effect but this failed to achieve statistical significance (-3.77, 95% CI: -7.83, 0.29 
mmHg, p=0.07; I
2
=0%). 
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Abbreviation: MRA: mineralocorticoid receptor antagonist; CI: confidence interval; IV: inverse variance. 
Figure 3-2: Effect of mineralocorticoid receptor antagonists on systolic blood pressure. 
 
Similar results were noted with respect to DBP (Figure 3-3). Overall, there was a significant 
reduction of DBP (-1.96, 95% CI: -3.22, -0.69 mmHg, p=0.002) although there was moderate 
heterogeneity (χ2=31.43, p=0.03; I2=43).  Heterogeneity was significantly reduced (χ2=15.02, 
p=0.6; I
2
=0%) by the exclusion of the only study on patients with resistant hypertension (354) 
with only a small change on the treatment effect (-1.42, 95% CI: -2.29, -0.55 mmHg, 
p=0.001). Further exclusion of crossover studies made little difference (-1.37, 95% CI: -2.44, 
-0.30 mmHg, p=0.01) with low heterogeneity (χ2=13.04, p=0.4; I2=8%). Against placebo, 
MRA lowered DBP (-1.62, 95% CI: -2.73, -0.51 mmHg, p=0.004; χ2=5.05, p=0.9; I2=0%) but 
not when compared with another anti-hypertensive agent (-0.84, 95% CI: -3.07, 1.40 mmHg, 
p=0.4; χ2=10.21, p=0.1; I2=41%). 
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Spironolactone reduced DBP (-1.33, 95% CI: -2.23, -0.43 mmHg, p=0.004; I
2
=0%); it was 
more effective than placebo (-1.39, 95% CI: -2.53, -0.26 mmHg, p=0.02; χ2=3.88, p=0.9; 
I
2
=0%) but not more effective than an active comparator (-0.58, 95% CI: -3.00, 1.87 mmHg: 
p=0.5; χ2=9.77, p=0.08; I2=41%). Analysis of the two studies using eplerenone suggested a 
non-significant DBP-lowering effect (-2.73, 95% CI: -6.14, 0.68 mmHg, p=0.1; χ2=0.31, 
p=0.6; I
2
=0%). 
 
Abbreviation: MRA: mineralocorticoid receptor antagonist; CI: confidence interval; IV: inverse variance. 
Figure 3-3: Effect of mineralocorticoid receptor antagonists on diastolic blood pressure. 
 
3.3.4 Arterial Stiffness 
Two studies examined PWV as the primary outcome (140, 357). In a randomised, open-label 
study of 46 patients with CKD stage 3-4, 24-weeks of treatment with eplerenone did not 
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significantly reduce PWV or BP (357). Nonetheless, in a larger, double-blinded, placebo-
controlled RCT of 112 patients with CKD Stages 2-3, treatment with spironolactone for 40 
weeks significantly reduced PWV (-0.8 ± 1.0 vs. -0.1 ± 0.9 m/s, p<0.01) and increased aortic 
distensibility with a significant reduction in BP (140). 
 
3.3.5 Endothelial Function and Oxidative Stress 
Two studies examined the actions of MRA on endothelial function with neither study 
showing a significant effect (364, 371). Takebayashi et al demonstrated a significant 
reduction in 8-iso-prostaglandin F2α, a marker of oxidative stress, with spironolactone while 
no significant change occurred with amlodipine 2.5mg daily after 12 weeks of treatment 
(377). 
 
3.3.6 Carotid Intima-Media Thickness 
Only one study examined the actions of MRA on CIMT. Spironolactone thrice weekly post-
dialysis was shown to significantly reduce the progression of CIMT after 2 years as compared 
to placebo (379).  
 
3.3.7 Left Ventricular Ejection Function and Mass 
Among patients on haemodialysis or peritoneal dialysis with a clinical diagnosis of heart 
failure (New York Heart Association III-IV and ejection fraction <45%), spironolactone 
thrice weekly in addition to ACEi or ARB was shown to significantly improve LV ejection 
fraction after 24 weeks as compared to placebo (375, 376). Whilst there was no detectable 
difference in LV ejection fraction between those receiving spironolactone and placebo in a 
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RCT of 112 patients with CKD stage 2-3 without a clinical diagnosis of heart failure and with 
normal LV function, Edwards et al demonstrated significant improvements in other indices of 
systolic and diastolic function including LV long-axis systolic function, torsion, myocardial 
deformation and markers of LV relaxation and suction in the spironolactone group (249). In 
patients with diabetic nephropathy, myocardial perfusion reserve improved after 6 weeks of 
eplerenone while there was no change in the control group treated with hydrochlorothiazide 
(364). Three RCTs examined the effect of MRA on brain natriuretic peptide with all studies 
reporting significant reductions (249, 366, 371). Two placebo-controlled studies examining 
the actions of MRA on LV mass reported a reduction with the use of spironolactone after 40 
weeks (-14 ± 3 g, p<0.01) (140) and after 6 months (-8 ± 4 g, p=0.02) (375). 
 
3.3.8 End of Study Serum Potassium and Hyperkalaemia Events  
Twenty-one studies (1015 patients) reported end of study serum potassium. Overall, the use 
of MRA was associated with an increase in serum potassium (serum K
+
> 5.5 mmol/L) (0.23, 
95% CI: 0.13, 0.33 mmol/L, p<0.001) but with high heterogeneity (χ2=90.29%, p<0.001; 
I
2
=77%; Figure 3-4). Two studies used additional potassium supplementation or potassium 
binders (361, 364). Exclusion of these two studies made little difference to the result (0.24, 
95% CI: 012, 0.36 mmol/L; p<0.001) with persistent high heterogeneity (χ2=87.80, P<0.001, 
I
2
=78%). Exclusion of crossover studies did not materially affect the result (0.25, 95% CI: 
0.11, 0.40 p<0.001: χ2=67.48, p<0.001, I2=82%). Excluding three studies in which MRA was 
not co-administered with an ACEi and/or ARB did not significantly affect the result (0.22, 
95% CI: 0.11, 0.34 mmol/L; p<0.001: χ2=80.48, p<0.001, I2=78%). Spironolactone (0.26, 
95% CI: 0.14, 0.37 mmol/L; p<0.001) but not eplerenone (0.14, 95% CI: -0.08, 0.36 mmol/L; 
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p=0.2) increased end of study serum potassium although both analyses had high heterogeneity 
(χ2=69.45, p<0.001; I2=77%  & χ2=18.21, p=0.001; I2=78% respectively).  
 
Twenty-six studies (1619 patients) reported episodes of hyperkalaemia. Overall, use of MRA 
was associated with a higher risk ratio (1.76, 95% CI: 1.20 - 2.57, p=0.004) of hyperkalaemia 
with low heterogeneity (χ2=13.73, p=0.8; I2=0%). Neither the exclusion of crossover studies 
(risk ratio 1.77, 95% CI: 1.19, 2.64, p=0.005; χ2=10.89, p=0.7; I2=0%), nor exclusion of 
studies without concomitant ACEi and/or ARB (risk ratio 1.76, 95% CI: 1.18, 2.60, p=0.005: 
χ2=13.62, p=0.8; I2=0%) materially affected the result. Both spironolactone (risk ratio 1.97, 
95% CI: 1.29, 3.00, p=0.002; χ2=10.82, p=0.8; I2=0%) and eplerenone (risk ratio 1.97, 95% 
CI: 1.29, 3.00, p=0.002; χ2=2.70, p=0.4; I2=0%) were associated with increased risk of 
hyperkalaemic events. 
 
Abbreviations: MRA: mineralocorticoid receptor antagonist; CI: confidence interval; IV: inverse variance. 
Figure 3-4: Effect of mineralocorticoid receptor antagonists on serum potassium. 
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3.3.9 End of Treatment Serum Creatinine and Glomerular Filtration Rate 
Seventeen studies (827 patients) reported change in serum creatinine. Overall, there was no 
significant change in serum creatinine (0.04, 95% CI: -0.03, 0.11 mg/dl, p=0.3; Figure 3-5) 
with the use of MRAs. Exclusion of seven crossover studies made no appreciable difference 
to the result (0.02, 95% CI: -0.09, 0.13 mg/dl; p=0.7), although there was moderate 
heterogeneity (χ2=20.82, p=0.7, I2=52%). Fourteen studies used spironolactone (665 patients) 
and three (162 patients) used eplerenone with neither agent affecting serum creatinine (0.04, 
95% CI: -0.04, 0.12 mg/dl; p=0.1 and 0.04, 95% CI: -0.15, 0.23mg/dl; p=0.7, respectively). 
Only two studies did not allow concomitant use of an ACEi and/or ARB. Excluding these two 
studies did not alter the result (0.02, 95% CI: -0.05, 0.09; p=0.6). 
 
Twenty-one studies (1,217 patients) reported changes in GFR. Overall, there was no 
significant change in the pooled estimate (0.03, 95% CI: -0.08, 0.14 ml/min/1.73m
2
) with low 
heterogeneity (χ2=15.05, p=0.8, I2=0%; Figure 3-5). As for serum creatinine, sub-analyses, 
excluding crossover studies and studies not allowing concomitant use of ACEi and/or ARB, 
as well as separate analyses for spironolactone or eplerenone, did not significantly affect the 
result. Data for doubling of serum creatinine and incidence of ESRD was not extractable in a 
format required for analysis or not reported in the included studies. 
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Figure 3-5: Effect of mineralocorticoid receptor antagonist on serum creatinine. 
 
 
Figure 3-6: Effect of mineralocorticoid receptor antagonist on glomerular filtration rate 
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3.3.10 Cardiovascular Morbidity and Mortality Outcomes 
Mortality outcome was reported in three studies, all of which included patients on dialysis 
only (375, 376, 379). The study durations ranged from six months to two years and included 
100 patients. There were six deaths in the placebo arm and three in the MRA arm. 
 
Short-term CV morbidity data was available in two RCTs (367, 375). In a RCT of 81 patients 
with DM, the hospitalisation rates for CV events were not different for spironolactone, 
losartan or placebo (367). In contrast, in a RCT study of 16 haemodialysis patients with heart 
failure, there was a significantly higher number of CV-related hospitalisation events due to 
ischaemic heart disease and decompensated congestive heart failure in the placebo than the 
spironolactone arm (12 vs. 2 events, p>0.01) (375). 
 
3.3.11 Other Adverse Events 
Very few studies reported adverse events with any consistency. In all of the studies included, 
only nine reported breast tenderness/gynaecomastia with a further two reporting them as a 
cause for study withdrawal. In total, only ten cases of gynecomastia/breast tenderness were 
reported. 
 
 Discussion 3.4
Our study shows that MRAs potentially improve multiple surrogate markers of CV disease 
although these studies were relatively few and most included low number of patients. The 
majority of the endpoints studied are, to a greater or lesser extent, BP dependent and perhaps 
one of the more important findings from this analysis is that of a significant reduction in SBP 
and DBP with MRAs even when already treated with an ACEi and/or ARB. Indeed, control 
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of hypertension is arguably the most important intervention for reducing the increased risk of 
CV disease and to slow progression to later stages of CKD. Two other important endpoints 
with prognostic significance, arterial stiffness and LV mass, are causatively influenced by BP 
(58). Indeed a positive effect on arterial stiffness was only observed in association with BP 
reduction in one study (140), a finding not replicated in another without any effect on BP 
(357). Given that MRA use is associated with a significantly increased risk of hyperkalaemia, 
it remains to be seen whether the use of other “safer” antihypertensive agents, producing the 
same degree of BP reduction would achieve the same effects.  No studies have been powered 
to examine the impact of MRA on CV morbidity and mortality or indeed any other patient-
centred endpoints.  
 
Inhibition of the RAAS with either ACEi or ARB in patients with CKD reduces the rate of 
deterioration of renal function and the increased CV risk associated with this condition (227). 
While treatment with MRA might be thought to be of limited efficacy in patients on ACEi or 
ARB therapy, detailed study of patients on this treatment revealed that in many cases use of 
ACEi and ARB decreased levels of circulating aldosterone only for a period of weeks (240).  
In 10-50% of patients, circulating aldosterone concentrations returned to pre-treatment levels, 
a phenomenon termed aldosterone breakthrough (240). There are reports that patients who 
demonstrated aldosterone breakthrough had a worse prognosis than those who did not (240). 
It has been suggested that the use of MRA in this context would be beneficial, especially in 
the context of renal impairment, and there are many animal and human studies to support this 
(227). 
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A further important and not unexpected finding of this analysis was that there was a 
significant increase in serum potassium concentrations and a significant increase in the risk of 
hyperkalaemia. In general, there were no data available to examine the influence of baseline 
renal function on any of these parameters, as has been previously described in robustly 
conducted meta-analyses examining the actions of MRAs on proteinuria (245, 246). On 
theoretical grounds, there is reason to believe that hyperkalaemia might be more prevalent in 
patients with lower GFR values and it is important to note that the actions and safety of MRA 
in patients with GFR below 30 ml/min/1.73m
2
 have not been examined in significant numbers 
of patients. Also, other potential adverse effects of MRA such as gynecomastia have been 
poorly reported and are likely to underestimate the true incidence. Reduction in proteinuria, a 
recognised association with CV risk, was the commonest end-point of the studies examined 
and MRAs are effective at lowering proteinuria (245, 246). However, studies of agents that 
reduce proteinuria have not always produced concomitant reductions in mortality (382). 
 
Our study has a number of strengths and limitations. We followed current guidelines and 
identified a large number of studies. The major limitation is the lack of long-term studies on 
mortality and CV events. The majority of the studies included enrolled few patients and were 
powered to observe differences in surrogate end-points, mainly reduction in proteinuria. Most 
studies did not adequately report study methods to assess trial quality. Consistent with other 
reviews we were also unable to perform separate analyses based on baseline renal function, as 
data stratified by renal function were unavailable from all the studies (245, 246). 
 
Long-term studies analysing the effect of MRAs on CV events and mortality are warranted. 
Studies should also examine whether the actions of MRAs are independent of BP reduction 
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ideally by using a control drug resulting in equal effects on BP. Furthermore, these studies 
should analyse the efficacy of MRAs in patients who exhibit aldosterone breakthrough, versus 
those who do not as the beneficial or adverse effects might be different between these two 
groups. Other factors that could potentially affect response, such as ethnicity (383), level of 
kidney function, dialysis and transplant status need examining. 
 
In summary, the current evidence does not yet support recommending treatment with MRA 
for patients with CKD to lower their CV risk.  Nevertheless, our increasing understanding of 
the myriad adverse effects of aldosterone in CKD patients clearly justifies further study of the 
potential benefits and risks of MRAs drugs in these patients.  
 
 Update on Recent Published Literature  3.5
A repeat electronic search on MEDLINE and EMBASE databases were performed according 
to the search strategies outlined in the systematic review protocol (Appendix 4-1) on the 29
th
 
July 2015. The search identified eight relevant studies which have been published since the 
previous search (in September 2013) and were not included in the systematic review. Three 
were on patients with diabetic nephropathy, one on hypertensive population with albuminuria, 
one on live-kidney transplant recipient, one on peritoneal dialysis population and two on 
haemodialysis population. These studies were reviewed and their findings are summarised in 
Table 3-2.  
 
Overall, the recent studies of patients with diabetic nephropathy (384-386) or hypertensive 
nephropathy (387) continued to demonstrate the beneficial effect of MRAs in albuminuria 
reduction when compared to diuretics and placebo. Its use was however associated with 
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increased serum potassium. These findings are in agreement with the results of the systematic 
review. In a study of 20 live-kidney transplant recipients, Ojeda-Cervantes et al showed that 
the use of low-dose spironolactone 1-day pre- and 3-days post-transplantation significantly 
reduced the oxidative stress as assessed by the urinary hydrogen peroxide excretion although 
there was no difference in renal function or reduction in tubular injury biomarkers (388). 
Whilst a small study of chronic haemodialysis population without heart failure found that 
although there was no change in LV dimension or mass over 4 months with the use of 
spironolactone 25mg daily, it did improve BP, endothelial function and cardiac autonomic 
status (as assessed by heart rate variability) when compared to placebo (389). In contrast, an 
RCT of 158 patients on peritoneal dialysis demonstrated statistically significant improvement 
of the rate of change in both the LV mass index and ejection fraction after 2 years of 
treatment with low-dose spironolactone or eplerenone when compared to placebo. 
Encouragingly, there was no serious hyperkalaemia reported during the study (390).  
 
The DOHAS study represented the first RCT examining the effect of MRA on long-term 
hard-endpoint as primary outcome amongst patients on maintenance haemodialysis (391). 
This open-label, multicentre Japanese study of 309 patients on haemodialysis reported a 
statistically significant reduction of death from cerebrovascular/cardiovascular events (CCV) 
or hospitalisation for CCV (adjusted HR: 0.355, 95% CI: 0.173-0.832, p=0.016) and all-cause 
mortality (adjusted HR: 0.335, 95% CI: 0.162-0.693, p=0.003) at 3 years after adjusted for 
sex, duration of dialysis and cardiothoracic ratio amongst those who received spironolactone 
25mg daily compared to those without (391). During the study, gynaecomastia or breast pain 
was reported in 10% of the treatment group and only 2% of the patients discontinued with 
spironolactone treatment due to hyperkalaemia (391). 
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To date, the majority of studies of MRAs in CKD population continued to focus on its effect 
on short-term surrogate markers instead of long-term renal, CV or survival outcomes. 
Conversely, the success of DOHAS study was encouraging, not least for the haemodialysis 
population, but also for the nephrology field as a whole. The next few years are likely to see 
exciting advances especially with the development of aldosterone synthase inhibitors (392) 
and more cardiac selective MRA (393). With large definitive RCTs, BARACK-D (Benefits of 
Aldosterone Receptor Antagonism in Chronic Kidney Disease) and ALCHEMIST 
(ALdosterone Antagonist Chronic HEModialysis Interventional Survival Trial) studies which 
aim to test the effect of spironolactone on CV morbidity and mortality in patients with stage 
3b CKD and patients on haemodialysis, respectively, currently underway; their findings are 
eagerly anticipated. For now, the concept of MRA being a “renal aspirin” (349) will have to 
wait. 
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Table 3-2: Characteristics of the populations and interventions of the additional trials which were published since September 2013. 
 
Study Type of 
study 
Study population Intervention(s) Also 
on 
ACEi/
ARB 
Study 
duration  
Outcomes measured Summary of findings 
Ojeda-
Cervantes et 
al, 2013 
(388) 
RCT, 
double-
blinded, 
parallel. 
 
20 Live-kidney 
transplant 
recipients 
Spironolactone 25mg 
given 1 day before 
and 3 day post-
transplantation vs 
placebo 
 
no 5 days Renal function, urinary 
KIM-1, IL-18, HSP-72, 
hydrogen peroxide 
levels  
Spironolactone significantly reduced urinary 
hydrogen peroxide levels. There was no difference 
in renal function or reduction in tubular injury 
biomarkers between the groups.  
 
Matsumoto 
et al, 2014 
(391) 
RCT, open-
label, 
multicentre, 
parellel 
309 oligo-anuric 
patients on 
haemodialysis  
Spironolactone 
25mg/day vs none  
Yes 
(43% 
vs 
41%) 
3 years Composite of death or 
hospitalization from 
CCV events, all-cause 
mortality 
Primary composite outcome (HR 0.355, 95% CI: 
0.173-0.832) and all cause-mortality (HR 0.355, 
95% CI: 0.162-0.693) were reduced in the 
spironolactone group after adjustment.  
 
Gynaecomastia or breast pain was reported in 10% 
of treatment group. Serum K
+
 >6.5 mmol/L required 
discontinuation of treatment occurred in 2% of 
treatment group.  
  
Flevari et al, 
2013 (389) 
Placebo-
controlled, 
sequential 
trial 
14 patients on 
maintenance 
haemodialysis 
without heart 
failure 
Spironolactone 25mg 
thrice weekly vs 
placebo 
 4 months Forearm reactive 
hyperemic during after 
venous occlusion 
plethysmography, heart 
rate variability, BP, 
echocardiographic and 
laboratory data. 
 
 
 
Improvement in endothelial function (p<0.05), heart 
rate variability (p<0.05) and blood pressure control 
(p<0.05) in spironolactone group compared with 
control. No change in LV dimension or mass 
between groups.  
Ito et al, 
2013 (390) 
RCT, open-
label, 
multicentre, 
parellel 
158 patients on 
peritoneal dialysis 
with NYHA I or 
II 
Spironolactone 
25mg/day or 
Eplerenone 50mg/day 
vs none 
yes 2 years LVMI and LVEF, 
residual renal function, 
peritoneal membrane 
function. 
 
 
Improvement in rate of change in LVMI (p=0.01) 
and LVEF (p=0.02) in spironolactone group 
compared with control. There was no difference in 
secondary outcomes between the groups. 
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Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker; BD, twice daily; BP, blood pressure; CCV, cerebrovascular and 
cardiovascular; CI, confidence interval; HR, hazard ratio; HSP, heat shock protein; IL, interleukin; K
+
, potassium; KIM, kidney injury molecule; LVEF, left 
ventricular ejection function; LVMI, left ventricular mass index; NYHA, New York Heart Association; uACR, urine albumin:creatinine ratio.
Study Type of 
study 
Study population Intervention(s) Also 
on 
ACEi/
ARB 
Study 
duration  
Outcomes measured Summary of findings 
Momeni et 
al, 2015 
(384) 
RCT, 
double-
blinded, 
parellel 
60 patients with 
diabetic 
nephropathy, 
proteinuria 
>150mg/day, CG 
GFR >30 mL/min 
(1)spironolactone 
50mg/day + placebo; 
(2)spironolactone 
50mg/day + 
hydrochlorothiazide 
25mg /day; 
(3)hydrochlorothiazid
e 25mg /day + 
placebo 
 
Yes  3 months 24-hour urine protein, 
serum potassium, renal 
function 
Reduction of proteinuria in group 1 & 2 compared 
to group 3 (p<0.001). 
 
Increase serum K+ of .026 mEq/L (p=0.002) in 
group 1, but not in group 2 or 3. There was no 
difference in GFR amongst the groups. 
Makhlough 
et al, 2014 
(385) 
RCT, 
double-
blinded, 
parellel 
60 patients with 
Type II diabetic 
and 
microalbuminuria 
Spironolactone 
25mg/day + placebo 
vs  Spironolactone 
25mg/day + losartan 
12.5mg BD 
No  3 months Reduction of 
albuminuria > 50% 
(treatment success 
rate), BP, serum 
potassium and renal 
function. 
 
No statistical significant difference in treatment 
success rate (p=0.4), serum potassium (p=0.08), BP 
(p=0.6) and serum creatinine (p=0.4) between the 
groups.  
Ando, et al, 
2014 (387) 
RCT, 
double-
blinded, 
parellel 
336 Patients with 
hypertension with 
uACR=30-599 
mg/g and eGFR > 
50mL/min/1.73m
2
) 
Eplerenone 50 
mg/day vs placebo 
Yes  1 year Percent change in 
uACR in the first 
morning void urine at 
week 52 from baseline 
 
Significant reduction of uACR in eplerenone group 
compared to placebo (absolute mean difference -
276%, p=0.022). 
Van Buren 
et al, 2014 
(386) 
RCT, 
double-
blinded, 
parellel 
80 patients with 
diabetic 
nephropathy 
(1) spironolactone 
25mg/day; 
(2) losartan 
100mg/day; 
(3) placebo 
Yes. 
Lisinop
ril 
80mg/d
ay 
48 weeks Serum potassium, 
aldosterone, 24 hour 
urine sodium, 
potassium and 
creatinine 
 
Spironolactone raised serum potassium more than 
losartan, despite similar renal sodium and potassium 
excretion. 
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CHAPTER 4 SPIRONOLACTONE TO PREVENT 
CARDIOVASCULAR EVENTS IN EARLY STAGE 
CHRONIC KIDNEY DISEASE (STOP-CKD) STUDY: 
MIXED METHODS APPROACH 
 
 Introduction 4.1
To date, systematic reviews have convincingly concluded the proteinuria reduction effect of 
the use of MRAs in additional to ACEi or ARB therapy in patients with CKD (244-246). 
Nonetheless, its effects on the long-term CV and survival outcomes in this population remain 
undetermined and clearly warrant further investigations (see Chapter 3).  
 
CKD is associated with increased arterial stiffness even in the early stages and this is thought 
to be a key mediator in the pathophysiology of its increased CV risk (394). Notably, many of 
these abnormalities are evident even in patients with early stages of CKD (65, 66) despite 
satisfactory BP control (67). In a recent randomised, double-blinded, placebo-controlled trial 
of 112 patients with stage 2-3 CKD in secondary care setting (CRIB II study), Edwards et al 
demonstrated the significant beneficial effects of low-dose, non-selective MRA 
(spironolactone 25mg/day) in reducing LV mass and improving arterial stiffness, as measured 
by cfPWV (140, 248, 249). These promising, though, preliminary findings from CRIB II 
study suggested a potential under-utilisation of this well-established medication. In addition, 
it also provided a strong basis for further research to examine the effects of MRAs in CV and 
survival outcomes in the CKD population.  
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Patients with stage 3 CKD (eGFR 30-59 ml/min/1.73m
2
) represent the largest group amongst 
the CKD population and they accounts for approximately 3.7% of the total U.K. adult 
population (35). Patients with such moderate degree of CKD have been shown to have much 
greater risk of dying from adverse CV events than progressing to ESRD (61). While majority 
of the CKD studies were conducted in secondary care, patients with stage 3 CKD in the U.K. 
are in fact mostly managed in the primary care setting (395, 396) and are often older with less 
well-defined renal phenotypes than the patients included in the hospital-based study. In 
addition, there were often concerns amongst the general practitioners regarding the risk of 
hyperkalaemia and renal dysfunction associated with the use of MRAs in the CKD population 
(245).   
 
A pilot study to examine if desirable intermediate CV end-points changes can equally be 
achieved via the use of low-dose spironolactone in the primary care CKD cohort and to test 
the feasibility of a large and appropriately powered definitive trial is clearly warranted. The 
STOP-CKD study was therefore conceived and designed out of such needs. It was a mix-
method study, involving both a RCT (quantitative arm) as well as an interview study 
(qualitative arm).  Its primary objective was to determine the effect of spironolactone on 
arterial stiffness in non-diabetic patients with stage 3 CKD managed in primary care. In 
addition, the study also aimed to determine the safety of spironolactone in stage 3 CKD stage 
in the community; assess the effect of low-dose spironolactone on BP and albuminuria in 
stage 3 CKD and qualitatively explore patients’ and healthcare professionals’ attitudes 
towards CKD, research in CKD and potential barriers to the use of spironolactone in CKD in 
a community setting (Table 4-1).  
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This chapter focuses on the methodology of the quantitative STOP-CKD RCT. The methods 
and results of the qualitative STOP-CKD interview are detailed in Chapter 6 and 7. 
 
 Hypothesis of STOP-CKD Study 4.2
Low-dose spironolactone decreases arterial stiffness in patients with stage 3 CKD. The 
objectives of the study are detailed in Table 4-1. 
 
Table 4-1: STOP-CKD study objectives 
Pilot study To determine the recruitment rate and feasibility of the study. 
Quantitative arm Primary To determine the effect of low-dose spironolactone on arterial 
stiffness in patients with stage 3 CKD. 
Secondary To determine the safety of spironolactone in patients with stage 3 
CKD in primary care setting, in regards to the incidence of 
hyperkalaemia, worsened renal function and other adverse events. 
To assess the effect of spironolactone on blood pressure and 
albuminuria.  
To assess the effect of spironolactone on pulse wave 
characteristics. 
Qualitative arm To examine patients’ and healthcare professionals’ attitudes 
towards CKD and research in CKD in the community setting. 
Explore patients’ and healthcare professionals’ attitudes towards 
the use of spironolactone in CKD in a community setting and the 
potential barriers which might exist to its use. 
(The methods and results of this qualitative study were presented in 
Chapter 6 & 7) 
Abbreviation: CKD, chronic kidney disease. 
 
 Quantitative Study Design 4.3
The quantitative arm of STOP-CKD study was a multicentre, prospective, randomised, 
placebo-controlled, double-blinded pilot trial in patients with stage 3 CKD. Patients registered 
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in participating primary care practices within South Birmingham, England were screened with 
a view to recruiting 240 eligible participants. Potential participants were identified by 
searching computerised primary care clinical records for patients with a latest eGFR value of 
30 to 59 ml/min per 1.73 m
2
 in the preceding 12 months. The GFR was estimated by the four-
variable MDRD formula with serum creatinine recalibrated to be traceable to an isotope-
derived mass spectroscopy method (24). The details of this computerised search are available 
in Appendix 4-1.  
 
Decision was made to perform the search on patients’ eGFR records instead of practices’ 
coded CKD diagnosis as a recent retrospective cohort study highlighted the issue with 
identification and accurate classification of CKD in primary care (35). Approximately 1% of 
the population were reported not to be on practice CKD register though they fulfilled the 
biochemical criteria for CKD (un-coded CKD) and 2% were erroneously included on the 
register when they did not fulfil the biochemical criteria (mis-coded CKD) (35). Therefore, 
short-listing patients according to practices’ coded CKD would not only result in overlooking 
large pool of potentially eligible patients but would also incorrectly inviting many who were 
in fact not suitable for the study and therefore, affecting the efficiency of the research 
screening process. By searching using previous eGFR record, the study was able to capture a 
larger pool of potential participants. As eGFR was rechecked during research screening visit, 
the diagnosis of CKD would then be confirmed or refuted and this information was also used 
to feed back to the practice to improve their coding of CKD diagnosis. Nevertheless, the 
research team was also aware of the risk of inviting patients who were not aware of their 
potential CKD diagnosis or might not in fact have CKD after the confirmatory eGFR test on 
the screening visit. Therefore, the patients’ research invitation letter had been carefully 
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phrased in order to minimise patients’ anxiety towards this potentially unconfirmed diagnosis. 
The invitation letter approved by the ethics committee stated that patients had been invited for 
STOP-CKD study as they ‘have had blood tests in the past indicating they may have a 
lowered kidney function’ (Appendix 4-2). 
 
The research invitation letters (Appendix 4-2) as well as patient information sheets (Appendix 
4-3) were sent out to all potentially eligible patients. They were invited to attend a screening 
visit with the research team at their own general practice, where the study was explained 
further. The research team obtained written consent from all willing participants prior to their 
enrolment into the study (Appendix 4-4). Following the screening visit, all recruited eligible, 
consenting participants were randomised to receive either placebo or spironolactone 25 mg 
once daily orally for an intended period of 40 weeks (Figure 4-1). The cfPWV was measured 
using a Vicorder system (Skidmore, Bristol, UK) at baseline and at end-of-study to detect any 
change in arterial stiffness (309). Outcomes were analysed using an intention-to-treat 
analysis. 
 
Ethical approval has been received from the National Research Ethics Service West Midlands 
Coventry and Warwickshire (Reference No 12/WM/0168) and clinical trial authorisation has 
been granted by the Medicine and Healthcare Products Regulatory Agency (MHRA) 
(Reference No 21761/0274/001-0001). The sponsor, investigators, trial steering committee 
(TSC), data management committee (DMC), coordinating centre, recruiting sites, all members 
of the study team and all trial participants were informed of the modifications. The study was 
coordinated by the Primary Care Clinical Research & Trials Unit (PC-CRTU), which has 
been fully accredited by the National Institute for Health Research (NIHR) as a trials unit at 
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the University of Birmingham according to the current guidelines for Good Clinical Practice. 
The study was monitored to confirm compliance with the protocol and the protection of 
patients’ rights, as detailed in the Declaration of Helsinki. The inclusion and exclusion criteria 
are detailed in Table 4-2. 
 
Patients with diabetes mellitus are excluded in this study for a number of reasons. The 
pathophysiology of arterial stiffness might be different, with a greater importance of advanced 
glycation end-products, for example (58). Furthermore, vascular calcification is more 
common and thus arterial stiffness may be less likely to improve with spironolactone (58). 
Hyperkalaemia is more common in patients with CKD and diabetes than without; and this 
may be markedly worsened by spironolactone. Diabetes would be expected to affect 20-30% 
of a community sample of CKD, and hence would form a large subgroup within the trial. 
Thus, although diabetes is an important issue in CKD, this would be best explored in a 
separate study concentrating on diabetes rather than affecting the risk: benefit ratio of the 
proposed study in terms of reduced chance of outcome and a greater number of adverse 
events than expected. 
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Table 4-2: Inclusion and exclusion criteria of STOP-CKD study 
Inclusion criteria 
 
Age over 18 years  
Diagnosis of CKD Stage 3 (MDRD eGFR 30-59 ml/min/1.73m
2
)  
 
Exclusion criteria 
 
Diabetes Mellitus 
Terminal disease or considered otherwise unsuitable by GP 
Clinical diagnosis of chronic heart failure 
Atrial fibrillation 
Alcohol or drug abuse 
Inability to comply with trial medication and follow-up 
Documented previous hyperkalaemia or intolerance of spironolactone 
Documented Addisonian crisis or taking fludrocortisone 
Severe hypertension: BP ≥ 180/110 mmHg 
Systolic BP < 120 mmHg 
Recent acute kidney injury or hospital admission (within previous 6 weeks) 
Chronic diarrhoea 
Urine albumin:creatinine ratio (uACR) ≥ 70 mg/mmol 
Serum potassium ≥ 5 mEq/l on screening visit 
Concomitant co-trimoxazole medication 
Concomitant ACEI and ARB medication (dual-blockade) 
Concomitant lithium medication 
Concomitant warfarin medication 
Pregnancy 
Breastfeeding 
Planned major surgical intervention within 46 weeks of recruitment 
 
4.3.1 Study Procedure 
The study timeline and schedule of follow-ups and assessments are summarised in Figure 4-
1 and Table 4-3. 
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Abbreviation: OD, once daily.  
Figure 4-1: Study timeline of STOP-CKD RCT 
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Table 4-3: Flowchart of assessment for STOP-CKD RCT 
 Treatment   
Visit (week) Screening Randomisation 2 4 8 16 28 40 46 
Valid informed consent gained √ √        
Full demographic details √         
Relevant medical history taken √ √        
Concomitant medications √ √ √ √ √ √ √   
Anthropometric measurements  √        
Blood pressure measurement √ √ √ √ √ √ √ √ √ 
Pulse wave velocity and pulse waveform 
analysis measurement 
 √      √ √ 
Haematological &  
Full biochemical profile 
√  √     √ √ 
Renal profile    √ √ √ √   
Urine albumin:creatinine ratio √       √ √ 
EQ5D-5L Questionnaire  √      √  
Medication Monitoring 
Questionnaire 
 √ √ √ √ √ √ √ √ 
Abbreviation: EQ5D-5L, European quality of life-5 dimensions  
 
4.3.2 Screening Visit 
All consenting participants attended screening visit during which the following were carried 
out: (i) completion of a questionnaire regarding demographic details, relevant medical history 
and concomitant medication; (ii) non-invasive BP measurement using an automated BpTRU 
machine (BPM-100, BpTRU™) (see section 4.3.5.1) (308); (iii) blood and urine sampling. 
Estimated GFR on this screening visit confirmed the diagnosis of stage 3 CKD (two MDRD 
eGFR measurements of 30 to 59 ml/min per 1.73 m
2
 at least 90 days apart). A urine test was 
used to exclude patients who have a uACR > 70 mg/mmol. Participants with BP 
>140/90 mmHg and a uACR of 30 to 69 mg/mmol but not receiving either ACEi or ARB 
were referred to their GP to be considered for ACEi or ARB treatment. They were re-invited 
to the screening visit after at least 6 weeks treatment with ACEi or ARB. 
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4.3.3 Randomisation Visit 
Eligible patients were invited back no later than two weeks after their initial visit to attend a 
randomisation clinic. Informed consent was sought again before randomisation to commence 
trial medication (Appendix 4-5). Consenting participants underwent the following 
assessments: (i) EQ5D-5 L (European Quality of Life, 5 Dimensions, 5 Levels) (397) and 
medication monitoring questionnaires (Appendix 4-6); (ii) anthropometric measurements, 
which included height, weight and neck, waist and hip circumferences ; (iii) BP measurement; 
(iv) cfPWV measurement and PWA (see section 4.3.5.1.2). All participants were randomised 
to receive either inactive placebo or spironolactone 25 mg once daily orally. 
 
4.3.4 Follow-up Visits 
Following randomisation, all participants attended follow-up visits at weeks 2, 4, 8, 16 and 
28. The medication monitoring questionnaires were filled in and brachial BP measurements as 
well as blood samples to monitor serum electrolytes and renal function were taken at each 
visit. Abnormal BP readings were managed according to STOP-CKD working instruction 
(Appendix 4-7). Participants with a persistently elevated BP of more than 150/90 mmHg were 
referred to their GP for BP management according to the NICE guidelines (398) . Participants 
with hyperkalaemia or renal function deterioration during the follow-up visits were managed 
according to the study protocol (Figure 4-2). 
 
All measurements performed at the screening and randomised visits were planned to be at 40 
weeks after the randomisation, marking the end of the treatment phase. All participants 
discontinued the trial medication and adherence was assessed via pill count. After a wash-out 
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period of six weeks, all participants were planned to have final follow-up visits (week 46 
visit) whereby all measurements performed at the week 40 visit were repeated.  
 
Abbreviations: eGFR, estimated glomerular filtration rate; K+, serum potassium concentration. 
Figure 4-2: Study flowchart on management of renal dysfunction and hyperkalaemia in the 
STOP-CKD trial. 
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4.3.5 Study Assessments 
4.3.5.1 Blood Pressure Measurement 
Blood pressure was measured using the BpTRU™ BPM-100 automated BP monitor (308) 
(Appendix 4-8). During the screening visit, six serial sitting BP measurements were taken 
simultaneously on both arms, to identify which arm to use for BP monitoring for all future 
visits. These six BP measurements were performed via the automated machine at 1 minute 
intervals. Each BP reading was recorded. The office mean BP was derived from the mean of 
the 2
nd
 and 3
rd
 BP readings, whereas the mean BpTRU reading was derived from the mean of 
the 2
nd
, 3
rd
, 4
th
, 5
th
 and 6
th
 readings. If there was >20 mmHg difference in systolic BP or 
>10 mmHg difference in diastolic BP on the office meanBP reading between the arms, the 
arm with the higher reading was selected for all future BP and Vicorder measurements. If not, 
the non-dominant arm was the selected measured arm. After measurement of sitting BP, 
postural BP was measured after asking the participant to stand up for 1 minute from sitting 
position. Postural hypotension is defined as a drop of systolic BP >20 mmHg on standing. 
Serial sitting BpTRU BP measurements and postural BP was repeated during each follow-up 
visits and at end-of-study. 
 
4.3.5.2 Carotid-Femoral Pulse Wave Velocity and Pulse Wave Analysis Measurements 
The Vicorder system provides a non-invasive, non-operator-dependent method of obtaining 
cfPWV and pulse wave characteristics using a volume displacement technique (Appendix 4-
9). In comparison to SphygmoCor device, although Vicorder appeared to report lower cfPWV 
values at higher cfPWV measured by SphygmoCor, it was found to have high repeatability 
with low within-subject coefficient variation of 2.8% (309). After correction for the distance 
to the pulse detection point between the devices, Vicorder was reported to have, in general, 
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good agreement with SphygmoCor in cfPWV measurements (309). Additionally, Pucci et al 
also demonstrated that the estimated central BP generated by Vicorder device was reliable 
when calibrated to invasive pressure (310). 
 
Carotid-femoral PWV measurements were obtained by placing a 100-mm-wide BP cuff on 
the proximal thigh to measure the femoral pulse and a 30-mm-wide partial cuff on the neck at 
the level of the carotid artery. The aortic path length is defined as the distance between the 
mid-clavicular point and the middle of the thigh cuff. This length was measured by the 
operator and input into the Vicorder System. With the participants lying supine at 
approximately 30° with the head and shoulders supported by a pillow to prevent flexion of the 
neck, the cuffs each inflated to 60 mmHg and the corresponding oscillometric signal from 
each cuff was digitally analysed to extract, in real time, the pulse waveforms and pulse transit 
time from carotid to femoral sites. Subsequently, cfPWV was derived from the measured 
pulse transit time and aortic path length. Similarly, pulse wave characteristics and analysis 
was performed by placing the 100-mm-wide BP cuffs on the selected arm and proximal thigh. 
 
PWV = K x Transit Time/Distance 
 
The cfPWV and PWA measurements were performed on the same side as for BP for each 
participant after 5 minutes of rest. The cfPWV and PWA measurements were performed in 
triplicate. The mean value of the three recordings was used for subsequent analysis. 
Inconsistent values among the three recordings were further examined by a designated senior 
investigator not involved in taking the measurements, to determine the validity of each 
measurement. Example of the Vicorder outputs, demonstrating transit time, calculated PWV 
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and carotid and femoral wave form as well as pulse wave analysis (PWA) are shown in Figure 
1-1 and 1-2, respectively. 
 
 
Figure 4-3: An example of the output from the Vicorder device showing carotid and femoral 
pulse wave (cfPWV), transit time (TT) and the calculated pulse wave velocity (PWV). 
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Figure 4-4: An example of the output from the Vicorder device showing an analysis of the 
arterial pulse waveform (pulse wave analysis: PWA) which includes measurements of heart 
rate, mean arterial pressure, aortic and brachial blood pressure and pulse pressure, 
augmentation pressure, augmentation index and sub-endocardial viability ratio (SEVR). 
 
 Randomisation 4.4
Investigators, outcome assessors, data analysts and participants were all blinded to the 
treatment allocation via the use of an apparently identical inert placebo and a central 
automated allocation procedure. Participants were stratified by practice location, SBP (above 
or below 140 mmHg) and urine albuminuria (uACR above or below 30 mg/mmol) and 
assigned to either active treatment or inactive placebo using a minimization algorithm with a 
70:30 weighted-coined approach if there is an imbalance. This randomisation assignment was 
centrally operated using the PC-CRTU secured web-based randomisation system. A unique 
five-digit trial medication number, which corresponded to either active or placebo treatment, 
was generated for each participant randomised.  
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 Treatment 4.5
The trial medication was supplied by an authorised trial medication manufacturing unit. The 
placebo medications were made with Swedish Orange Gelatin capsules, size DBAA capsules 
filled with Cellulose, Microcrystalline with 1% Magnesium Stearate. Whilst the active 
medications were manufactured via the over-encapsulation of a 25mg Spironolactone tablet in 
a Swedish Orange Gelatin capsule, size DBAA and back-filled with Cellulose, 
Microcrystalline with 1% Magnesium Stearate to match the aspect and weight of the placebo 
capsules. These capsules were further packed into Plastic White HDPE Screw Neck 200ml 
bottles, each consisting of 100 capsules of either active medication or placebo. The bottles 
were labelled according to Good Manufacturing Practice Annex 13 Investigational Medicinal 
Products as per approved label. In addition to the labels, there were small tear-off labels 
containing unblinded information, either A or B, on the bottles. This information indicated if 
the bottles contained active or placebo medication.  
 
These packaged trial medications were then delivered to a designated community pharmacy 
hub. STOP-CKD study delegated the duty of storing and dispensing the trial medication to a 
large community pharmacy operator. A standard operating procedure (SOP) of such 
responsibilities were drawn up and agreed between both parties. All pharmacists involved in 
the dispensing of the STOP-CKD trial medications underwent training from the research team 
and had read and understood the SOP.  
 
The list which contained all the unique trial medication numbers and their corresponding 
treatment options (A or B) were sent from the informatics team responsible for the 
randomisation programme at the PC-CRTU to the designated hub pharmacy. Upon receiving 
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the STOP-CKD prescription from the research team, pharmacist at the hub pharmacy verified 
the prescription, matched up the unique trial medication number on the prescription to their 
identifier (A or B), dispensed the corresponding trial medication bottles and removed the tear-
off labels. The trial medication was then delivered to the local community pharmacy closest 
to the recruiting practice for collection by the participant.  
 
During the 40 weeks treatment, all participants completed the medication monitoring 
questionnaire at each research visit to record any side effect related to the trial medication and 
self-report trial medication compliance. In the event when participant’s serum potassium 
concentration was 5.5 to 5.9 mmol/l on repeat samplings, the trial medication was reduced 
from once daily to once every other day (see Figure 4-2).  
 
 Withdrawal Criteria 4.6
Participants were withdrawn from the trial when they chose not to continue, when their GP 
considered that continued participation in the trial was inappropriate or when they were no 
longer eligible according to the withdrawal criteria listed in Table 4-4. Participants who 
withdrew from the trial were asked if they were willing to attend a final research visit within 
seven days of stopping the trial medication for blood and urine sampling, BP and Vicorder 
measurement and completion of the EQ5D-5L (European Quality of Life- 5 dimensions) and 
medication monitoring questionnaire. Data were collected for an intention-to-treat analysis. 
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Table 4-4: Withdrawal criteria for STOP-CKD study. 
System Adverse effect Actions 
 
Blood pressure Hypotension To withdrawal trial medication if SBP 
<100 mmHg or postural drop of SBP >20 
mmHg. 
Metabolic Hyperkalaemia Serum potassium ≥ 6 mmol/L on repeat 
sampling. 
Hyponatremia To withdraw trial medication if serum 
sodium <130 mmol/L on 2 occasions. 
Renal Renal Dysfunction Serum creatinine increment ≥30% or 
eGFR reduction ≥25% from baseline. 
Endocrine Male: Gynaecomastia, impotence, 
diminished libido. 
Female: hirsutism, oligomenorrhoea, 
amenorrhoea, menorrhagia, breast 
tenderness 
To withdraw trial medication if participant 
is intolerant of the side effect/effects.  
 
Nervous system Headache To withdraw trial medication if symptom 
persists for >1 week. 
Confusion, ataxia, drowsiness To check postural blood pressure and 
serum sodium level. If postural blood 
pressure and serum sodium are within 
normal level, but symptom persist for > 1 
week, to withdraw trial medication. 
Lethargy To withdraw trial medication if symptom 
persists for > 1 week. 
Dermatologic Rash To withdraw trial medication. 
Lichen planus, lupus-like syndrome To withdraw trial medication. 
Hypersensitivity Anaphylaxis, contact dermatitis, 
eosinophilia. 
To withdraw trial medication immediately. 
Gastrointestinal  General abdominal discomfort To withdraw trial medication if persistent 
discomfort for > 1 weeks. 
Diarrhoea or vomiting To withdraw trial medication if persistent 
diarrhoea or vomiting for >3 days. 
Gastric/ duodenal ulcer or bleeding To withdraw trial medication. 
Haematological Agranulocytosis To withdraw trial medication. 
Hepatic Hepatotoxicity (ALT > 123 U/L OR 
bilirubin > 44 μmol/L) 
To withdraw trial medication. 
 
Oncologic Animal studies suggested association 
between spironolactone with benign 
adenoma of the thyroid and testes, 
malignant breast tumours, hepatocellular 
carcinoma and leukemia. 
To withdraw trial medication. 
 
 
Abbreviation: ALT: Alanine transferase; SBP: systolic blood pressure 
 
  112 
 Endpoints 4.7
The primary endpoint of the study was the change in cfPWV between baseline and 40 weeks. 
Secondary endpoints were: (i) change in brachial BP; (ii) change in MDRD eGFR; (iii) 
change in uACR; (iv) change in pulse waveform characteristics; (v) incidence of 
hyperkalaemia; (vi) incidence of renal dysfunction (increment of creatinine ≥ 30% or 
reduction of eGFR ≥ 25% from baseline); (vii) incidence of other adverse events. 
 
 Sample Size Calculation  4.8
In the previous study of the effect of spironolactone, the Chronic Renal Impairment in 
Birmingham II (CRIB II) study, the standard deviation of the change in cfPWV was 1.0 m/s 
in the active treatment group and 0.9 m/s in the control group (140). Hence, 100 subjects in 
each arm will provide 90% power with an α value of 0.05 to demonstrate a difference in 
change of cfPWV of 0.5 m/s between the active treatment and control groups. We intended to 
recruit 240 patients to account for an approximate drop-out rate of 20%, which would result in 
at least 200 patients completing this randomized control trial, with 100 patients in each arm 
(inactive placebo versus spironolactone). 
 
 Trial Management 4.9
The STOP-CKD study was coordinated by the PC-CRTU at the University of Birmingham 
according to the current guidelines for Good Clinical Practice. Data entry, coding, security, 
storage, access and quality assurance were managed according to the PC-CRTU policy. The 
chief investigator (Dr Charles Ferro) took overall responsibility for the conduct of study. Any 
delegated or devolved responsibility was documented in a delegation log. An investigators 
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group met monthly to provide oversight of the developing trial, with more frequent 
operational meeting of the chief investigator, trial manager and trial team as required. 
 
A TSC was appointed and provided overall supervision for the trial, in particular: trial 
progress, protocol compliance, patient safety and review of updated information. The TSC 
included the trial management group, two lay representatives and an independent chair who 
has expertise relevant to the study (Appendix 4-10). The TSC met every 3 to 6 months, 
depending on the phase of the study. 
 
An independent DMC for the trial was responsible for the regular monitoring of trial data. 
The committee consisted of an independent secondary care clinician, an independent 
academic GP and an independent statistician (Appendix 4-11). The DMC assessed the 
progress of the trial and gave advice on whether the accumulated data from the trial, together 
with the results from other relevant trials, justified the continuing recruitment of further 
patients. The committee met in person or by teleconference prior to the trial commencement 
and then 3 and 6 months after initiation of the trial. The DMC made confidential 
recommendations to the TSC as the decision-making committee for the trial (Appendix 4-11).  
 
 Monitoring and Safety Assessments 4.10
Monitoring which was performed according to the PC-CRTU policy was conducted centrally 
and at each local recruitment sites. Any major problems identified during monitoring were 
reported to the TSC. All records were maintained in accordance with local regulations and in 
a manner that ensured security and confidentiality. All adverse events and severe adverse 
events were recorded and followed up for the duration of the study or until resolution. 
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Assessment of adverse events was performed by the study investigators. All serious adverse 
events were graded and reported to the sponsor. Any suspected unexpected serious adverse 
reactions were reported to the sponsor, ethics committee as well as MHRA. 
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CHAPTER 5 SPIRONOLACTONE TO PREVENT 
CARDIOVASCULAR EVENTS IN EARLY STAGE 
CHRONIC KIDNEY DISEASE (STOP-CKD) STUDY: 
QUANTITATIVE OUTCOMES REPORTING 
 
 Introduction 5.1
The STOP-CKD pilot RCT was conducted as described in the methodology chapter (see 
Chapter 4). In brief, the aims of this quantitative arm of the study were primarily to determine 
the recruitment rate and feasibility of the study design as well as examine the effect of low-
dose spironolactone on arterial stiffness in patients with stage 3 CKD in primary care. The 
secondary aims of the RCT included determining the safety of low-dose spironolactone and 
its effect on BP, albuminuria and pulse wave characteristics in such population. Using the 
data generated from the STOP-CKD RCT, this chapter outlines the statistical analyses 
performed and details the outcomes in chronological order. The chapter concludes with a 
discussion deliberating the implications of the outcomes reported. 
 
 Statistical Analysis 5.2
Statistical analyses were performed using SPSS version 20 (SPSS Inc, Chicago, IL), and SAS 
version 9.4 (SAS Institute; Cary, NC). Numerical values are expressed as mean (SD) for 
parametric data or median (interquartile range [IQR]) for non-parametric data. Normality of 
the distribution of data was assessed by visual inspection of histogram and normal probability 
plot. Non-parametric data were loge-transformed before comparative analyses. Continuous 
data were compared using Student t-tests.  
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Exploratory analyses were performed to identify any potential factors influencing patients’ 
willingness to participate. The information available on invited patients invited was limited to 
their age, gender, ethnicity, general practice and last recorded eGFR. These five factors were 
therefore assessed by binary logistic regression using a forced enter method with regard to 
their impact on patient’s research participation. Patients who expressed interest in 
participating were categorised as ‘willing invitees’ whereas patients who either did not 
respond to the invitation or replied but declined participation were grouped together as ‘non-
willing invitees’. Patients’ gender (male/female) and ethnicity (white/others) were analysed as 
dichotomous data whereas age and last recorded eGFR were analysed as continuous data. 
Supplementary analyses were performed with eGFR being dichotomised either into CKD 
stage 3a (eGFR: 45- 59 ml/min/1.73m
2
) and stage 3b (eGFR: 30- 44 ml/min/1.73m
2
) or into 
categories above or below the median of eGFR (54 ml/min/1.73m
2
). Non-linearity of age and 
eGFR were examined using restricted cubic spline models.  Models were selected on 
achieving a significant improvement in Akaike’s Information Criterion. Statistical 
significance was defined as a two-tailed p value < 0.05.  
 
 Results  5.3
All 71 primary care practices within the former South Birmingham Primary Care Trust with 
more than 3,000 patients registered were invited to participate. Eleven practices (15%) agreed 
to take part, with a total population of 112,462 (Table 5-1). Electronic database searches 
identified 2,044 potentially eligible patients. A further 446 (21.8%) patients were excluded by 
their GPs with the proportion excluded varying considerably between the practices (2.3 – 
52.6%). Five of the 11 practices were known to be ‘research-active’ and had dedicated 
research nurses on-site. There was no statistically significant difference in regards to 
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proportions of patients excluded between ‘research-active’ practices compared to their 
counterparts (median: 19 [IQR: 10-47] vs 11 [IQR: 4-28] %, p=0.2). 
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Table 5-1: Eleven recruiting practices’ population, prevalence of stage 3-5 CKD, numbers of patients invited, screened and randomised for 
STOP-CKD study. 
Practice Practice 
population 
Prevalence 
of stage 3-5 
CKD* 
Patients 
eligible from 
computerised 
search (%) 
Patients 
excluded by 
GP (%)** 
Patients 
invited (%) 
Patients 
replying 
(%)*** 
Patients 
expressing 
interest (%)† 
Patients 
attending 
screening visit 
(%)† 
Patients 
randomized 
(%)† 
#1
R
 7,501 4.72 % 260 (3.5) 49 (18.8) 211 (2.8) 105 (49.8) 37 (17.5) 22 (10.4) 3 (1.4) 
#2
R
 3,838 1.86 % 38 (1.0) 20(52.6) 18 (0.5) 7 (38.9) 3 (16.7) 3 (16.7) 0 
#3 27,025 4.82 % 360 (1.3) 183 (50.8) 177 (0.6) 102 (57.6) 21 (11.9) 15 (8.5) 1 (0.6) 
#4 7,113 3.58 % 179 (2.5) 7 (3.9) 172 (2.4) 81 (47.1) 20 (11.6) 12 (7.0) 2 (1.2) 
#5 24,553 2.97 % 478 (1.9) 97 (20.3) 381 (1.6) 152 (39.9) 41 (10.8) 29 (7.6) 5 (1.3) 
#6
 R
 8,729 4.19 % 157 (1.8) 17 (10.8) 140 (1.6) 61 (43.6) 20 (14.3) 16 (11.4) 3 (2.1) 
#7
 R
 5,817 4.69 % 129 (2.2) 13 (10.1) 116 (2.0) 44 (37.9) 15 (12.9) 10 (8.6) 1 (0.9) 
#8 4,824 3.58 % 114 (2.4) 13 (11.4) 101 (2.1) 44 (43.6) 11 (10.9) 10 (9.9) 0 
#9 9,436 6.67 % 236 (2.5) 25 (10.6) 211 (2.2) 97 (46.0) 19 (9.0) 12 (5.7) 0 
#10 7,104 2.75 % 43 (0.6) 1 (2.3) 42 (0.6) 27 (64.3) 6 (14.3) 3 (7.1) 1 (2.4) 
#11
 R
 6,522 2.97 % 50 (0.8) 21 (42.0) 29 (0.4) 13 (44.8) 3 (10.3) 2 (6.9) 0 
Total 112,462  2,044 446 1,598 733 196 134 16 
Mean %  3.89% 1.82% 21.8% 1.42%     
 
R
 Signify general practices which were research-active and had dedicate on-site practice research nurses. 
*Data obtained from Quality and Outcomes Framework 2013/2014 report 
(%) indicates percentage of total practice population 
** indicates percentage of potentially eligible patients excluded by their general practitioner 
†indicates percentage of patients invited 
Abbreviations: CKD, chronic kidney disease; GP, general practitioner
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* multiple adverse reaction to anti-hypertensive in the past and previous endovascular aortic aneurysm repair which would affect 
PWV measurements 
Figure 5-1: STOP-CKD study consort diagram 
 
Patients invited (n=1598) 
 
Patients accepted invitation for screening visit (n=196) 
Patients declined invitation (n=537) 
Did not reply (n=865)  
 
Patients attended screening visit (n= 134) 
Not contactable or declined further involvement after telephone contact 
(n=62) 
Patient eligible on screening questionnaire (n=79) 
Excluded (n=55) 
Declined further participation (n=3) 
Ineligible at screening (n=52)  
 Systolic blood pressure <120 mmHg (n=32) 
 eGFR ≥ 60 ml/min/1.73m2 on last GP record (n=7) 
 Pre-planned major surgical intervention (n=5) 
 Postural hypotension (n=4) 
 Ongoing chronic diarrhoea (n=4) 
 Systolic BP ≥ 180/110 mmHg (n=3) 
 Diabetes mellitus (n=2) 
 Atrial fibrillation (n=2) 
 Heart failure (n=1) 
 Intolerance to anti-hypertensive medication (n=1) 
 Recent hospital admission (n=1) 
Patients attended randomization visit (n=28) 
Patient eligible on screening blood test (n=33) 
Excluded (n=46) 
eGFR ≥ 60 ml/min/1.73m2  (n=29) 
eGFR ≥ 60 ml/min/1.73m2  and serum K+≥ 5 mEq/L (n=2) 
eGFR <30 ml/min/1.73m2  and serum K+≥ 5 mEq/L (n=1) 
Serum K+≥ 5 mEq/L (n=10) 
Significant reduction in eGFR on screening (n=2) 
Other abnormal blood tests (n=2) 
Excluded (n=5) 
Withdrew consent (n=2) 
Did not attend (n=1) 
Unsuitable medical conditions* (n=2) 
Patients randomised (n=16)  
Excluded (n=12) 
Systolic blood pressure <120 mmHg (n=8) 
Postural hypotension (n=3) 
Systolic BP ≥ 180/110 mmHg (n=1) 
 
Allocated to Spironolactone (n=8) 
Received intervention (n=7) 
Did not receive intervention (n=1, withdrew 
consent after randomisation) 
Allocated to placebo (n=8) 
Received intervention (n=8) 
 
Discontinued intervention due to AE  
(n=3, persistent hyperkalaemia, itchiness, 
diarrhoea and vomiting) 
 
Lost to follow-up (n=1, did not attend 
withdrawal visit) 
Discontinued intervention due to AE  
(n=2, joints pain and stiffness, breast swelling) 
 
Lost to follow-up (n=1, did not attend 
withdrawal visit 
 
PWW not performed on final visit (n=1)  
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5.3.1 Invitation to Study Participation 
A total of 1,598 invitation letters were sent out to all potentially eligible patients 
(Figure 5-1). Sixty-three percent were female. The mean age of those invited was 71 
(SD: 12) years and median eGFR was 53 (IQR: 48-57) ml/min/1.73m
2
. Most patients’ 
(84%) last eGFR readings were within the range of 45-59 ml/min/1.73m
2
. The 
ethnicity of those receiving invitations was 83.4% white British, 3.4% black British, 
3.3% South Asian, 1% mixed or other ethnicity and 8.9% unknown. 
 
5.3.2 Patients’ Response to Study Invitation Letter 
Responses were received from 733 patients (46%) who had a mean age of 73 (SD: 11) 
years and 34 % were male. Of these, 196 (12%) expressed interest in participating in 
the study. Percentages of those who were interested in participation ranged from 9% 
to 18% across the 11 practices (Table 5-1).  
 
Of the 537 patients who responded declining participation, 295 (55%) did not wish to 
take a new medication, 220 (41%) did not wish to be part of a research trial, 134 
(25%) indicated that they did not have time to take part in the study, 86 (16%) did not 
wish to have further blood tests, 48 (9%) were unable to attend the surgery, 21 (4%) 
believed kidney problems were of no concern to them and 80 (15%) did not give a 
reason. Other reasons for non-participation detailed in the free-text area on the 
research reply slip included old age, poor mobility, presence of other health issues, 
concerns regarding the side effects of spironolactone, reluctance to take additional 
medication, work commitments, being carer for other family members, being away 
from home during trial period as well as unawareness of CKD diagnosis.  
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Logistic regression model demonstrated that age, male gender and coming from 
research-active practices were associated with a greater likelihood to response 
positively to research invitation, whereas ethnicity and levels of eGFR were not 
predictive (Table 5-2). Age was noticeably non-linear in relation to recruitment, with 
younger and older age associated with a lower likelihood (Figure 5-2).   
 
Table 5-2: Logistic regression demonstrating factors associated with increased 
likelihood of patients’ positive response to research invitation. (Age as Restricted 
Cubic Spline) 
 
Variable Odds Ratio Lower 95% 
CI 
Upper 95% 
CI 
P value 
Intercept 0.01931 0.00095 0.394 0.0103 
eGFR 1.00513 0.98076 1.030 0.6827 
Male gender 1.36905 1.00544 1.864 0.0461 
White Ethnicity 1.51474 0.96679 2.373 0.0699 
Research-Active Practice 1.42223 1.04079 1.943 0.0270 
AGE 1.02677 0.97659 1.080 0.3014 
AGE1 0.93568 0.79398 1.103 0.4275 
AGE2 0.79572 0.15232 4.157 0.7865 
AGE3 3.30525 0.10044 108.771 0.5024 
P for non-linearity for Age    0.0111 
P for overall effect of Age    0.0003                  
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Figure 5-2: Relative odds and 95% confidence interval of recruitment by age using 
restricted cubic spline. 
 
 NB: Solid line = estimate, dotted lines = 95% CIs. 
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Nevertheless, a significant proportion (32%) of patients who replied positively to the 
STOP-CKD research invitation did not, in actual fact, attend the screening visit; they 
either declined further research involvement after telephone invitation to the 
screening visit or were not contactable by the research team (Figure 5-1). Hence, 
further logistic regression was performed to examine factors which were associated 
with increased likelihood of actual attendance at the STOP-CKD study screening visit 
(Table 5-3). Compared to the previous model (Table 5-2), age and male gender 
remained to be strongly associated with actual attendance at screening visit while 
research-active practice was no longer a statistically significant factor. A trend 
towards increased likelihood of research screening attendance was noted amongst 
patients of white ethnicity.  
 
Table 5-3: Logistic regression demonstrating factors associated with increased 
likelihood of actual attendance at the STOP-CKD study screening visit.  
 
Variable Odds Ratio Lower 95% 
CI 
Upper 95% 
CI 
P 
Intercept 0.098   0.025 
eGFR 1.008 0.979 1.037 0.599 
Male gender 1.521 1.063 2.178 0.022 
White Ethnicity 1.716 0.989 2.978 0.055 
Research-Active Practice 1.352 0.937 1.951 0.107 
P for overall effect of Age    0.024                  
 
 
5.3.3 Screening Visit 
Of the 196 patients who initially expressed an interest in participating in the study, 
134 patients (69%) actually attended the screening visit. The characteristics of these 
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patients are presented in Table 3. The cause of CKD was unclear in the majority of 
the patients and only 17 patients (13%) had a documented cause of CKD. The median 
last-recorded MDRD eGFR was 55 (IQR: 51-57) ml/min/1.73m
2
 with 88% within the 
range of 45-59 ml/min/1.73m
2
.  
 
In total, 52 (39%) patients were found to be ineligible for the study during the 
screening visit. The reasons for exclusion are listed in Figure 5-1. The main cause for 
exclusion was low BP. Thirty-two patients had an office SBP lower than 120 mmHg 
with 16 patients receiving at least one anti-hypertensive agent, although five of these 
patients were known to have ischaemic heart disease and thus another potential 
indication for treatment with these agents other than hypertension. Of the 79 
remaining eligible patients, a further 46 were excluded after the screening blood test 
(Figure 5-1). The main reason for exclusion (31 patients) was having an eGFR greater 
than 60 ml/min/1.73m
2
.  
 
5.3.4 Randomisation Visit  
Of the 33 remaining eligible patients, 28 (85%) attended the randomisation visit 
(Figure 5-1). A further 12 patients were excluded at this point. Eight had an office 
SBP less than 120 mmHg, three had postural hypotension and one had uncontrolled 
hypertension. Sixteen patients were randomised and their baseline characteristics 
were shown in Table 5-3.  
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Table 5-4: Baseline demographics, clinical characteristics, blood pressure 
measurements and biochemistry profiles of patients attended screening visit and 
patients randomised to receive trial medication.  
 Attended screening 
visit 
Randomised into 
STOP-CKD study 
Number of patients 134 16 
Male gender, n. (%) 62 (46) 7 (44) 
White ethnicity, n. (%) 125 (93) 16 (100) 
Mean age (SD), years 68 (10) 71 (7) 
Medical history, n. (%) 
 Hypertension 
 Hypercholesterolaemia 
 Coronary heart disease 
 Coronary artery bypass graft/angioplasty 
 Stroke/transient ischaemic attack 
 Peripheral vascular disease 
Total number of comorbidities, median (IQR) 
 
62 (46) 
42 (31) 
17 (13) 
13 (10) 
11 (8) 
8 (6) 
1 (0-2) 
 
5 (31) 
3 (19) 
1 (6) 
0 
1 (6) 
0 
0 (0-1) 
Medications, n. (%) 
Anti-platelet agents 
Lipid lowering agents 
Use of anti-hypertensive agents 
 Diuretics 
 β-blockers 
 ACEi/ARB 
 Nitrates 
 Calcium channel blockers 
 α channel blockers 
Patients not receiving any anti-hypertensive agents 
 
34 (25) 
54 (40) 
74 (55) 
20 (15) 
20 (15) 
48 (36) 
5 (4) 
21 (16) 
11 (8) 
60 (45) 
 
4 (25) 
4 (25) 
9 (56) 
1 (6) 
2 (13) 
5 (31) 
0 
4 (25) 
0 
7 (44) 
Smoking history, n (%) 
 Current smoker 
 Ex-smoker 
 Never smoker 
 
8 (6) 
55 (41) 
71 (53) 
 
1 (6) 
7 (44) 
8 (50) 
BP Measurements 
 Office  systolic BP, mean (SD), mmHg 
 Office  diastolic BP, mean (SD), mmHg 
 Office systolic BP ≥ 140 or diastolic BP ≥ 90 
mmHg, n. (%) 
 Office BP within NICE CKD targets, n. (%) 
 Office systolic BP <120 mmHg, n. (%) 
 
 
132 (19) 
79 (10) 
 
47 (35) 
54 (40) 
34 (25) 
 
133 (10) 
78 (8) 
 
10 (62) 
6 (38) 
0 
Number of patients 79 16 
Na+,  mmol/L 141 (3) 142 (2) 
K+, mmol/L 4.5 (0.6) 4.5 (0.4) 
Urea, mg/dL 6.8 (2.0) 6.9 (1.4) 
Creatinine, median (IQR),  μmol/L 98 (85-112) 101 (86-121) 
MDRD eGFR (median, IQR),  ml/min/1.73m2 57 (51-65) 54 (48-57) 
CKD EPI eGFR (mean, SD),  ml/min/1.73m2 59 (12) 53 (7) 
Urine ACR (median, IQR), mg/mmol 
 < 3 mg/mmol, n. (%) 
 3-30 mg/mmol, n. (%) 
 > 30 mg/mmol, n. (%) 
0.9 (0-2.0) 
62 (79) 
16 (20) 
1 (1) 
0.85 (0.08- 1.95) 
13 (81) 
3 (19) 
0 
Ca+2,  mmol/L 2.38 (0.10) 2.38 (0.13) 
Albumin, g/L 46 (2) 45 (1) 
Total protein, g/L 72 (4) 71 (3) 
Alkaline phosphatase, U/L 78 (25) 79 (17) 
Alanine Aminotransferase,  U/L 20 (8) 19 (7) 
 
Abbreviations: ACEi, angiotensin converting enzyme inhibitor; ARB, angiotensin II receptor blocker; BP, blood pressure,; 
Ca+2,serum calcium; eGFR, estimated glomerular filtration rate; IQR, interquartile range; K+, serum potassium; Na+, serum 
sodium; n., number of patients; SD, standard deviation. 
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5.3.5 Early Termination of Study 
The STOP-CKD study was terminated early because of unfeasibility. In order to 
achieve the original planned sample size of 240 patients, the projected number of 
primary care practices required to be involved in the study would be 145 practices 
covering a population of more than 1.5 million. After thorough discussion, the trial 
DMC and TSC collectively agreed that the study was not feasible with the allocated 
resources. All participants received telephone contacts from the chief investigator 
informing them of the early closure of the study. They were asked to stop taking their 
trial medications with immediate effect and to attend study withdrawal visit.  
 
 Discussion 5.4
In the UK, as indeed in many countries, most patients with early-stage CKD are 
managed in primary care. Many observational studies have established that patients 
with CKD managed in primary care have several differences compared with patients 
managed in secondary care (29). They tend to be older with a lower prevalence of 
proteinuria and more preserved eGFR (29). These differences are important if any 
intervention shown to be effective for the treatment of CKD in the minority of 
patients treated in secondary care is rolled out to the community. The STOP-CKD 
trial was an attempt to establish whether low-dose spironolactone, a treatment shown 
to be safe and effective in improving surrogate markers of CV risk in patients with 
CKD managed in secondary care, was equally safe and effective in patients with CKD 
managed in primary care. Although the study proved not to be feasible, there are 
several important findings and lessons that can be learnt from it to inform future 
interventional studies in this population. 
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5.4.1 Estimating the Number of Patients Needed 
Assessing the number of patients needed to invite in order to recruit to the sample size 
is an essential but challenging requirement in planning any study. Recently, a 
Japanese study explored the use of information technology in predicting the success 
or failure of study recruitment (30). The study derived the eligible EPR index by 
dividing the number of eligible patients identified from the EPR by the target sample 
size. An EPR index of more than 1.7 was reported to have a sensitivity and specificity 
of approximately 70% and 100%, respectively in predicting recruitment success. 
However, in spite of a much higher EPR index of 6.7 that should have predicted 
successful recruitment, the STOP-CKD study failed to reach its target sample size, 
suggesting that other recruitment issues were involved. 
 
Following the EPR search for the STOP-CKD study, the number of patients deemed 
suitable for research invitation reduced considerably after GP review. The variation 
observed in the proportion of patients excluded by the GPs across the practices 
suggests that there were large elements of subjectivity and inconsistency amongst the 
GPs in their assessment of characteristics of patients suitable for this interventional 
study. It is likely that many patients fulfilling the inclusion criteria were excluded at 
this stage. While the review of the list of potential participants by their corresponding 
GPs was well-intentioned, significant selection-bias might have occurred during the 
process and we suggest that in future studies, this step requires revision with clear and 
transparent criteria.  
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5.4.2 Prevalence of Chronic Kidney Disease 
In the UK, primary care physicians are required to keep a register of patients with 
stages 3-5 CKD as part of the Quality and Outcomes Framework (2, 30). Published 
data from the participating practices showed the average percentage of total patients 
on the CKD register was 3.89%, which is lower than the recently published reports 
from UK research databases of 5.15% (31) and 5.9% (32) using The Health 
Improvement Network (THIN) and the Clinical Practice Research Datalink (CPRD), 
respectively and marginally lower than that reported for all English practices over 
2010-2012 of 4.3% (33). Nevertheless, it appears that the observed prevalence of 
CKD is much lower than the 10% figure which was the finding in prospective 
epidemiological work in the UK (33) and globally (34). It has been suggested that the 
prevalence of CKD has been significantly overestimated by using a single serum 
creatinine measurement to define CKD (35) and this has been confirmed in a recent 
UK study using two creatinine measurements which reported a CKD prevalence of 
3.9% (36). 
 
In order to increase patient inclusivity and bypass the issues of un-coded or mis-coded 
CKD (5), we searched and short-listed all patients with a latest recorded eGFR of 30-
59 ml/min/1.73m
2
 in the preceding 24 months. The serum blood test performed at 
screening visit served as a confirmation of CKD diagnosis for all eligible patients. 
Despite having an eGFR within 30-59 ml/min/1.73m
2
 previously, 40% of such 
patients were excluded due to an eGFR greater than 60 ml/min/1.73m
2
 at screening, 
and therefore, by definition did not have CKD stage 3. Of those who fulfilled the 
biochemical eligibility criteria, most had only modest reduction in eGFR with a 
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median eGFR of 54 ml/min/1.73m
2
 and none were found to have significant levels of 
albuminuria (37, 399). 
 
Several limitations associated with such computer screening strategy should be 
highlighted here. In routine practice, blood tests are often performed when patients 
are unwell. Transient, minor reduction in eGFR to the level of below 60 
ml/min/1.73m
2
, most likely reflecting the temporary change of renal haemodynamic 
during the period of illness, might therefore occur. Upon recovery, the majority of 
these patients often return to their baseline eGFRs, especially for those who did not 
have evidence of CKD. Conceivably, such might be the case for some of the patients 
who were invited to the STOP-CKD research following the initial computer screening 
process. Hence, in addition to the well-known fluctuating nature of eGFRs, especially 
at higher readings (400), as well as the impact of dietary intake of protein on the 
measurements, it is perhaps unsurprising that out of the 79 patients who were eligible 
for the screening blood test, 31 were excluded as they do not in fact have evidence of 
CKD with the repeat eGFR ≥ 60 ml/min/1.73m2. Equally, screening for the latest 
eGFRs might have also missed out patients with CKD stage 3b who might have 
transient reduction of eGFR to below the levels of 30 ml/min/1.73m
2
.  
 
Such high numbers of ineligible participants invited to the STOP-CKD study did not 
only have significant implications on the research resources and finances, more 
importantly, despite careful wordings in the research invitation letters, it might have 
also resulted in unnecessary anxiety to the patients. Additionally, as not all patients 
invited to the study have confirmed diagnosis of CKD, their seeming lack of illness 
awareness would therefore need to be interpreted with caution during the qualitative 
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interview study.  In retrospect, these issues could potentially be minimised with the 
use of more than one previous recorded eGFRs. Ideally, on-going effort to improve 
CKD coding by the general practices will greatly facilitate CKD research in primary 
care in the future.  
5.4.3 Blood Pressure 
The treatment of hypertension is still the cornerstone of management of CKD, both in 
terms of CKD progression and the reduction of CV risk (35, 39). In agreement with 
other studies, we found less than half of patients attending the screening visit 
achieved both the SBP and DBP target recommended by the NICE CKD guidelines 
(1). Amongst those with SBP ≥ 140 mmHg or DBP ≥ 90 mmHg, more than 40% were 
in fact not receiving any anti-hypertensive medication. It has long been believed that 
lowering office/clinic BP to levels lower than 120/80 mmHg is associated with worse 
outcomes and increased mortality, especially in the elderly (401). This is reflected in 
recent guidelines on the management of CKD that recommend BP not be lowered 
below these levels (36, 37). The results of the recent SPRINT trial challenge these 
guidelines (402). In the STOP-CKD study, we excluded patients only if they had 
uncontrolled hypertension (BP ≥ 180/110 mmHg), had evidence of postural 
hypotension or had SBP of less than 120 mmHg. Although these criteria were in line 
with current guidelines, in light of the results of the SPRINT trial, future studies 
might consider the inclusion of such patients. 
 
5.4.4 Primary Care Practice Recruitment Strategies 
Though we designed the STOP-CKD study to minimize any extra workload on the 
participating primary care practices, most practices declined the initial approach and it 
took a lot of effort from one or more of the investigators to recruit the 11 practices 
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that participated. In order to improve the quality and quantity of primary care 
research, the NIHR Clinical Research Network and the Royal College of General 
Practitioners have developed a ‘research ready self-accreditation’ initiative to support 
general practices in meeting the legal requirements of the UK for carrying out 
research (5). Thus far, there are more than 1,000 research-ready general practices in 
the UK (5). Our study demonstrated a significant positive influence of research-active 
practices on patients’ reply to research invitation providing further support for these 
measures. Disappointingly, such positive influence of research-active sites did not 
appear to translate into increased research recruitment. The considerable discrepancy 
between positive response to research invitation and actual attendance at research 
screening visit was a noteworthy finding and suggested that other factors were in play 
during the process. Further research to explore and overcome such issues is clearly 
warranted.  
 
5.4.5 Patient Recruitment Strategies 
Although the need for a robust evidence base, usually in the form of RCTs, for any 
intervention before it becomes accepted practice is now well-established, there is 
surprisingly little evidence on how best to conduct an RCT (301, 302). Regulatory 
and ethical issues compelled us to contact potentially eligible patients by mailshot 
through their GPs. This is a notoriously inefficient and costly process with large 
number of invitations needing to be sent to recruit the target number of patients. Two 
key reviews previously explored the value of various strategies in improving 
participants’ recruitment in research studies (6, 41). The STEPS study suggested that 
being flexible and robust in adapting to unexpected issues was important to ensure 
trials success (40) whilst in the systematic review by Treweek et al, telephone 
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reminders to non-responders, opt-out rather than opt-in system of being contacted 
about the study, financial incentives and open designs all appeared to be effective 
strategies (40). We suggest that an initial approach using telephone, text or email may 
yield better results and that further research examining the acceptability and efficacy 
of initial recruitment strategies is of major importance. Our logistic regression model 
showed that younger and older patients were significantly less likely to participate. As 
discussed, the older patients were those we were trying to recruit into the study. This, 
although we designed the study with broad inclusivity, criteria with the aim of 
increasing the generalisability of our results, we still did not manage to recruit the 
“real-life CKD population”, which may be reflecting patients’ self-selection bias. 
Strategies to recruit these patients therefore need developing and testing in future 
studies.  
 
 Conclusions 5.5
The STOP-CKD study was a non-age restricted, investigator-led, feasibility RCT 
designed to inform a future larger, hard end-point study addressing most of the 
problems associated with research in CKD populations detailed above. However, such 
an approach was unsuccessful. The study highlighted the unique characteristics of 
non-diabetic CKD population recruited in the primary care which challenged our 
preconceived knowledge about the appropriate intervention and management of this 
sizeable group of patients. With the majority of interventional studies on CKD 
populations thus far based in secondary and tertiary centres, there remains an urgent 
need to optimise the generalisability of future CKD research, especially in primary 
care. The experience and lessons learnt from this study provide important information 
for all CKD researchers, especially those in the UK to meticulously reflect on their 
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future research aims, study design, choices of intervention and most importantly 
recruitment strategies. As Henry Ford once said, ‘failure is only the opportunity to 
begin again, only this time more wisely’. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 PATIENTS’ PERCEPTIONS OF EARLY 
OR MODERATE CHRONIC KIDNEY DISEASE 
IN PRIMARY CARE 
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 Introduction 6.1
Though quantitative research is widely known for its strength in generating objective, 
reliable and generalisable information if designed and conducted with meticulous 
rigour (403), it is not suitable for investigating certain type of research questions, such 
as understanding patients’ experience or examining barriers to research participation. 
Characterised by its ability to produce rich, comprehensive and in-depth data, 
qualitative research is therefore an ideal method to address such complex or 
unquantifiable social and healthcare research questions (404).  
 
Strauss and Corbin defined qualitative research as ‘any type of research that produces 
findings not arrived at by statistical procedures or other means of quantification’ 
(405). However, the contrast between quantitative and qualitative research is not 
purely confined to the use of numbers (406). Mohr et al described the distinctive 
difference with regards to the ‘mental model’ between the two approaches: 
quantitative research has a ‘variance theory’ approach as it deals with ‘analysis of the 
contribution of differences in values of particular variables to differences in other 
variables’, while qualitative research adopts a ‘process theory’ approach (406, 407). 
This ‘process theory’ approach generates knowledge by analysing ‘the process by 
which some events influence others’ (406) and convey contextual, explanatory, 
evaluative and generative data (404). This provides a way of addressing complex 
issues, which are often difficult or impossible to quantify. In addition, as there is less 
restriction or assumption placed on the data collected, qualitative studies also allow 
broader topics to be studied which are not limited to rigidly defined variables and 
enable in-depth examination of the phenomena using subjective information. Hence, 
they are useful for hypothesis generating or exploratory research (404).  
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As both quantitative and qualitative research approaches have their own unique 
strengths and weaknesses, rather than being in competition, both methods are believed 
to be complementary to each other (Figure 6-1) (408). Steckler et al proposed four 
possible ways to integrate qualitative and quantitative methods: 1. Using qualitative 
methods to help develop quantitative measures and instruments; 2. Using qualitative 
methods to help explain quantitative findings; 3. Integrating quantitative methods to 
embellish a primarily qualitative study; 4. Using both qualitative and quantitative 
methods equally and in parallel (408). When implemented wisely, both methods used 
in tandem can produce fuller and more comprehensive results. The use of qualitative 
research is indisputably valuable in closing the knowledge gap not amenable to 
quantitative research (409, 410). 
 
 
Figure 6-1: Integrating qualitative and quantitative research methods 
 
Although there is an obvious trend of growing awareness and interest in qualitative 
research among healthcare professionals and researchers (411), a study by Lewin et al 
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examining the use of qualitative methods alongside RCTs of complex healthcare 
interventions concluded that the integration of the two methods remained uncommon 
(412). Disappointingly, even when both approaches were used in combination, 
methodological shortcomings and poor timing of the qualitative studies were 
common. Often, findings of the embedded qualitative studies were also inadequately 
integrated with their corresponding RCTs  (412). These reflected under-utilisation of 
crucial opportunities to better evaluate the effects of the interventions and improve 
understanding of participants’ experience (412). 
 
In this current climate whereby patient-centered care is strongly advocated (413), 
better understanding of patients’ perceptions and experience will undoubtedly be 
invaluable in guiding healthcare service providers and commissioners to enhance the 
quality of care provided for patients with CKD. While there has been growing interest 
and improved understanding of patients’ illness perceptions and experience amongst 
those with ESRD (250, 289), research examining similar issues in patients with early 
or moderate stage CKD remains very limited. Though disease burden is generally less 
in patients with early or moderate stage CKD, its significant negative impact on 
patients’ physical and mental QOL is nonetheless noticeable even in its early stages 
(255). 
 
The qualitative interview study nested within the STOP-CKD pilot RCT therefore 
aimed to examine patients’ attitudes towards CKD and research in CKD in the 
community setting. Additionally, it also set out to identify potential barriers to 
research participation and explored potential solutions to overcome the barriers. This 
chapter describes the qualitative methodology of the interview study and details the 
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results of the findings on patients’ perceptions of CKD. In-depth understanding of 
patients’ perceptions of CKD is crucial and forms the foundation for exploring the 
barriers to their participation in research studies in the next Chapter. 
 
 Patient Recruitment for Interview Study 6.2
Patients who were invited to participate in the STOP-CKD RCT were also invited to 
participate in the qualitative interview study.  
 
A total of 1,598 invitations for the STOP-CKD study were sent out to patients with 
stage 3 CKD (Figure 6-2). Together with the STOP-CKD RCT invitation letter and 
patient information sheet, there was a one-page reply slip and a pre-paid envelope for 
patients to inform the study team of their willingness to participate (Appendix 6-1). 
Irrespective of their willingness or unwillingness to participate in the RCT study, on 
the reply slips, all patients were asked if they were interested in taking part in this 
interview study. The reply slip stated that the interview study aimed to explore 
people’s view about a research study in kidney disease in the community. One 
hundred patients replied and agreed to be contacted for the interview study. Based on 
the reply slip, the researcher made contact with willing participants and sent out a 
patient information sheet regarding the interview study. In total, 17 patients were 
consented for the study and interviewed.  
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Figure 6-2: Flow chart of patient recruitment for interview study 
 
 Data Collection 6.3
The data was collected using one-to-one interviews. As the qualitative study primarily 
aimed to examine patients’ attitudes towards CKD and research in CKD, in-depth 
interviews were therefore chosen as the data collection method as opposed to focus 
groups. Focus groups offer less opportunity for the detailed generation of individual 
accounts whilst in-depth interviews allow such delicate and complex issues to be 
explored at a detailed level, enable thorough investigations of each individual’s 
personal perspective and therefore provide an opportunity for in-depth understanding 
of the personal context within which the research phenomenon is located (404). In 
addition, understanding motivations and decisions within complex processes are also 
generally considered to be best addressed in in-depth interviews as it required the 
detailed personal focus that interviews allow.  
 
The interviews were carried out at a place that was convenient to the interviewees, 
either at the interviewees’ home or in a private consultation room at their primary care 
practice. Prior to the interviews, the researcher confirmed that participants had correct 
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understanding of the interview study and obtained informed, written consent from all 
participants (Appendix 6-2). Interviews involved both patients who agreed or declined 
to participate in the STOP-CKD RCT. Purposive sampling aimed to include the range 
of views from participants of different ages, ethnicity and gender (405). These 
sampling factors were chosen in order to maximise the demographic variation of the 
data (414). In addition, the research also aimed to achieve phenomenal variation 
(variation on the target phenomenon under study) in the data by interviewing patients 
who agreed, declined or were found ineligible to participate in the STOP-CKD RCT 
(414). 
 
The interviews were semi-structured, guided by a topic prompt (Appendix 6-3); to 
elicit interviewees’ perception of CKD, views on research in primary care and the 
barriers that exist to research participation. Interviewees were encouraged to openly 
convey their views.  The topic prompt was refined over the course of the study (415) 
and was pilot tested prior to the interview study. After the first four interviews, it was 
noted that some interviewees were not aware of their CKD diagnosis. When asked 
about their understanding of the effect of reduced kidney function, interviewees often 
highlighted their knowledge gap about their kidney condition. In addition, they also 
commented on the term ‘chronic kidney disease’ written on the STOP-CKD RCT 
research invitation letter. Therefore, several changes were made to the topic prompt in 
order to incorporate questions to explore patients’ awareness of CKD diagnosis, 
perception of the term ‘chronic kidney disease’ and perceived knowledge gap about 
CKD.  
 
All interviews were audio-taped, with the interviewees’ permission, and transcribed 
verbatim. Interviewee transcript review (ITR) is a process whereby interviewees are 
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provided with their interview transcripts for verification and review (416). As this 
study aimed to produce data which reflected precisely what was said at the time of the 
interview, the researcher therefore chose not to perform ITR. In addition, this decision 
was also made in order to avoid issues with inconsistent data sources or loss of data 
when the interviewee chose to remove valuable material (416). All transcripts were 
read and checked for accuracy by the researcher and the text entered into a 
computerized database using the NVivo (QSR International) qualitative software 
package for coding and analysis. Interviewing continued until no new relevant 
knowledge was generated from new participants and adequate data saturation 
appeared to be achieved (17 interviews) (417).  
 
 Data Analysis Method 6.4
A grounded theory approach was used to inform and guide data collection and 
analyses (418). Developed by Glaser and Strauss in 1967, grounded theory derives its 
theoretical underpinnings from Pragmatism and Symbolic Interactionism (405). 
Pragmatism assumes that ‘knowledge is created through action and interaction’ 
whereas symbolic interactionism aims to ‘explore behaviours and social roles to 
understand how people interpret and react to their environment’ (405). The grounded 
theory provides a systematic approach to the analysis of qualitative data and enables 
the development of theory that is ‘grounded’ in the reality of the data (418). This 
grounding of concepts in the data ensures theory-observation compatibility and 
guards against researcher bias. (419). The key methodological procedures of 
grounded theory research are an iterative approach, theoretical sampling and constant 
comparisons during data analysis (Figure 6-2) (405). Corbin and Strauss advocated 
data collection and analysis as interrelated processes (419). The iterative approach of 
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grounded theory represents cycles of simultaneous data collection and analysis, in 
which the results of the ongoing data analysis inform the next cycle of data collection 
(420). This responsive data collection method based on concepts derived from the 
previous data collected is therefore termed ‘theoretical sampling’. In contrast to a 
conventional sampling method which has a predefined sampling population, 
theoretical sampling is both concept-driven and cumulative (405). Data sources are 
selected purposively for their potential ability to develop further emerging analytical 
considerations. (420). With each cycle of sampling bringing in more data to build 
upon the previous analysis, the subsequent sampling becomes more specific with time 
until categories reach the point of ‘saturation’. (405). While ‘total saturation’ of data 
is unlikely to be fully achieved in reality, ‘data saturation’ is generally considered as 
the point in data collection when new information does not contribute any new 
insights relevant to the overall model, theory or framework (405).  
 
Constant comparison is the central principle of data analysis in grounded theory 
research. All issues of interest noted in the data are continuously compared against 
other examples for similarities and differences (419). This facilitates greater precision 
and consistency in labelling and grouping of concepts (419). Through this iterative 
approach and constant comparison process, the grounded theory method allows 
relevant concepts to be identified as soon as they are perceived and these concepts can 
then be challenged, expanded, evolved, refined and developed in depth as the study 
continues (419). With time, such concepts accumulate in number, become more 
abstract and allow development of categories (419). Described as the ‘cornerstones’ 
of developing theory, well-defined categories provide explanatory power to facilitate 
emergence and integration of theory (419).  
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Figure 6-3: Concept of grounded theory approach (405). 
 
Coding forms the basis of data analysis. In qualitative research, a code refers to ‘a 
word or short phrase that symbolically assigns a summative, salient, essence-
capturing, and/or evocative attribute’ for a portion of data (421). Grounded theory 
described the use of three basic types of coding: opening coding, axial coding and 
selective coding (419). In open coding, issues of interest are compared with others for 
similarities or differences and the conceptual labels (codes) are then assigned to the 
raw data. As the codes and categories grow, axial coding aims to establish the 
relationship between the categories and codes. At the later stage of study, selective 
coding unifies all categories around a ‘core’ category (419).  
 
The use of numbers in qualitative research has been a matter of ongoing debate. 
Though several qualitative researchers valued the use of numbers as a complement to 
an overall process orientation to the research (422-425), concerns about the 
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appropriateness of its use remain (404, 426, 427). As the sampling strategy in 
qualitative research does not aim to identify a statistically representative set of 
respondents, incorporating numbers in results might lead to the inference of greater 
generality for the conclusions than is justified (406). In addition, it can also detract 
from the reading style and risk imposing a ‘variance theory mental model’ on the 
research which potentially undercuts the strength of the ‘process theory’ that 
qualitative research offers (section 6.1) (406). Based on these arguments, this study 
has therefore chosen mainly to make quantitative claims in verbal form, using terms 
such as some, several, many, often, typically, sometimes. Numbers were used on 
limited occasions when researcher felt that its use would complement the reporting of 
qualitative information. 
 
The findings of this interview study are organised under two main research areas, 
which are ‘patients’ perceptions of early or moderate CKD in primary care’ and 
‘factors influencing research participation in patients with early to moderate CKD’. 
They are presented in chapter 6 and 7, respectively.  
 
 Interviewer Characteristics 6.5
All interviews were conducted by a single researcher (the author). The researcher was 
a 33 year-old female, of Chinese ethnicity, with good command of English. She was a 
clinical researcher in CKD and a hospital doctor specialising in renal medicine at a 
large tertiary referral hospital who was familiar with the diagnosis, treatment and 
management of patients at different stages of CKD. She introduced herself as a 
‘kidney doctor who is involved in the STOP-CKD study’ to the interviewees and 
explained that all general queries would be answered at the end of the interviews. 
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Aware of the potential influence of her professional role as a doctor on the interview 
(428), the researcher made it clear that she was not involved in interviewees’ medical 
care and did not have access to patients’ personal medical information. Therefore, all 
personal health queries raised by the interviewees were referred to their own GPs.   
 
The researcher was involved in both the recruitment of the quantitative RCT and the 
qualitative interview component of the STOP-CKD study. Hence, she had prior face-
to-face encounter with several of the interviewees who had been screened or recruited 
in the quantitative RCT before the interviews. Rapport appeared to be achieved more 
readily with those she had a prior face-to-face encounter with compared to others. 
However, she attempted to maintain similar structure and coverage during the study 
with the help of the topic prompts in all the interviews. Being interviewed by a person 
who was also the ‘research doctor’ might influence interviewees’ level of openness 
towards the RCT study. The researcher therefore attempted to alleviate the issue by 
emphasising that one of the aims of the interview study was to try to identify barriers 
in order to facilitate future studies and therefore encouraging interviewees’ opinions 
and input.  
 
She adopts a subtle realism stance, assuming that there is an objective reality apart 
from the human knower however, ‘our understanding of the world is inevitably a 
construction from our own perspective or standpoint’ (429). Hence, ‘one can only 
know reality from his/her own perspective of it’ (404).  
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 Results 6.6
6.6.1 Interview Settings  
All interviews with patients were conducted at home, apart from one who chose to be 
interviewed in a private consultation room at his GP practice. Patients were given the 
choice regarding the presence of a non-interviewee during the interview. Non-
interviewees were present during three of the interviews with the patients 
(Interviewees #1, #5 and #9) and two of the non-interviewees contributed some of the 
data generated during the interviews (Interviewees #5 and #9). The duration of the 
interviews ranged from 12 to 43 minutes.  
 
6.6.2 Patients’ Characteristics 
Of the 1,598 patients invited to participate in the interview study, 100 (6%) patients 
expressed interest in being interviewed. Of these 100 patients, the majority were of 
white ethnicity (96 patients), only three patients were Afro-Caribbean and one was 
Asian. After telephone contact or mailing of interview information sheet to the 
potential participants, 17 patients responded and eventually agreed to the interviews 
(Figure 6-1). Purposive sampling of patients with different age and ethnicity were not 
achieved as the vast majority of patients willing to be interviewed were of older age 
and white ethnicity. Patients from different general practices and of various levels of 
involvement in STOP-CKD RCT (see Table 6-1) were therefore purposively sampled 
for interviews in order to enhance the diversity of the opinions captured in the study.  
 
The majority of the patients interviewed were female and older than 65 years. All 
interviewees were of white ethnicity. They were from six different general practices 
in the south Birmingham area. Two patients were enrolled into the RCT; one had 
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withdrawn from the RCT; one was waiting for a screening appointment; seven were 
ineligible for the RCT while six declined RCT participation but agreed to the 
interview study. Interviewees’ characteristics are summarised in Table 6-1. 
 
Table 6-1: Interviewees’ characteristics  
No. Age Gender Practices Ethnicity Participation in STOP-CKD RCT 
#1 70 Male A White Attended screening visit but was ineligible for the study  
#2 65 Male A White Attended screening visit but was ineligible for the study  
#3 71 Female A White Attended screening visit but was ineligible for the study  
#4 41 Female A White Attended screening visit but was ineligible for the study  
#5 71 Male B White Declined participation 
#6 70 Female A White Withdrawn from study due to adverse events  
#7 77 Female C White Attended screening visit but was ineligible for the study 
#8 68 Male A White In study 
#9 63 Female A White Attended screening visit but was ineligible for the study  
#10 67 Male D White Attended screening visit but was ineligible for the study  
#11 80 Female D White Declined participation 
#12 75 Female D White Declined participation 
#13 76 Female E White Await screening visit 
#14 74 Male D White In study 
#15 69 Male E White Declined participation 
#16 80 Female F White Declined participation 
#17 79 Female D White Declined participation 
 
6.6.3 Interview Themes 
Six themes emerged from the interviews with regards to patients’ perception of CKD: 
awareness, explanation provided, emotions, perceived knowledge, views on the term 
CKD and perceived knowledge gap. Though ‘views about the term CKD’ came under 
the umbrella theme of ‘knowledge’, it was intentionally singled out as a stand-alone 
emergent theme as it was found to be an influential factor in understanding patients’ 
perception of CKD diagnosis as well as their willingness to participate in the STOP-
CKD study. Each theme is summarised in Table 6-2.  
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All these themes interact with and influence one and another. The relationship 
between the six themes is illustrated in Figure 6-3. Patients’ perception of CKD 
encompasses awareness, emotions and their perceived knowledge of the diagnosis. 
All of which in particular, the awareness of diagnosis, are influenced by the 
explanation (or the lack of explanation) received. Conversely, patients’ existing 
knowledge regarding the effect and long-term implications of reduced kidney 
function as well as their views on the term ‘CKD’ were also found to affect their 
diagnosis awareness and emotions. As patients with early or moderate stage CKD are 
often asymptomatic, for those who perceived CKD as a severe, debilitating illness, 
some rejected the diagnosis due to the incongruence between their perceived 
knowledge of CKD and their current state of health. Whilst for others who accepted 
the diagnosis, such perceived knowledge of CKD invariably resulted in significant 
negative emotions.  
 
During most of the interviews, patients expressed their illness experience or views on 
CKD in the sequence of illness awareness, explanation provided and emotions 
reactions towards the diagnosis. These were then followed by the researcher further 
exploring their views on the term ‘CKD’ and their perceived knowledge as well as 
perceived knowledge gap. Hence, the flow of the themes are presented in the manner 
which represents both the order of how the story was unveiled and the gradual 
increasing depth of data providing understanding of patients’ perceptions of CKD.  
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Figure 6-4: The relationship between themes of patients’ perception of chronic kidney 
disease. 
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Table 6-2: Descriptions of the emergent themes on patients’ perception of chronic 
kidney disease. 
Theme Description 
 
Awareness 
 Related to long-standing renal condition 
 Related to other illness 
 Incidental finding during routine blood 
test 
 From STOP-CKD invitation 
 Unaware 
 
 
Patients’ awareness of their current kidney function, 
their diagnosis of CKD and how they were made 
aware of their kidney condition.  
Explanation provided 
 By hospital doctors 
 By GP 
 By Research team 
 
 
The information and explanation provided by the 
healthcare professionals to the patients’ regarding 
their CKD diagnosis. 
Emotions 
 Unaffected 
 Fear 
 Concerned  
 
 
Patients’ emotional reactions when they became 
aware of their diagnosis of reduced kidney 
function/CKD.  
Views on the term ‘chronic kidney disease’ 
 Patients’ definition of chronic kidney 
disease 
 Emotional reaction to the term 
 Suggestion of alternative terms 
 
 
Patients’ view of the term, chronic kidney disease 
and their emotional reaction towards to the 
terminology. Patients were also asked to suggest a 
more appropriate alternative to describe the 
condition if they disagreed with the use of the term.  
 
Perceived knowledge 
 CKD and ageing 
 Symptoms of reduced kidney function 
 Need for dialysis 
 Need for transplant 
 Impact of quality of life 
 Impact of life expectancy 
 
 
Patients’ existing knowledge regarding the effect of 
reduced kidney function and its long-term 
implications.  
Perceived knowledge gap 
 Current level of kidney function 
 ‘Dangerous level’ of kidney function 
 Cause of CKD 
 Implication of CKD diagnosis 
 Lifestyle and diet advice 
 
 
Patients’ perceived knowledge gap of their current 
kidney condition or overall knowledge of kidney 
disease.  
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6.6.3.1 Awareness 
CKD, in its early and moderate stage, is usually a silent condition. The diagnosis is 
often made as a result of an incidental finding during routine blood tests or while 
investigating for other illnesses. The majority of patients with CKD remain 
asymptomatic, unless the disease progresses to the advanced stage (ESRD) which 
occurs only in a minority. Hence, understanding patients’ awareness of the diagnosis 
of their kidney condition is the crucial first step in gaining deeper insight into their 
perception of CKD. 
 
However, not all CKD diagnoses were accidental findings. Several interviewees had 
an established cause of kidney disease, for instance, unilateral nephrectomy due to a 
kidney tumour (interviewee #8, #14) or kidney stones (interviewee #4, #15). 
Invariably, these patients have been through extensive investigations in the secondary 
care setting and were followed-up closely after the operation was performed.  
 
“So I had one kidney taken away and everything else and then I was under the 
consultant there for about two years or more looking at, seeing how I progressed and 
everything else and various blood tests.” Interviewee #14 
 
Though these interviewees were aware of their ‘kidney condition’ and were able to 
explain in detail the events leading up to the diagnosis, it was intriguing to find out 
that three of these four interviewees (interviewees #8, #14 and #15) did not perceive 
themselves as having CKD.  
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“I don’t know really because I haven’t got chronic kidney disease as far as I know.  I 
had kidney stones years and years ago and it caused a blockage and therefore one of 
my kidneys stopped working.  So that’s what my problem is.  That is all I know 
really.” Interviewee #15 
 
“I don’t think of myself as having (chronic kidney disease), no, I don’t think so, no. I 
think I have moderate probably kidney disease.” Interviewee #8 
 
Some of the interviewees were informed by their GP of their reduced kidney function 
as part of routine blood tests. More often than not, the wording of ‘kidney function 
being slightly reduced’ was being used by the GP when informing patients rather than 
the term CKD.  
 
“Well, the last 3 to 4 years, when I’ve had my MOT, as you call it, which we refer to 
it, my doctor has said to me that there’s a slight failing of the kidney...” Interviewee 
#1 
 
Nonetheless, not all patients were aware of their diagnosis of CKD. Several patients 
were only made aware of their CKD diagnosis when they received the invitation for 
the STOP-CKD study.  
 
“Well, I went to the doctors and I had a blood test.  I never heard any results of it.  
The next thing is what I had off you, the letter off you saying your kidney function is 
low…” Interviewee #5 
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In addition to the varying levels of awareness of kidney diagnosis among the 
interviewees, it was also noted that there was clear discrepancy between awareness of 
‘kidney problems’ and awareness of the CKD diagnosis among the interviewees. The 
term CKD was often not brought up by the GP to the patients when explaining the 
findings of their reduced GFR on the blood tests. Upon receiving the STOP-CKD 
invitation letter, while some patients were alarmed by their unexpected diagnosis of 
CKD, others remained adamant that the term CKD was not applicable to them as they 
felt ‘too well’ to be labelled with such a term. Consequently, some of the patients 
regarded the STOP-CKD study as irrelevant to them, even those who knew there was 
‘slight failing of their kidney functions’, and therefore chose not to participate in the 
RCT. Such rejection of the diagnostic label of ‘CKD’ is a noteworthy and crucial 
finding among this group of patients and appeared to be influenced by their ‘views 
about the term CKD’. This is further explored in section 6.4.6. 
 
6.6.3.2 Explanation Provided 
Though not all interviewees in this study said that they were informed of their 
diagnosis, among those who were, the researcher explored the explanation they 
recounted being given when they were informed of their reduced kidney function or 
diagnosis of CKD.  
 
When the automated reporting of eGFR was first implemented, some GPs were not 
fully convinced of the usefulness of the test. One of the interviewees clearly described 
the frustration and uncertainty he sensed from his GP when the blood test was initially 
offered to him a few years ago. Nonetheless, he was unsure of the exact reasons 
underlying such uncertainty. 
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“He said there is this test you can now have for kidneys. He said but sometimes it can 
be a little bit of a nuisance sort of thing, so why I don’t know.” Interviewee #11 
 
One of the patients was given an explanation about the fluctuating nature of the eGFR 
test and was reassured about the finding of a reduced eGFR. The same patient was 
also told that it might be related to the medication he was taking. 
  
“(He) said my kidney function was a lower figure than what it was previously, but as 
long as it keeps filtering and it keeps me alive I don’t mind too much, but they did 
explain that it can fluctuate – next year it could be different – it could be up again… 
… Again, of course, you ….. it depends upon what medication you are on, I mean 
there is no medication you take without having some adverse effects, and I’m on 
Lisinopril, which is for blood pressure and that, I believe, can have certain adverse 
effects, although slight, on kidney function.” Interviewee #2 
 
In general, one of the most common explanations received by the interviewees was 
that CKD was part of the ageing process. 
 
“They just said your kidneys look slightly down on what they used to be, but that 
comes with age.” Interviewee #1 
 
While some interviewees accepted the brief explanation that reduced kidney function 
was just an invariable effect of ageing, one interviewee clearly felt that further 
information and elaboration was warranted.  
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“Yes, well I think the letter that was sent out highlighted that kidney function goes 
down in connection with age but then I think to myself, well there is (are) an awful lot 
of the various functions that we have that go down with age but I think perhaps that 
might be useful if there were more information available...” Interviewee #17 
 
Nevertheless, some of the interviewees did not recall a detailed explanation of their 
blood test results (eGFR) by their GP but they were often reassured that it was not of 
any significance.  
 
“I was told that my blood sample wasn’t quite right, but nothing significant, nothing 
to be concerned about.” Interviewee #3 
 
Patients with early or moderate stage CKD, especially in the elderly population, are 
known to have far greater risk of CV disease and death than progression to ESRD. 
Although some patients were made aware of the importance of regular surveillance in 
order to monitor for any decline in the kidney function, the majority of the patients 
were not informed of the long-term implications of CKD on the CV system.  
 
“Not really.  He didn’t seem to think, provided it did not deteriorate anymore, 
because I think, I don’t know, I forget what the level is now, I can go down to 10% 
before it is critical really so there is still a way to go before I would be in any trouble 
...”  Interviewee #8 
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Overall, interviewees recalled different aspects of information given regarding their 
diagnosis of reduced kidney function. The overriding features of the theme are the 
lack of awareness of CKD diagnosis and the perceived reassurance from their GPs 
regarding the condition. While a brief, reassuring explanation might be adequate for 
some patients, others clearly could have benefited from further explanation, 
elaboration and discussion. In addition, an over-focus on reassuring the patients might 
also distract both the GPs and patients from discussion of other key issues related to 
the CKD diagnosis.  
 
6.6.3.3 Emotions  
Interviewees’ emotional reactions towards their CKD diagnosis were heavily 
influenced by the explanation provided as well as their views on the term CKD. The 
emotions interviewees experienced were of two kinds: alarm or acceptance. While 
some patients described only one emotion, others recounted their emotional transition 
from alarmed, worried and concerned to acceptance. Reassurance from the GPs was 
often associated with a more positive emotional response (i.e. acceptance) from the 
interviewees. However, the frequent omission of the term ‘chronic kidney disease’ by 
the GPs during their explanation of diagnosis occasionally caused a delayed 
outpouring of anxiety among some of the interviewees as they considered ‘slightly 
low/reduced kidney function’ and ‘chronic kidney disease’ to be of two complete 
different entities.  
 
When interviewees were told that their reduced kidney functions were related to 
ageing, many accepted the explanation and were not overly concerned. The absence 
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of symptoms to ascribe the diagnosis to appeared to have also decreased the 
significance of the condition perceived by the interviewees and lessened their anxiety. 
 
“Well, the fact that I was…. well you know, I mean I know we all grow old and things 
start to fail me, so I thought well if it comes with age then you’ve just got to take it.” 
Interviewee #1 
 
“Just accepted it, I wasn’t having any problems so why worry about something that 
might not happen.” Interviewee #3 
 
Nevertheless, as explanations given to the patients often appeared to be brief, 
patients’ perceived knowledge gap could potentially lead to uncertainty and anxiety. 
Despite an initial feeling of indifference about his diagnosis, one interviewee started 
to question his own emotions on further probing. 
 
“Not unduly worried.  Erm… no I wouldn’t say so.  I mean, when should I be unduly 
worried?  I mean, how would you know if you should be unduly worried?  What are 
the signs and symptoms that you may come across?  Is it excessive tiredness, 
excessive drinking, dryness?” Interviewee #2 
 
In contrast, some interviewees described fear and anxiety when they first found out 
about their diagnosis of CKD. One of the interviewees who used to work as a health-
care assistant in a haemodialysis unit likened the diagnosis to a death sentence. She 
portrayed vividly the upsetting complications and the inevitably shortened lifespan 
patients receiving haemodialysis suffered. Such experience undoubtedly evoked a 
strong negative emotion when she was made aware of her condition.  
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“First thing is ‘God, am I gonna die?’… And then you think to yourself, you feel like 
have I got a death sentence? It must be the same kind of feeling as when you know 
you’ve got cancer.  I mean I know it’s not as bad, but you know, you think to yourself 
– am I gonna die?  That’s your first thought.” Interviewee #4 
 
However, after she was reassured by her urologist and nephrologist that she was 
unlikely to require haemodialysis in the future, her fear and concerns dissipated.  
 
“I’m quite positive now, I’m … but you know when you first think, oh god – I’ve got a 
death sentence.” Interviewee #4 
 
As some of the interviewees were unaware of their diagnosis of CKD, they were 
shocked by the invitation letter for the STOP-CKD study. The unexpected diagnosis 
conveyed in the form of a research invitation letter was frightening for these 
interviewees. Without prior notification from the GP regarding their kidney function 
and the absence of any kidney-related symptoms, the interviewees undoubtedly found 
it hard to accept the diagnosis. 
 
“Well it is a little bit of concern when you get a letter.  I’ve just had a…. not long had 
a blood test and then you get this letter saying, you know, noticed in your blood when 
you had your last blood test at the doctors, there’s chronic disease.  I thought 
whoops, you know, they’ve sent this out to the wrong person.” Interviewee #6 
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“I was surprised when I had the letter. My doctor had never told me I had got 
problems at all and I don’t feel I have problems so it came as a bit of shock.” 
Interviewee #13 
 
 
Even among those who had been informed by their GP of their recent kidney function 
test and were unperturbed by the diagnosis previously, one interviewee was still 
alarmed when he received the STOP-CKD invitation as he assumed that his kidney 
condition had significantly deteriorated for him to be labelled with CKD.  
 
“I was very blasé when he (patient’s GP) told me. I wasn’t frightened of anything. I 
don’t know whether I should have been.  The only thing was I suppose I was a little 
bit, I wouldn’t say shocked that is a bit strong, but I was a bit alarmed and I had 
something from yourselves (STOP-CKD invitation letter) that said critical, critical 
(chronic) kidney…He (patient’s GP) didn’t use that word chronic…” Interviewee #10 
 
As expected, interviewees’ emotional response was closely linked to how they were 
made aware of their CKD diagnosis and the explanation given. A few of the 
interviewees found out about their CKD diagnosis as a consequence of kidney 
tumours or kidney stones disease. These patients were seen and cared for mainly by 
the secondary care centre and they invariably went through the initial emotional phase 
of shock (due to diagnosis of kidney tumour) to a later phase of acceptance. In 
contrast, interviewees who were informed of their reduced kidney function as an 
incidental finding and were reassured by their GPs were relatively unaffected by the 
diagnosis. Some accepted it as an inexorable by-product of ageing and therefore felt 
that there was no reason to be worried since they ‘couldn’t do anything about it’. In 
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addition, the lack of any perceived kidney-related symptoms also seemed to have 
reassured the interviewees. However, those who had only realised their CKD 
diagnosis via the STOP-CKD research invitation letter were understandably shocked 
and upset on realisation of their diagnosis. Interviewees typically equated CKD to a 
form of severe, advanced illness. Denial of the diagnosis was evident among a few 
interviewees as they ‘felt too well’ to have CKD while some interviewees described 
resentment towards their GPs as they were not informed of any kidney problem prior 
to the research invitation letter.  
 
6.6.3.4 Views on the term ‘Chronic Kidney Disease’  
An interesting observation which arose during the study was that not only were a 
significant proportion of the interviewees not aware of their diagnosis of CKD, but 
among those who were informed by secondary or primary healthcare providers of 
their kidney condition, the majority did not believe that the term was applicable to 
them. Most of the interviewees only encountered the term via the STOP-CKD 
invitation letter. Thus, the interviews explored patients’ views on the term ‘chronic 
kidney disease’ in order to examine the issues underpinning the above finding. 
 
The majority found the term ‘chronic kidney disease’ alarming and frightening. In 
medical terminology, chronic is an adjective relating to time and is used to define any 
illness that is persistent or constantly recurring (430). Knowing chronic meant 
permanent and incurable had triggered fear in one of the interviewees.  
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“It is a shock to actually know, you know, that you’ve got something that you’ve got 
to live with for the rest of your life.” Interviewee #4 
 
Though a few patients had correctly understood the meaning of ‘chronic’, a number 
of patients assumed that it defined the severity of an illness and believed that it 
denoted ‘critical’, ‘bad’ or ‘very severe’.  
 
“Chronic? Erm… it’s bad and they just keep failing… you know kidney disease yeah, 
but chronic kidney disease, it’s a bit alarming really.” Interviewee #6 
 
“Chronic to me is a level that is much higher than kidney disease.  It is a level that 
has gone beyond the point of just having a little bit of kidney disease. Being in 
chronic; you are right at the top end of the kidney disease.” Interviewee #10 
 
As many of the interviewees perceived CKD as a severe, advanced form of kidney 
disease, they believed that any patients with CKD would indisputably be suffering 
from all the ill-effects of having minimal or no kidney function. This perceived state 
of extreme ill-health related to CKD diagnosis was so distant from interviewees’ 
current state of health that they instinctively dissociated themselves from the label of 
CKD. One interviewee even felt the need to offer sympathy to ‘those with CKD’. 
 
“Chronic kidney disease, chronic kidney disease, I would think really is the worst 
type.  The people who really need the new kidneys or something, whereas with me I 
feel, no, I don’t need that…” Interviewee #13 
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“Well I am sorry for anybody who has it”. Interviewee #12# 
 
Besides having strong negative reactions to the word ‘chronic’, some interviewees 
also expressed trepidation about ‘kidney disease’. Kidney disease was equated to 
kidney failure among some of the interviewees and some also believed that it 
signified imminent death.  
 
“I think chronic kidney disease would probably be chronic kidney failure sort of 
thing.” Interviewee #14 
 
“Kidney disease means you are going to die if you don’t deal with it.” Interviewee 
#12 
 
In addition, one interviewee also associated the word ‘disease’ with something 
contagious.  
 
“I think straight away the first thought in your head is you know you say you’ve got a 
disease, you think, am I contagious?” Interviewee #4 
 
After the researcher collected interviewees’ views on the term CKD, she went on to 
explain the true meaning and the medical definition of the term. They were then asked 
if they considered the term CKD as appropriate or whether an alternative term should 
be used instead to describe the condition, especially in the early/moderate stage. 
While one interviewee believed that the term CKD was an appropriate medical term 
provided it could be explained to the public clearly, others suggested changing the 
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word ‘chronic’ or the word ‘disease’ to alternative terms, for instance, ‘slight kidney 
disease’, ‘mild kidney disease’, ‘manageable kidney disease’ or simply ‘kidney 
disorder’.  
 
“Well, I would call it manageable kidney disease because it is managing on 
medication on that basis.  Manageable that is how I would describe it now on that 
basis.  It is almost like a set of traffic lights your red, green and amber type thing.  
Green you are okay fine, amber half and half type thing and red and you are chronic 
on that basis type thing.” Interviewee #14 
 
Strong negative perceptions of the term CKD were closely linked to interviewees’ 
emotional reaction when they received the STOP-CKD research invitation letter, even 
among those who were aware of their reduced kidney function previously. Emphasis 
was laid upon the word ‘chronic’ which the interviewees perceived to have a strongly 
negative connotation. Though in medical terminology, chronic purely denotes long-
standing, (in contrast to acute), according to the Oxford Dictionary, ‘chronic’ has also 
been used informally to describe anything of poor quality (431). This perhaps helped 
to explain interviewees’ refusal of the CKD diagnosis and hence non-participation in 
the STOP-CKD study.  
 
6.6.3.5 Perceived knowledge 
Patients’ knowledge of the location and the functions of the kidneys as well as their 
understanding of the effects of reduced kidney function were explored in this study. 
The majority of the interviewees had vague ideas of the location of the kidneys and 
believed that they are around the middle of the back or sides of the abdomen. Most 
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also understood the basic, key functions of the kidneys. Interviewees described 
kidneys as the ‘filter for the body’, associated with the ‘water-works’ of the body 
which work to remove the waste products.  
 
“Well, I understand that they obviously purify your blood and that lots of things pass 
through your kidneys to clear them of toxins and things like that, yes.” Interviewee 
#16 
 
In addition, interviewees were also asked about their knowledge of the effects of 
reduced kidney function and its long-term complications. As most of the interviewees 
were aware of the main function of the kidney, they commented that the reduction of 
kidney functions would result in reduction of urine output, deterioration of health and 
inevitably lead to the ‘build-up of toxins in the body’. Some interviewees also went 
on to point out the consequent need for dialysis treatment, kidney transplant or even 
death.  
 
“You’re going to get a build-up of toxins in your body, which means you’re going to 
go into kidney failure and then might have to have removed or get an artificial 
kidney.” Interviewee #3 
 
“Well, very ill health.  Big problems!  I mean, can be death obviously.” Interviewee 
#18 
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Some also commented on other issues associated with reduced kidney function, for 
instance, ‘blood in the urine’, hypertension, lethargy and reduction of quality of life. 
In general, most perceived it as a serious, life-threatening condition. 
 
“Well, I think high blood pressure and general reduction in energy and everything 
that goes with you know being alive.” Interviewee #17 
 
“Well I haven’t come across it a lot but I understand it is in its worst aspects, quite 
serious and it can alter you know your condition and quality of life.” Interviewee #16 
 
Interestingly, one interviewee was aware of the impact of CKD on arteries based on 
the experience of his relative with kidney disease.  
 
“I think it reduces flow of blood to the extremities of your body, like your toes, your 
hands and things like that where…. I  am only saying this out of experience of an aunt 
of mine who is a diabetic which it’s the same sort of thing, it has an effect on the 
kidney and unfortunately for her, her arteries narrowed, or whatever it does do and 
she has had an amputation…Now that is what I call chronic.” Interviewee #10  
 
Though several of the interviewees sounded uncertain when they were asked about 
the effects of reduced kidney function, the majority of them did have good 
understanding of the impacts of advanced CKD. The description ‘reduced kidney 
function’ was often used loosely throughout the interviews by the researcher to denote 
any severity of CKD, however, as mentioned under the themes ‘awareness’ and 
‘explanation provided’, interviewees appeared to perceive the two descriptions, 
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‘slightly low/reduced kidney function’ and ‘CKD’, rather differently with the former 
seemingly being a much less severe, less significant condition compared to the latter. 
Nevertheless, when they were asked about the effects of ‘reduced kidney function’, 
the majority of the interviewees described a rather advanced condition and portrayed 
a bleak outlook, which they would not apply to themselves. The significant disparity 
between patients’ perception of their own ‘slightly reduced kidney function’ diagnosis 
being a much less severe medical condition than their general view of ‘reduced 
kidney function’ among some of the interviewees was clearly a noteworthy 
observation.  
 
6.6.3.6 Perceived Knowledge Gap 
In the midst of the interviews, some interviewees began to ask the researcher various 
questions in relation to their kidney function, CKD diagnosis and its implication. 
These included those who had apparently received diagnosis information, explanation 
and reassurance from their GPs previously. As GPs’ consultation time was limited, 
some felt that they ‘did not want to waste their GPs’ time by asking more questions.  
 
Understanding CKD to be a long-standing illness, information regarding lifestyle- or 
diet-change to improve or prevent any decline in their kidney function were topics 
that emerged repeatedly during the study. In addition, one interviewee also 
commented on the conflicting information he encountered regarding dietary 
restriction and said he would appreciate clarification from the healthcare 
professionals. 
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“Yes, I probably should have asked if there was anything I can do, as I did with my 
angina - I knew I’d got to pack up salt or as the hospital said, salt - cut down, 
cigarettes, alcohol, exercise, you know.” Interviewee #1 
 
Another commonly raised question was regarding the cause of their CKD, especially 
for one interviewee whose father died of kidney cancer. 
 
“If I have got reduced kidney function, then why have I got it?  I got a bit scared 
about it really because I lost my father to kidney cancer…” Interviewee #9 
 
Prognosis, progression, frequency of monitoring and long-term implications of having 
CKD were other areas where the interviewees felt they had been poorly informed.  
 
“If my kidneys aren’t as good as they were what can I expect to happen?” 
Interviewee #1 
 
“Whether it is detrimental to my health, if not now perhaps but a little later on and if 
you can sort of find that out, yes I would prefer to know.” Interviewee #13 
 
“How do you know if the kidney…. If the number fluctuates, and there’s a year 
intermittently, how do you know that there’s no damage going on between the next 
examination and the previous one?  Is a year safe?” Interviewee #2 
 
While one of the interviewees simply wished that her GP had told her about her 
kidney diagnosis, others were keen to find out more about their current level of 
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kidney function as well as the different stages of CKD. As CKD encompasses a wide 
spectrum of severity, interviewees clearly felt it was important to be informed about 
the scale of their own condition.   
 
“I don’t really know the extent of my kidney function and what it means to me.  I don’t 
know what my level of…” Interviewee #10 
 
“Nobody’s ever told me what stage I’m on, because obviously we have patients and 
like they’ll have like CKD stage 3 or something, and like I don’t understand the 
stages…” Interview #4 
 
Nonetheless, a simple description of kidney function in either numerical (i.e.: 52, 47, 
etc.) or ordinal scale forms (i.e.: mild, slight, etc.) did not appear to be adequate for 
some of the patients. Without knowing the breadth of the disease spectrum and how 
far or close they were to the all-important ‘critical level’, some interviewees struggled 
to relate to this information in isolation.  
 
“Numbers mean nothing to me unless you explain what it means, then, like, 47 could 
be dangerous…. don’t know, what is the danger level?”  Interviewee #2 
 
“He said it is just a little bit low but nothing you know.  How low is low, I don’t really 
know.” Interviewee #5 
 
Though one interviewee did not know exactly what his current kidney function was, 
he recalled being told and reassured that he was far from reaching the ‘critical stage’.  
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“I forget what the level is now, I can go down to 10% before it is critical really so 
there is still a way to go before I would be in any trouble.” Interviewee #8 
 
When asked if having a kidney condition affected interviewees’ life, some found it a 
surprisingly difficult question to answer as they were unsure of the signs and 
symptoms related to CKD. They wondered if some of the common symptoms they 
experienced in day-to-day life, for instance, lethargy, back pain, joint pain or change 
of urine colour, could be attributed to their kidney condition. In addition, some were 
also concerned if there were any red-flag signs and symptoms associated with 
worsening kidney function which they should be aware of. 
 
“I get a bit of backache occasionally, is that related to kidneys?” Interviewee #5 
 
“I mean, when should I be unduly worried?  I mean, how would you know if you 
should be unduly worried?  What are the signs and symptoms that you may come 
across?  Is it excessive tiredness, excessive drinking, dryness?” Interviewee #2 
 
While the majority of the interviewees mainly focused on their self-perceived gap in 
knowledge, one interviewee brought up the issue of public education on kidney 
disease.  
 
The perceived knowledge gaps among all the interviewees covered a diverse area. 
Interestingly, there was no consistent association between explanation provided and 
perceived knowledge gaps. Two of the interviewees did not feel that they required 
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further information regarding their kidney condition: one had been informed about the 
importance of blood pressure control and monitoring and was reassured about his 
level of kidney function while the other interviewee only recalled being told that her 
kidney condition was of no significant concern. These two patients clearly recounted 
two very distinct explanations provided when they were made aware of their kidney 
diagnosis but both were satisfied with their current state of knowledge for two very 
different reasons: one was fully-informed while the other did not feel the need of 
further information as she was asymptomatic. This demonstrated the complex 
interaction between the awareness and the perception of self-knowledge. 
 
This once again emphasised the well-known fact that the breadth and depth of the 
information required by patients are very heterogeneous. What one deemed to be 
adequate reassurance and information (i.e. slightly lowered kidney function), others 
might yearn for further clarification if given the chance. In addition, providing 
information which is context-sensitive and easy to relate to is also crucial in 
facilitating patients’ retention of the information provided and minimising uncertainty 
or anxiety amongst the patients.  
 
 Discussion 6.7
Illness perception among the early to moderate stage CKD population has been an 
under-researched subject. This interview study elicited six main themes in regards to 
patients’ perception of CKD: awareness, explanation provided, emotions, knowledge, 
views on the term CKD and perceived knowledge gap. 
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Though CKD is prevalent in the ageing population, the general public often do not 
consider the condition as one of the top health concerns (432). Even amongst patients 
with CKD, awareness has been shown to be suboptimal and it was reported to be as 
low as 10 -15 % in some studies (433-436). It is therefore crucial to explore the 
possible factors underpinning this issue. 
 
Often, patients’ awareness of their medical diagnosis is governed by the explanation 
provided, or the lack of it, by their healthcare professionals. Additionally, the 
explanation provided also directly influences patients’ perceived knowledge, their 
views on the term CKD as well as the perceived knowledge gap. In general, effective 
doctor-patient communication is believed to correlate with improved patient health 
outcomes (437). However, a cross-sectional study showed that CKD discussions 
occurred only in approximately a quarter of consultations between patients with 
hypertension and their GPs (438). A focus group study by Crinson et al highlighted 
reluctance amongst some GPs to embrace the CKD label and their perceived 
difficulty in explaining the concept to patients (439). In a qualitative interview study 
of GPs and practice nurses in the U.K., Blakeman et al also reported a predominant 
theme of anxiety about disclosure of early-stage CKD to patients (440). Similarly, the 
patients’ narrative accounts in another qualitative interview study reflected limited or 
partial disclosure of CKD diagnosis in the primary care setting (441). Findings from 
this interview study coincided with those previous studies as unawareness of CKD 
diagnosis was a recurring issue observed during data collection and at times, posed 
significant challenges to exploring CKD perceptions and barriers to CKD research.  
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Though CKD is defined and globally accepted by healthcare professionals as ‘kidney 
damage or eGFR <60 mL/min/1.73 m
2
 for three months or more, irrespective of 
cause’ (13), many patients have not encountered, understood or agreed with the term 
or its definition. While some patients were not even aware of their kidney function 
being checked during their routine blood test or informed of the lowered eGFR 
readings, the lack of awareness also seemed to be fuelled by the omission of the term 
CKD by the healthcare professionals when explaining the kidney condition. There 
appeared to be a tendency for GPs to substitute ‘CKD’ with descriptions such as, 
‘slight failing of the kidney’ or ‘slightly reduced kidney function’. This tendency was 
certainly not confined to primary care as some who were managed in secondary care 
for their kidney conditions appeared to portray similar levels of awareness and 
experience. As a consequence, an interesting discrepancy between patients’ 
knowledge of ‘slight reduction of their kidney functions’ and their awareness of the 
diagnosis of ‘chronic kidney disease’ was observed in some of the interviewees. This 
disjointed awareness of having a kidney condition was epitomised by one of the 
interviewees who clearly rejected the diagnosis of CKD despite knowing that he only 
has one functioning kidney due to kidney stones.  
 
Given that some of the patients were in fact aware of their kidney function being 
‘slightly reduced’ but unaware of the CKD diagnosis label, how should patients’ 
illness awareness of kidney disease be defined? Is awareness of having ‘slightly 
reduced kidney function’ adequate or should healthcare professionals be more 
insistent on patients’ awareness of the diagnosis label of ‘chronic kidney disease’? 
Ultimately, does the label of ‘chronic kidney disease’ matter?  
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The STOP-CKD research invitation unwittingly created an unusual scenario in 
challenging patients’ awareness of their diagnosis. Patients were informed of their 
lowered kidney function and possibly the diagnosis of CKD in the research letter. 
This ‘new information’ challenged both the patients who were completely unaware of 
their kidney condition as well as those who had been informed and reassured of their 
‘slightly reduced kidney function’. Amongst the emergent themes, patients’ views 
about the term ‘CKD’ provide valuable insight into understanding the disjointed 
illness awareness among the patients. Intriguingly, irrespective of their overall illness 
perceptions of a kidney condition, patients perceived the term ‘CKD’ as a severe, 
advanced form of kidney condition, which they invariably associated with significant 
illness consequences. It appeared that patients’ lack of awareness of their CKD 
diagnosis often attributed to their misconception of the term. As the majority only 
encountered the term CKD via the research invitation letter and had no prior 
explanation by a healthcare professional regarding the meaning of such a diagnostic 
label, many ‘borrowed’ the commonly known illness consequence of severe renal 
failure requiring dialysis to construct their illness representation of ‘chronic kidney 
disease’. Hence, the majority were unable to reconcile this ‘CKD’ label with their 
current health state or the reassuring explanation that they had received from their 
GPs previously. This did not only result in the discrepancy in illness awareness as 
mentioned above, but also invariably triggered negative emotional response.  
 
Leventhal’s proposed five domains of illness representation provide a useful 
framework to further examine this issue (268). Instead of representing the illness 
timeline, ‘chronic’ was perceived by some to denote severe or advanced illness 
consequences. Even among some who had the correct understanding, the word 
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‘chronic’ still triggered an ‘alarmed’ emotional response as they perceived the 
condition to be incurable. Moreover, some patients also associated ‘kidney disease’ 
with ‘kidney failure’, therefore related that to severe illness identity, serious illness 
consequence and even death. This association with death implied their perceived lack 
of control regarding the condition. Remarkably, despite being given the explanation 
and correct definition of the medical term by the researcher, many interviewees 
suggested alternative terms to replace CKD by excluding the word ‘chronic’ or 
substituting it with words which indicate the severity of illness. It seemed that when 
given the choice to formulate a diagnostic label, patients prioritised description of 
illness consequence over description of illness timeline. Though there has been a 
clear, agreed classification of different stages of CKD since 2003 (19), most patients 
are not aware of or fully understand what the numerical staging signifies. 
 
Judging from the data that emerged from the patients’ perception of the term CKD, 
one might now assume that the disjointed illness awareness is simply due to the 
difference in the perceived illness consequence between the two terms (i.e.: CKD or 
‘reduced kidney function’). Nonetheless, it did not appear to be the case. In fact, there 
was a puzzling mismatch between patients’ emotional response and perceived illness 
consequence in regards to the term ‘reduced kidney function’. Though patients 
interviewed in this study were often not aware of other important functions of the 
kidneys, most had good level of basic knowledge regarding the excretory function of 
the kidneys which is crucial in sustaining life. Hence, when asked about the 
consequence of ‘reduced kidney function’, most believed it to be catastrophic and 
life-threatening. This instinctive association of ‘reduced kidney function’ with 
‘complete loss of kidney function’, similar to their perception of the term ‘CKD’, was 
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an unexpected and contradictory finding as there appeared to be a mismatch between 
such perceived illness consequences and their emotion reaction. It could be presumed 
that patients who continued to hold this negative illness consequence view on 
‘reduced kidney function’ would have unvaryingly triggered a negative emotional 
response when they were first informed of this issue despite the reassurance from 
GPs. Alternatively, if they had accepted the explanation and reassurance from the 
GPs, their perception regarding the illness consequences of ‘reduced kidney function’ 
should have been moderated, become less severe or more akin to their current state of 
health (that is, mostly asymptomatic). Yet, these two beliefs had somehow been kept 
intact but completely disconnected from each another. What is worth emphasizing is 
that their emotional response to such a diagnosis appeared to be more closely 
governed by the explanation provided by the GPs than their perceived knowledge. 
This observation suggested that patients’ emotional reaction towards diagnosis 
disclosure might therefore be less affected by the term used (i.e. CKD or ‘reduced 
kidney function’), but mostly influenced by the ensuing details given regarding the 
diagnosis’ implications. Such finding clearly warrants further exploration in future 
studies. 
 
Several studies have highlighted the issue concerning the limited knowledge of CKD 
among the general public (432, 442, 443). Despite being at considerably high risk of 
developing the condition, a large study of  patients with diabetes showed that the 
majority were unaware of the risk factors associated with kidney disease (444). Even 
amongst patients with CKD under the care of a nephrologist, Finkelstein et al reported 
dismal results whereby a third perceived limited or no understanding of their CKD 
and were unaware of their treatment options (445).  In addition, another U.S.-based 
 175 
 
study of 399 patients with non-dialysis-dependent CKD, demonstrated that patients 
felt they have no or limited knowledge in areas regarding ‘medications that help the 
kidney’, ‘medications that hurt the kidney’, ‘foods that should be avoided if a person 
has low kidney function’ and ‘symptoms of CKD’ (446). Older age and higher eGFR 
were found to be associated with less overall perceived knowledge (446). 
Furthermore, the same study also highlighted the important discrepancy that existed 
between patients’ perceived and objective knowledge (446). As one of the emergent 
themes, understanding patients’ perceived knowledge gap provides an additional, 
valuable angle to evaluate patients’ illness perceptions of CKD. Similar to the 
findings from previous studies, the majority of the patients interviewed identified 
several knowledge gaps regarding CKD, including those who have previously 
received an explanation from their GPs, though it might also be plausible that the 
interview process intensified patients’ anxiety about kidney disease. The areas of 
knowledge gaps highlighted were cause and severity of their kidney condition, 
lifestyle and diet advice, symptoms related to CKD, prognosis and long-term 
implications of CKD.  
 
Amongst patients who had been informed of their kidney condition, the interview data 
demonstrated variation in patients’ perceived explanation given regarding their kidney 
diagnosis. GPs’ attitudes and beliefs about CKD diagnosis invariably cascaded down 
to the patients. One such example was relating to the accuracy of eGFR. Although 
MDRD derived eGFR is a widely accepted method in defining CKD, issues regarding 
its accuracy and its variability, particularly in the early stages, have been one of the 
concerns among the GPs (447). The description of the eGFR test as ‘a nuisance’ by a 
GP as reported by one patient suggested GPs’ uncertainty regarding how the result of 
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the eGFR should be interpreted. Such comment was likely to have confused the 
patients and potentially affected the patient’s perception of the condition. 
Interestingly, not all GPs were negative with regards to the variability of the eGFR 
results as others used it as a reassuring feature and suggested to patients not to be too 
concerned by a single lower reading on their eGFR result.  
 
Though the cause of CKD was often not explained to the patients, when it was, the 
majority were told that that advancing age was the reason for ‘reduced kidney 
function’. Understanding the cause of illness is crucial for patients and it embodies 
one of the five cognitive domains of illness representations (268). While it is a well-
known fact that eGFR declines with age (448) and prevalence of CKD increases in 
the older population (449), a previous study reported high variability in the rate of 
eGFR decline among individuals (450). In fact, around a third of patients showed no 
absolute decline in renal function in a longitudinal study (450). Hence, attribution of 
declining eGFR as just part of the normal physiological ageing process remains a 
contentious subject (451, 452). Furthermore, lower eGFR was reported to be 
independently associated with higher mortality across all ages (453), suggesting that 
regardless of age, reduced eGFR is most likely to be of clinical significance. This is in 
contrast to the brief explanations patients recalled receiving from their GPs whereby 
emphasis was frequently placed on reassuring patients that the finding was of no 
particular significance. Such GPs’ effort to reassure the patients was the predominant 
feature of the theme, and resonated with the findings of a recent qualitative study by 
Daker-White et al, which reported that disclosure of CKD diagnosis was limited or 
partial and often cast in vague terms as ‘nothing to worry about’ (441).  
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While patients with early to moderate CKD are often asymptomatic, many patients 
were unaware of such a fact. Indeed, a quantitative study evaluating the usability of 
the illness perception questionnaire (IPQ-R) highlighted the issue with uncertainty in 
‘illness identity’ in early stage CKD (264), which was echoed by this interview study. 
The ‘rule of symmetry’ proposed by Cameron et al appeared to come into play as 
some of the interviewees felt the pressure to haphazardly attribute any abstract or 
concrete symptoms they were experiencing to the condition in order to formulate a 
more tangible illness representation (268). In general, illness identity and illness 
consequence provide evidence for the existence of the conditions and act as the 
anchor for illness representations. This sense of uncertainty therefore surfaced and 
intensified when patients were probed about the impact CKD had on their daily life. 
Furthermore, disease severity was highlighted to be an important component of the 
CKD diagnostic label among the interviewees. Belief in more severe illness 
consequences was shown to be associated with worse outcomes in studies of other 
chronic illnesses (454-456). Contrary to patients’ perception of the consequences of 
early or moderate stage CKD, large epidemiological studies have long established the 
fact that the risk of progression to ESRD requiring dialysis among early or moderate 
stage CKD is low, however, the risk of CV disease is substantial (2, 41, 457). 
Therefore, it is paramount that these misconceptions and knowledge gaps regarding 
short- and long-term implications of having CKD among the patients are fully 
addressed and corrected.  
 
Despite the trivialisation of the CKD diagnosis and fervent reassurance by healthcare 
professionals, there was nonetheless a prevailing sense of lack of control among some 
of the interviewees as they were either unaware of the cause of their kidney condition 
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or were often informed by their healthcare professionals that their kidney condition 
was simply part of an ageing process. Patients’ request for lifestyle or diet advice 
perhaps symbolised their wish to establish a certain degree of illness control. Previous 
quantitative studies of other chronic illnesses demonstrated that better perceived 
personal control over the illnesses were associated with better functioning and more 
positive mood (258, 458-460). Likewise, Lacroix et al also demonstrated that well-
informed patients with a chronic respiratory condition had better outcomes on 
physical, psychological and social functioning (461). Discussions regarding active 
self- or pharmacological management of other comorbidities, for instance, 
hypertension or hypercholesterolaemia, to reduce their CV risk were also often 
missed during the consultation with their GPs (438). These issues of over-focusing on 
laboratory findings and overlooking of CKD cause and risk factor management by the 
healthcare professionals during the explanation of CKD to the patients (438) clearly 
need to be addressed.  
 
While the common-sense self-regulatory model of illness and health behaviour 
proposed by Leventhal et al aid the understanding of illness representations, in this 
interview study of patients with early or moderate CKD, patients’ perceptions of their 
illness were shown to be predominantly shaped by their awareness, explanation 
provided, emotional response, perceived knowledge, views on the term CKD as well 
as perceived knowledge gap. The multiple, often bi-directional interactions observed 
among these six key themes appeared to be crucial in providing the explanations of 
the varying CKD perceptions amongst the patients. In contrast to Leventhal’s model, 
the CKD illness perception model which emerged from this study highlighted the 
unique issues with disintegration of illness awareness, uncertainty of illness identity 
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and mismatch between emotional response and presumed illness consequence 
amongst this group of patients with early to moderate CKD. These distinctive issues 
pertinent to patients with early to moderate stage CKD might not only affect patients’ 
illness perception, but might also contribute to their coping mechanism and clinical 
outcomes as well as their participations in CKD research studies.  
 
In general, though strictly defining patients’ awareness of the condition by their 
recognition of the disease label is probably unwise, the findings from this study 
suggested that there is a perhaps a justified need to improve the disclosure of the CKD 
diagnosis by healthcare professionals to the patients. Although there have been 
concerns amongst some of the healthcare professionals regarding over-burdening 
patients with CKD diagnosis, especially in its early stage when it is asymptomatic 
(439, 440, 462), such failure or incomplete disclosure patients’ true state of health is a 
nonetheless a risky paternalistic approach which obliterates the prospect of 
implementing ‘shared decision making’ (463, 464). While some argue that the CKD 
definition leads to unnecessarily labelling (462), many more believe that it improves 
patients’ knowledge and  care (463).  
 
The data from this interview study demonstrated that non- or partial disclosure of 
kidney diagnosis led to mismatch of illness awareness and illness consequence, 
misconception of diagnostic label and ultimately cause undue stress and anxiety to 
patients. Additionally, this study also suggested that the lack of awareness of a CKD 
diagnosis formed a significant barrier to CKD research participation (Chapter 7). A 
diagnostic label does not only define an illness and facilitate communication among 
the healthcare professionals, it also serves as a key to patients’ illness awareness, 
 180 
 
enables patients to seek relevant illness information, facilitates correct illness 
perceptions and empowers patients’ self-management. In addition, this agreement on 
the diagnostic label also represents the first step in improving doctor-patient 
congruence on illness perceptions and avoiding patients’ negative emotional response 
when they encounter such a label later in the course of their illness. Indeed, 
invitations to participate in research bearing the diagnostic label in the STOP-CKD 
RCT had been shown to trigger significant stress and worries not only amongst those 
who were completely unaware of their kidney condition, but also in those who had 
previously received limited or partial disclosure of their diagnosis. Improving 
patients’ awareness of diagnostic label allows them to recognise research studies 
which are relevant to their own health, and therefore enable them to make informed 
decision regarding research participations.  
 
6.7.1 Implications for Practice and Research 
Despite the limitations regarding the lack of diversity in age and ethnicity of the 
patients interviewed, the findings from this interview study suggest that there is a 
need to improve public awareness and knowledge of CKD, encourage healthcare 
professionals in disclosing the CKD diagnosis and ensure shared decision making. 
This study highlighted the importance of disclosure of CKD diagnosis in improving 
patients’ illness perceptions, avoiding misconception, minimizing unnecessary stress 
amongst the patients as well as reducing barriers to CKD research. 
 
The seeming over-emphasis on reassurance by healthcare professionals should 
perhaps be moderated and followed-up with additional information to improve 
patients’ understanding of the condition and reduce uncertainty in their illness 
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identity. Educating patients regarding the lack of concrete disease identity in early or 
moderate stage CKD and highlighting the potential red-flag symptoms associated 
with deterioration of their kidney condition might therefore facilitate patients’ self-
regulation of their illness perception. In addition, as improved patient-doctor 
congruence on illness ‘identity’ and ‘cause’ have been shown to be associated with 
illness outcome in previous quantitative study, this crucial information might also 
help to improve patients’ coping strategy and outcomes (258). As patients appeared to 
value the distinction between early stage kidney disease and ESRD with regards to the 
disease label, incorporation of the staging classification during explanations of the 
CKD diagnosis by the healthcare professionals might also be valuable. Other areas of 
patients’ perceived knowledge gaps highlighted also included lifestyle and diet 
advice, prognosis and long-term implications of CKD, especially in terms of 
increased CV risk. It is therefore paramount that these misconceptions and knowledge 
gaps regarding short- and long-term implications of having CKD among the patients 
are addressed and corrected during diagnosis disclosure and follow-up consultations.  
 
While CKD is not a curable condition and ageing is clearly an inevitable process, 
provision of advice on self-management and optimising the treatment of other 
associated co-morbidities might not only influence clinical outcomes, but also be 
empowering for patients, improving their illness perceptions as well as coping 
mechanisms by enhancing their perceived illness control. Future research to assess the 
impact of improved healthcare professional-patient communication on patients’ 
illness awareness, perceptions and experience as well as research participation is 
clearly warranted.  
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CHAPTER 7 FACTORS INFLUENCING RESEARCH 
PARTICIPATION IN PATIENTS WITH EARLY 
TO MODERATE CHRONIC KIDNEY DISEASE   
 
 Introduction 7.1
Despite the potential of clinical research to advance medical treatments, poor 
recruitment, as faced by the STOP-CKD RCT, is regrettably a chronic and ubiquitous 
issue. The increasing cost of studies combined with declining funding, lack of 
motivation and growing responsibilities for clinical researchers, negative perception 
of industry and suboptimal distribution models for trial finances are all problems for 
clinical research in general (465). Furthermore, a recent report discussing the 
challenges faced by the conduct of clinical trials in the United States also highlighted 
problem with poor enrollment and retention of research participants (465). Indeed, 
nearly one in five of phase 2 and 3 interventional clinical trials were reported to have 
either terminated early due to failure to recruit or achieved less than 85% of the initial 
planned sample size (466). Additionally, a previous survey of authors of published 
primary care RCTs in the UK also estimated that less than one-third of the studies 
recruited to their original timescale (467). Poor recruitment does not only gravely 
compromise the power of the studies in addressing the relevant research questions; it 
also has strong implications on the time and financial resources as well as 
opportunities lost among the research participants, investigators, sponsors and the 
funders.  
 
Though altruism, perception of personal benefit and belief of the importance of 
clinical trials are a few of the various factors cited as the key motivators for research 
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participation (468-472), numerous barriers clearly remain and continue to hamper trial 
recruitment. A detailed literature summary performed by Lovato et al almost two 
decades ago concerning this issue emphasized the importance of having an overall 
recruitment plan, the identification and elimination of barriers to recruitment, 
development of further logistical recruitment strategies as well as recognition of 
specific recruitment problems in certain disease entities (473). In fact, in a recent 
priority setting exercise, ‘research into methods to boost recruitment in trials’ was 
regarded to be the top priority for trial methodological research amongst the directors 
of UK Clinical Research Collaboration Registered Clinical Trials Units (474).  
 
Thus far, several characteristics of research studies including earlier phase trials, non-
industrial funded trials, fewer number of research sites, non-placebo comparator, 
higher number of eligibility criteria and trials with 80% power (compared to 90% 
power) have been quantitatively identified to be associated with less successful 
accrual (466, 475). From the patients’ perspective, fear, worry due to uncertainty, 
distrust in medical research, lack of understanding of clinical trial process, 
unwillingness to be randomised due to preference of treatment, side effects of trial 
intervention, difficulty with informed consent as well as issues with transportation, 
time and work commitment were highlighted as the common barriers for potential 
research participants (473, 476-478). Additionally, frequency and total number of 
research appointments as well as procedure, trial duration, accessibility of study 
location and physical discomfort associated with procedures were also reported to 
influence patients’ participation (477, 479). Interestingly, a recent qualitative 
evaluation of patients’ participation in telephone care management program cited 
patients’ lack of perceived need as one of the most common barriers (480).  
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Understanding patients’ attitudes towards research participation is clearly an 
important first step in formulating strategies to improve recruitment. However, the 
majority of the studies exploring this issue were often not derived from the UK 
population and predominantly focused on cancer trials (481). Furthermore, none has 
examined the potential problems associated with RCT trial recruitment which are 
unique and pertinent to patients with CKD managed in the primary care.  
 
A qualitative study embedded within the STOP-CKD pilot RCT therefore aimed to 
explore patients’ decision-making process concerning interventional CKD research 
participation in primary care and to identify barriers to recruitment. This was planned 
with a future larger hard end-point study in mind. However, the failure of STOP-CKD 
to recruit patients meant such a study could provide some insights into why this had 
happened. Building on the findings of patients’ perception on early to moderate stage 
CKD detailed in the previous chapter, this chapter presents and discusses the 
qualitative outcomes of patients’ perceived motivators for and barriers to CKD 
research participation as well as their views on inclusion of elderly patients in clinical 
trials. 
 
 Methodology 7.2
The characteristics of the 17 interviewed patients, methods of data collection and data 
analysis were described in detail in the previous chapter (section 6.2, 6.3 & 6.4). Their 
involvement in the STOP-CKD RCT varied: two patients were enrolled into the RCT; 
one had withdrawn from the RCT; one was waiting for a screening appointment; 
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seven were ineligible for the RCT while six declined RCT participation but agreed to 
be interviewed. 
 
 After exploring their perceptions of CKD, all participants were asked about their 
previous medical research experience, reasons for participation or non-participation in 
the STOP-CKD RCT, the perceived advantages in taking part in research and 
disadvantages or barriers to research participations. Further questions regarding their 
suggestions for future improvement on STOP-CKD RCT study design was also posed 
during the interviews (Appendix 6-3). During the set-up of the STOP-CKD RCT, one 
of the recruiting general practices proposed to the STOP-CKD research team to 
exclude elderly patients above the age of 75 years from the research invitation letters. 
Conversely, one of the first interviewees voiced her gratitude towards the research 
team for inviting her to participate in the study despite her being 77 year-old. 
Therefore, an additional question was incorporated in the topic prompts for the 
subsequent interviews to explore patients’ views on inclusion of elderly participants 
into clinical trials. 
 
 Results 7.3
The six main themes regarding research participation amongst patients with early to 
moderate CKD emerged during the interview study. They were (1) past medical 
research experience; (2) motivators for research participation; (3) barriers to research 
participation; (4) impact of trial characteristics on research participations; (5) future 
research suggestions and (6) inclusion of elderly population in clinical trials. These 
themes provided a useful framework to study the different aspects of patients’ views 
on medical research, especially into CKD in primary care setting. The first theme sets 
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the scene for exploring participant’s attitudes towards medical research based on their 
previous research experience before moving on to identify the factors which 
motivated or deterred their participation in research. The fourth theme supplements 
the second and third themes by examining the influence of certain trial attributes, that 
is, interventional or non-interventional, primary or secondary care setting, industry or 
non-industry funded as well as duration or frequency of study visits, on patients’ 
participation in research. In view of the challenges encountered by the STOP-CKD 
RCT, the fifth and sixth theme gather patients’ suggestions to improve future CKD 
research and their views on the inclusion of elderly population in clinical trials, 
respectively.  
 
7.3.1 Past Medical Research Experience 
Before exploring their views on research participation, all patients were questioned on 
their general experience in medical research studies. Though a few declared no earlier 
research experiences, most had been involved in various research studies previously. 
In fact, a number of patients had previously taken part in more than one research 
study. Based on their descriptions of those studies, most appeared to have been 
observational in nature, conducted in either primary or secondary care settings. 
However, during the interview, it emerged that some of the patients might have 
misunderstood the term ‘research’ and confused it with being a volunteer patient for 
the purpose of teaching of medical students. 
 
“…and I am with that research now if you like.  I have been back and sort of how can 
I put it been a guinea pig for doctors doing their exams etc… at the QE. For them to 
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diagnose what’s the matter with me, then to prognosis and diagnosis and 
prognosis…” Interviewee #15 (declined participation in STOP-CKD RCT) 
 
In general, patients recalled positive experiences during their previous research 
participation. The additional medical attention and investigations appeared to have 
positively enhanced their research experience. 
 
“I think it is a very, very good thing, and I really mean that, I really and truly mean it.  
I think it’s excellent, hmm… you know, cos obviously I’m going years and years ago, 
nothing like that ever came, it was only if you didn’t feel right and you thought well, 
it’s the doctor I need, or go down…. that was it for whatever you went down for, but 
obviously these recent years, all the… I think it’s a very, very good thing, so….” 
Interviewee #7 (attended STOP-CKD RCT screening) 
 
“Well I enjoyed taking part in it because it was of a particular interest to me and also 
you know I discovered things when they were doing the various heart things, they look 
at the heart underneath, at the back, everywhere so you get an idea and somebody 
said, I said well can I have a look I wanted to see it on the screen which I did.” 
Interviewee #17 (declined participation in STOP-CKD RCT) 
 
However, despite having enjoyed taking part in research study, the interviewee voiced 
her frustration as the incidental finding of the investigation she underwent during the 
research study was not relayed back to her GP in a timely manner.  
 
 188 
 
 “….They said well actually you have got a bit of a leak and I said pardon, you know. 
Oh well lots of people have small leaks in the heart. So nobody picked up on that at 
all when those results went back.  So as far as I know I don’t have a problem…. 
(Researcher: “Did you know the outcome of the study at the end?”)…Yes, partly, but 
I had to ask a lot. Yes, we were told that the results would go back to the GP and I 
kept asking you know. They said well wait for so many weeks which I did. Eventually, 
I think they did come back but I know Dr A (patient’s GP) had a job to retrieve some.  
I don’t know the reason for that.  I just don’t….” Interviewee #17 
 
Additionally, a patient who was a retired nurse at a local hospital also highlighted the 
interesting observation she made concerning the changes in research regulation and 
documentation in the past few decades. 
 
“…We used to get used as guinea pigs occasionally to take bloods at the hospital 
when they were doing something, ‘Can we have a drop of your blood?’ when the 
research registrars were in the hospital… Yes, he was probably doing something and 
thinks ‘I need a drop more blood’, so he went around to the nurses and said, ‘go 
on…’… … Well, they just took the blood and off they went. (Researcher: “Did they 
get you to sign any consent form?”) Oh no, in those days, we are talking in the 80s’ 
and they didn’t do things like they do now. (Researcher: “Do you know what they use 
the blood for?”) Not really, no! There were a lot of researches going on AIDS and 
HIV as they were still learning an awful lot about it……It wouldn’t be set up like 
yours is now. It’s very much on their own back, doing their day job as well as, you 
know. It’s sort of in the side line.” Interviewee #3 (attended STOP-CKD RCT 
screening) 
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Interestingly, the presence or absence of previous medical research experience did not 
appear to directly explain or influence their willingness to participate in the STOP-
CKD RCT. 
 
7.3.2 Motivators for Research Participation 
The reasons for the participation or non-participation of the 17 interviewees in the 
STOP-CKD RCT could be broadly considered in the three key categories of altruism, 
self-interest and perceived relevance of the research topic to personal health. Other 
potential facilitators to patients’ research participation also included peer-pressure 
and awareness of the freedom to withdraw from research participation at any given 
time.  
 
7.3.2.1 Altruism  
Altruism is defined as ‘disinterested or selfless concern for the well-being of others’ 
(431). Many of the interviewees often conveyed elements of altruism while 
explaining their reasons for STOP-CKD RCT participation or when describing the 
advantage of any research participation. In general, their aim was to help others with 
the illness, help the researchers to find a ‘cure’ or advance medical knowledge. 
Awareness of the important role of research in facilitating the advancement of 
medical science appeared to be a key anchor of this belief.  
 
“When I first looked, I thought oh god, no, I don’t want to do that, don’t want to be 
stuck with needles and stuff like that, and then I thought, no, you’ve got to join 
because you know, a lot of people have got the disease and if we all said no, we don’t 
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want to do it, how are you ever going to find a cure?  Do you know what I mean? I’m 
not saying you will, but how are you ever going to… it’s like cancer, if you don’t take 
things from people how are you going to know how to help people, so that’s what I 
thought.  Yeah, if I could do a little bit just to help with research… I mean if we could 
wave a magic wand and just give us all a tablet and it would all go away, I think 
everyone would take it, you know what I mean.” Interviewee #4 (attended STOP-CKD 
RCT screening) 
 
One of the interviewees was clearly aware that her participation in the STOP-CKD 
RCT might not benefit her health. However, she hoped that her selfless act would 
reap rewards for the next generation.   
 
“Because I think the more people that can help in all this research and trials and 
everything, it might not benefit me at my age but it is possible that it is going to 
benefit younger people, like my little nieces and other children.” Interviewee #13 
(awaiting screening visit) 
 
Another interviewee expressed such ‘duty of altruism’ elegantly in reply to the 
reasons for her taking part in the STOP-CKD RCT. Interestingly, as she was 
asymptomatic from her CKD, her sense of altruism appeared to contain an element of 
guilt towards the ‘less well’. Being a retired nurse, this interviewee’s years of 
exposure to patients’ sufferings might have accentuated her empathetic reaction.  
 
“The fact that you have to find out these things and what happens to me or what my 
experiences are could help somebody that really needs your help in the future and I 
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think that is what you have to think about. You are well, so let’s try to get other 
people well at the same time. Sounds very pious, you know, you see so many people 
suffering and you think, you know, I am so well, I don’t deserve to be so well really.” 
Interviewee #3 (attended STOP-CKD RCT screening) 
 
7.3.2.2 Self-interest 
Self-interest featured strongly during the interview in regards to patients’ motivation 
for research participation. Most of the interviewees who were willing to take part in 
the STOP-CKD RCT indicated that one of the main drivers for their research 
participation was their perceived personal gain, in the form of increasing personal 
health knowledge on the specific condition (interviewee #1), having additional health 
monitoring (interviewee #8) or potentially improving their health status (interviewee 
#6). 
 
“Well, the fact that I’d been told I’d got failing kidneys. I thought well, you know, 
that’s what I said to you (turned to his wife), isn’t it? I said I’ll volunteer myself for 
this because I’m supposed to have failing kidneys so they could tell me how bad 
they’re failing, or how fast, or quick, or if there’s anything I can do to help the 
situation…” Interviewee #1 (attended STOP-CKD RCT screening) 
 
“Well, I don’t mind going on any trial because in a way they are monitoring your 
health really, so I think there are benefits for the patient really …” interviewee #8 
(STOP-CKD RCT participant) 
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“I thought it’d probably help me and it would help other people in the survey, cos I 
read the letter and it said that these tablets are supposed to help, err, that I was 
obviously taking, of people in hospital.  Erm… it’s good for their kidneys and they’ve 
got something else wrong with them...” Interviewee #6 (withdrawn from STOP-CKD 
RCT due to adverse event) 
 
Interestingly, an interviewee self-professed his motive of personal gain as 
‘selfishness’. This over-riding ‘selfishness’ seemed to be his primary driver for 
research participation and appeared to counteract the ‘fear’ which was often 
mentioned as the barrier to participation (section 6.3.4). 
 
“Selfishness. (Researcher: ‘In what way?’) Well, if I had got a kidney problem, I 
would rather go and see if I could find some way of solving a problem if that is what it 
could be. I am not frightened to do it but I have never been asked before. If you would 
have asked me without me having this identified in my tests, I would have said yes, I 
would do it, but I am not afraid to go on tests and things like that.  It doesn’t bother 
me one little bit.  I would quite easily say yes to trials.”  Interviewee #10 (attended 
STOP-CKD RCT screening) 
 
7.3.2.3 Perceived relevance of research topic to personal health  
Perceiving the research topic to be relevant to their own health was often an important 
prerequisite for perceiving research participation to be of personal gain. It therefore 
played an important role in driving patients’ research participation.  
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“…because of the conditions I’ve got.  To put it in a nutshell, if it was a cancer you 
were researching I wouldn’t bother, cos hopefully, touch wood, I haven’t got cancer.  
So that is why I went in because it was things I’d got wrong with me.” Interviewee #1 
(attended STOP-CKD RCT screening) 
 
“… It’s monitoring my blood so, you know, and blood pressure which I know is 
important in terms of my condition. So I am prepared to do that.” Interviewee #8 
(STOP-CKD RCT participant) 
 
In fact, another interviewee who elegantly illustrated this similar point demonstrated a 
key and significant finding from this interview study: patients’ acknowledgement of 
the relevance of the research topic to their own health was the indispensable first step 
in patients’ research participation. Without it, it appeared that patients would be 
unlikely to participate, even in the presence of other drivers. 
 
“Yes, because I mean in my case I doubt if I would have volunteered had it not been 
relevant to my medical, so that’s why I suppose, if you’re researching a particular 
thing and attach it somebody’s problem, then they’re wanna know a bit more and 
come and see you. “ Interviewee #1 (attended STOP-CKD RCT screening) 
 
7.3.2.4 Peer-pressure 
In addition to the three vital factors mentioned above, there were also several other 
factors which facilitated research participation. Two of the interviewees were 
encouraged by their family or friends to take part. Such encouragement appeared to 
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be based upon self-interest or altruism and reinforced interviewees’ willingness to 
research participation. 
 
Interviewee #9 (attended STOP-CKD RCT screening): “My husband, wasn’t it 
(turned to husband)? You influenced me to take part in this.”  
Interviewee #9’s Husband: “Yeah, I just advised her, thought it would be a good idea 
– she would be able to contribute to something and also the regular monitoring is not 
a bad thing either”. 
 
“I think talking to friends about it and they encouraged me to do it because they 
thought I had more to gain from it than I was to lose from it.” Interviewee #8 (STOP-
CKD RCT participant) 
 
7.3.2.5 Freedom to withdraw from research study  
Furthermore, awareness of being able to withdraw from the research study at any 
given time appeared to also help in alleviating the concerns one of the interviewees 
had with regard to the potential side effects of the trial medication. It seemed to be a 
reassuring feature, which conceivably provided participants with some degree of 
perceived control and therefore encouraged their participation.  
 
 “Well, I would have taken part and if it had been making me feel sick, then I would 
have stopped.” Interviewee #9 (attended STOP-CKD RCT screening) 
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7.3.3 Barriers to Research Participation  
The interview study further explored patients’ perceived barriers to research studies in 
relation to the STOP-CKD RCT as well as in general. 
 
7.3.3.1 Perceived lack of relevance of research topic to personal health 
While patients acknowledging the research to be relevant to their personal health was 
noted to be the fundamental driver of research participation, due to the low level of 
CKD awareness amongst asymptomatic patients (Chapter 6), research invitations, 
such as those from the STOP-CKD RCT, unfortunately failed to bear any relevance to 
the large proportion of its target population and did not appeal to potential 
participants’ self-interest. Such findings evidently echoed those described in Chapter 
6 and section 7.3.2. It represented a crucial and unique barrier for research 
participation pertinent to this group of patients managed in the primary care. This was 
clearly demonstrated by interviewee #12 who stated personal health gain and 
advancing medicine as the benefits of research during the interview but her perceived 
view of the irrelevance of the study took precedence and deterred her from taking part 
in the STOP-CKD RCT.  
 
“Well, if I had wanted to participate for any reason, I would have gone and asked my 
doctor first. You know, the for and against. I mean I am very much in favour of 
research and experimentation but I have got nothing wrong with me, so it was not 
applicable to me.” Interviewee #12 (declined to participate in STOP-CKD RCT) 
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7.3.3.2 Fear and uncertainty 
Fear was another predominant factor highlighted by the majority of the interviewees 
as the barrier to research participation. Delving deeper into the core of the issue, there 
were multiple factors contributing to such fear which emerged during the interview.  
 
Of particular interest was the high level of apprehension noted amongst some of the 
patients who regarded being invited to participate in research studies as ‘bad news’. In 
addition to the low diagnosis awareness, the term CKD was often perceived to have 
significant negative connotations amongst the interviewees as discussed in Chapter 6. 
Therefore, it was perhaps unsurprising that some interviewees expressed strong 
anxiety upon receiving the invitation which deterred them from participating in the 
research study. 
 
“Well, it’s like you know you receive a letter and you think ‘oh my god I didn’t think I 
had got anything wrong’, you know and then well maybe I should, maybe I shouldn’t, 
what should I do. I think people can be fearful of taking on something new. Hmm… 
also I think if you do receive something through the post, you may think well, you 
know why me and it may put people backs up a bit. Hmm… not to be very receptive or 
well I’m okay now so why should I be bothered….” Interviewee #17 (declined to 
participate in STOP-CKD RCT) 
 
Another key driver of the fear appeared to be the lack of control or uncertainty 
associated with trial medication assignment. The clinical equipoise which 
fundamentally provides the basis for medical research, and RCTs especially was felt 
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to be unacceptable for some and represented a significant barrier to participant 
recruitment. 
 
“Well, for example with this one, how would that benefit me?  I don’t know whether I 
am, you know, if I decide to take part and swallow the pills, I don’t know if they are 
placebo or if they are a drug...” Interviewee #17 (declined to participate in STOP-
CKD RCT) 
 
In addition to their uncertainty about research participation, which was compounded 
by the lack of understanding of equipoise in clinical trials with the use of a placebo, 
one of the interviewees also highlighted the uncertainty of end-of-trial arrangements. 
 
“How they are going to react to the tablet and how it’s going to leave them once 
they’ve finished it, because they are not going to be doing it for ever, so they are 
going to think ‘is something going to happen to me when I stop taking this tablet’, 
because they won’t know whether it’s the placebo or whether it’s the genuine or not, 
but they won’t know if it could make a difference to them later on.” Interviewee #3 
 
Furthermore, descriptions such as ‘being used as a guinea pig’ also conceptualised 
public feelings of uncertainty and lack of control of their personal health associated 
with research studies.  
 
“Well, I think some people might think they are using me as a guinea pig and they are 
trying drugs out or they are trying drugs out on me or they don’t quite know the 
results of them. I think some people might have that feeling behind, you know, you 
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don’t want to do that because you know a couple of people I have spoken to said, ‘oh 
no, you don’t want to do that’…” Interviewee #16 (declined to participate in STOP-
CKD RCT) 
 
While some of the interviewees believed additional monitoring of their health was an 
appealing feature of participating in a research study, interestingly, some were afraid 
of the potential for unexpected incidental findings that might be discovered during the 
research study.  
 
“Maybe some people are a bit frightened, you know, when they get the letter, you 
know they don’t wanna know. Hm… whether, you know, they might be afraid…if they 
find something else, you know, when they go on that study.” Interviewee #6 
(withdrawn from STOP-CKD RCT due to adverse event) 
 
“Because some people fear about their bodies and about death and all the rest of it. 
They would rather not know… a need to know basis attitude.” Interviewee #15 
(declined to participate in STOP-CKD RCT) 
 
Additionally, though some might not necessarily view venepuncture as an invasive 
procedure, others expressed apprehension about such procedures. Therefore, the 
frequency and invasiveness of these procedures could potentially affect research 
recruitment due to the fear patients have about procedures.  
 
“The only downside of being … is you’d have to keep sticking me with needles…. 
That’s the only thing. You know when you say you have to keep taking blood I’m 
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thinking ‘oh god I’m going to be a pincushion’. Because obviously when you go into 
hospital, ‘can we have some more blood, more blood’ – oh god, no more!  That’s the 
only downside I see.” Interviewee #4 (attended STOP-CKD RCT screening) 
 
7.3.3.3 Free-riding tendency 
In the face of uncertainty, a few of the interviewees believed that some may default to 
the perceived ‘safer’ option of not taking part, suggesting a ‘free-riding’ tendency 
amongst those who declined to participate. The term ‘free-rider’ was used to 
described ‘a member of a group who obtains benefits from group membership but 
does not bear a proportional share of the cost of providing the benefits’ (482). This 
‘free-riding’ tendency represents the counterforce of altruism and appeared to be the 
results of patients’ compelling urge to safeguard their self-interest.  
 
“Only not knowing what it may do to them. That’s naivety in a lot of cases, 
unfortunately.  Well, not naivety, that is the wrong word.  It is just being probably a 
little bit scared that it won’t do them any good and they will not feel very well and 
they would rather let somebody else do it.” Interviewee #10 (attended STOP-CKD 
RCT screening) 
 
“…They just say well I’m alright at the moment there is nothing wrong with me. They 
just put it in the background, don’t they, a lot of people do, don’t they? Instead of 
thinking well you know it might be helping somebody in the future…” Interviewee #5 
(declined to participate in STOP-CKD RCT) 
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7.3.3.4 Medication burden and side effects 
Whilst the majority of willing participants interviewed did not view the use of trial 
medication as a significant barrier, others who declined to participate were 
vehemently opposed to taking any extra medication when the benefits for themselves 
were uncertain. The potential side effects of the trial medications or their potential 
interaction with their existing medication also deterred some from taking part as they 
felt that the risks clearly outweighed the benefits. Such varied perceptions amongst 
the interviewees were likely to be influenced by their perceived personal health status, 
their interpretation of the potential benefits of the interventional medication 
(spironolactone), as well as their pre-existing medical conditions. 
 
“For me, because I looked up the side-effects, now I know that the side-effects don’t 
affect everybody and most people probably only have mild side-effects, but I’m just 
sort of thinking well I am coasting along and I would prefer to stay that way unless a 
particular problem comes up.” Interviewee #17 (declined to participate in STOP-
CKD RCT) 
 
“Well, this one obviously because of my own kidney problem but I don’t want to take 
any more tablets because I am already on tablets and I don’t want anything to stop 
the good work that is going on at the moment with my eyes (myasthenia gravis) and 
with you know my blood pressure one. I don’t want anything to react so that’s why 
I’ve said no more tablets.” Interviewee #15 (declined to participate in STOP-CKD 
RCT) 
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Furthermore, for those who already take a substantial number of pills, the addition of 
a further trial medication represented an unwelcome additional load on their already 
heavy medication burden.  
 
“… It is just that I don’t need to. I don’t take anything unless I have got to, you 
know.” Interviewee #12 (declined to participate in STOP-CKD RCT) 
 
“No, and I can see also that I don’t necessarily need to require a benefit to me. And 
plenty of people will say, well, maybe it doesn’t benefit me but hopefully (it) will 
benefit people in the future. I can see that but for the time being, I don’t wish to 
swallow tablets in order to prove that, you know.” Interviewee #17 (declined to 
participate in STOP-CKD RCT) 
 
7.3.3.5 Pre-existing medical issues 
In addition, patients’ pre-existing medical issues also played a role in deciding on 
research participation.  
 
“Well, because of this condition (skin rash) I have had.  I thought it is no good going 
on tablets, on placebos or whatever you are supposed to give me… Yes, and the 
tablets have supposedly caused this.  I thought there is no point going on a kidney 
test. Well you know a trial, until this has cleared up really.” Interviewee #5 (declined 
to participate in STOP-CKD RCT) 
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7.3.3.6 Impact on daily lives and other commitment 
Being the care-giver for a family member also represented a significant barrier to 
research participation due to the time required for research visits. 
 
“…I would have done this you know but there is no point me doing it if I have got the 
bladder problem (cancer) so … and ***** (her husband) being poorly as well, 
although he is a lot better now, the chemo really knocked him about.” Interviewee 
#11 (declined to participate in STOP-CKD RCT) 
 
With only one exception, all of the interviewees were either retired or not in a full-
time job. However, many did recognise time and work commitments as barrier to 
research participation, especially for working people.   
 
“I suppose, if people are at work – if people are doing 9 to 5 that can be difficult.  See 
I work shifts, so it’s a bit better for me, but if you’re doing 9 to 5 it’s difficult for 
people to fit it in.” Interviewee #4 (attended STOP-CKD screening) 
 
Another interviewee also expressed the possible issue with the intrusiveness of 
research participation on daily life.  
 
“The cons … I suppose the cons can be it can invade your life too much, I suppose, if 
you allowed it to.  You know you might not want to be called on too much and you 
didn’t want to do it.” Interviewee #15 (declined to participate in STOP-CKD RCT) 
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7.3.4 Pathway Leading to CKD Research Participation  
The relationship among the key motivators and barriers to patients’ participation in 
research are presented in Figure 7-1. Patients’ decisions whether to participate in the 
research study appeared to be primarily dependent on the balance between these 
factors. Above all, the perceived relevance of research topic to patients’ own health, 
or the lack of it, emerged as the crucial factors governing such decision amongst 
interviewees. Such perceptions were also closely linked to their self-interest as 
detailed in section 7.3.2.3. 
 
 
 
Figure 7-1: Key factors which influence patients’ research participation. 
 
The health belief model, which consists of four main dimensions: perceived 
susceptibility, perceived severity, perceived benefits and perceived barriers, has been 
widely used in explaining and predicting health-related behaviour since early 1950 
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(483). Perceived susceptibility was reported to be a more influential factor than 
perceived benefits in understanding preventive health behaviour while the reverse was 
the case in the understanding of sick role behaviour (483). Additionally, internal (i.e. 
symptoms) or external (i.e. interpersonal interactions) ‘cues to action’ were believed 
to be vital in triggering the decision-making process (483).  
 
Employing the concept of the health belief model (483), Figure 7-2 illustrates and 
summarises a conceivable linear pathway leading to CKD research participation. The 
pathway consists of three crucial links of patients’ perceived susceptibility, perceived 
severity and self-interest. The perceived relevance of the research topic to personal 
health was the key to initiate the pathway as without this fundamental belief about 
susceptibility, patients would be unlikely to consider research participation. Provided 
that patients accept their diagnosis of CKD, the perceived severity and hence the 
consequence of the illness appeared to be the next crucial step when deliberating their 
participation in an interventional study. The evaluation of the multiple factors relating 
to the pros and cons of participation, as discussed earlier, subsequently came into play 
once the susceptibility and severity of the illness were acknowledged. Maintaining a 
‘net personal gain’ and safeguarding their individual self-interest were found to be 
major factors in prompting research participation. Though altruism is often cited to be 
a major motivator for research participation, the findings of this interview study 
suggested that its role is perhaps much less important than the maintenance of self-
interest. ‘Peer-pressure’ and awareness of the ‘freedom to withdraw from research’ 
potentially act as the ‘cues to action’. As research-active GP sites appeared to have a 
statistically significantly greater recruitment rate compared to their counterparts (see 
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Chapter 5), it is conceivable that such effect might have been mediated via the 
‘perceived benefits’ or ‘cues to action’.   
 
 
Figure 7-2: Modified health belief model illustrating the pathway of patients’ decision 
in the STOP-CKD RCT research participation.  
 
7.3.5 Impact of Trial Characteristics on Research Participation 
In addition to examining the key factors which influenced their decisions in 
participating in the STOP-CKD RCT, interviewees were also asked specifically 
regarding the impact certain study attributes, for instance, trial intervention, trial 
setting (primary or secondary care), funding source and frequency or duration of 
study visits might have on their decision to participate in any research study.  
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7.3.5.1 Trial Intervention 
In general, the majority of the interviewees stated that they were not deterred by 
studies involving trial medications. Patients’ trust in researchers appeared to be 
fundamental to their willingness to participate in interventional studies. A well-
controlled study which involved only a low-dosage, once daily regime of a trial 
medication, like the STOP-CKD RCT, were reassuring features for one of the 
interviewees.  
 
“As long as it’s well controlled and it’s not being given to you in a massive dose so 
that it is only like a little test to see how you respond or how the body reacts to it, it’s 
got to be well looked after.” Interviewee #3 (attended STOP-CKD RCT screening) 
 
Although the serious side effects of low-dose spironolactone are infrequent and 
common side effects are often mild, the STOP-CKD RCT patients’ information sheet 
clearly listed the potential side effects to ensure all participants were well-informed of 
the risks involved. One of the willing participants of the STOP-CKD RCT seemed to 
have underplayed the risks and was not concerned about taking part in an 
interventional study. 
 
“It didn’t scare me because, as I say, you said one was gonna be nothing so I knew 
that if it was nothing, it was just going to be a vitamin, or something silly like that, 
and I knew the other would be a water tablet.  So knew it wasn’t gonna do…. I just 
knew if I’d got the water tablet I’d go to the toilet more often, but apart from that I 
wasn’t too worried.  I knew it wasn’t something that was gonna to affect my heart, 
liver or anything like that…..I just knew it was gonna…… you know, I know a lot of 
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people who are on water tablets – I mean I’m on water tablets now.  I know it doesn’t 
affect them at all, just obviously more trips to the bathroom.” Interviewee #4 
(attended STOP-CKD RCT screening) 
 
In contrast, whilst another interviewee also did not view trials involving 
pharmacological intervention as a barrier to participation, it was based on the 
condition that the trial would not interfere with his existing medications and that the 
trial intervention had a substantially high benefit to risk ratio.  
 
Providing the trial medication… providing you would tell me what it’s for – if it is to 
improve my kidney function, that’s fine, I can accept that over even the real 
medication, or the placebo – it wouldn’t make any difference because then in the end 
you would say it either works or it doesn’t work.  You are the ones who would have 
all the knowledge.  That’s it. It’s got to be beneficial to me, but not detrimental, that 
I’d have to substitute a placebo for my original medication.  Like, can you 
understand? Interviewee #2 (attended STOP-CKD RCT screening) 
 
However, for another interviewee, despite stating that she would not mind taking part 
in an interventional study as long as it was not too radical, for instance, a surgical 
operation, she declined to take part in the STOP-CKD RCT as she felt that trial 
medication might worsen her symptoms associated with over-active bladder. This 
highlighted the fact that although the majority of the interviewees did not state any 
apparent strong objection against interventional studies, they were unlikely to take 
part in the research if the studies did not appeal to their self-interest.  
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“…There was only this one with the tablets that put me off.  I mean if the tablet had 
not been a water tablet I might have gone for it but I thought well that is just the 
opposite to what I need really. .. Yes, I have what they think is an over-active bladder 
and I do keep getting recurring urinary tract infections quite often really, so much so 
that the doctor did put me on an antibiotic just one low dosage one daily to try and 
keep it at bay...” Interviewee #16 (declined to participate in STOP-CKD RCT) 
 
For some, they simply had a strong aversion towards taking additional tablets or 
concerns about the potential side effects and therefore would not participate in 
interventional studies (section 7.3.3.4). 
 
“I would not be in favour of taking something if I didn’t need it or wasn’t told to for a 
reason from the doctor, I wouldn’t do that.” Interviewee #12 (declined to participate 
in STOP-CKD RCT) 
 
7.3.5.2 Trial Setting 
In addition, interviewees were also asked if they had any preference for research 
conducted in primary or secondary care settings. While some had no preference, 
others generally preferred the convenience of a shorter travelling time as well as the 
free parking available to the primary care-based research studies. Another interviewee 
also felt that research conducted in primary care had the advantage of being more 
personal for the participants. 
 
“Well, for my personal, I would rather it be done in the doctors surgery, for one thing 
it is more convenient.  See, I don’t drive.  It is more inconvenient to get to the hospital 
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and I think it is possibly a bit more personal in your doctors’ surgery than going to a 
big hospital.” Interviewee #16 (declined to participate in STOP-CKD RCT) 
 
7.3.5.3 Funding Source 
There were diverging opinions and views in terms of the funding source for research 
studies. Several interviewees expressed no preference about the funding source 
provided the research helps to advance medical science. Poignantly, against the 
backdrop of the financial challenge faced by the NHS, an interviewee’s wife who was 
present during the interview also alluded to the fact the government is unlikely to be 
able to fund all medical research studies without the help of pharmaceutical 
companies.   
 
“… now, if it’s good for people’s health, I don’t care where the money comes from 
(laughing).” Interviewee #1 (attended STOP-CKD RCT screening) 
 
“Well, the pharmaceutical companies are bound to want to fund it and I can’t 
imagine that the NHS would have the funding to do it all, they just wouldn’t.  So there 
has got to be the balance between, you know the NHS and the drug companies and 
drug companies obviously provide a lot of research which is always going to be 
needed for any drug.” Wife of Interviewee #5 (declined to participate in STOP-CKD 
RCT) 
 
A similar opinion was voiced by another interviewee as she witnessed the 
contributions pharmaceutical companies made in advancing medical treatment. 
Nonetheless, there was still an element of guardedness towards the pharmaceutical 
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industries and it appeared that she would only participate in industry-funded research 
if their trial design stood up to her scrutiny.  
 
“No, but I’d like to think that if it is a drug company, that you are not going to just 
abide by what they do or their drugs because others might be just as efficient, so until 
you know that you can’t make a decision, but no, I think drug companies have got to 
do this to be able to create new drugs and that’s how we’ve got so many new drugs 
these days is because the research was done years ago… It’s usually drugs isn’t it? 
The government haven’t got the cash these days to be able to fund things. If they have 
the money to do it, then fair enough. There are an awful lot of things that need our 
government money nowadays.” Interviewee #3 (attended STOP-CKD RCT screening) 
 
Nevertheless, not all of the interviewees were impartial about pharmaceutical 
company funded studies. One of the interviewee associated such research with that of 
the disastrous first-in human drug trial in Northwick Park, which was extensively 
covered and heavily criticised by the media in 2006 (484).  
  
“I don’t know, because the private one … I don’t know, because you remember those 
gentlemen a few years ago, you think straight away when they had theirs and 
obviously it all went wrong, sometimes you think, hmm… you know, but you didn’t 
hear the story of what they were going…” Interviewee #4 (attended STOP-CKD RCT 
screening) 
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Several of the interviewees expressed strong preference for government funded 
research studies as they were wary that the primary intention of the pharmaceutical 
companies might be of financial rather than patient benefit.  
 
“Well, I have a horrible feeling that it is the money that kind of triggers the whole 
thing and it may not altogether be in the interest of the patient but you know may be 
I’m wrong in that but I do have that sort of feeling.” Interviewee #17 (declined to 
participate in STOP-CKD RCT) 
 
“To some degree I suppose. I think possibly if you are thinking you are promoting the 
drug company’s profits you might have a bit of an issue with it. I think if it is the 
medical profession as a whole and the government is trying to see the best way of 
treating a certain area, then I think if people realise that then they would be more 
than willing to be helpful in this.” Interviewee #16 (declined to participate in STOP-
CKD RCT) 
 
Despite having limited financial resources, one interviewee stated that the government 
should increase their financial support, in a timelier manner, for research studies of 
common medical conditions. 
 
“My only view is that I think the government should do a little bit more for you 
definitely.  I know that they are saying this morning on the TV; they are going to do a 
lot more now for Alzheimer’s disease and allow more money for it, which actually 
should have been done a long time ago and the same with kidneys really.” 
Interviewee #16 (declined to participate in STOP-CKD RCT) 
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7.3.5.4 Duration or Frequency of Study Visits 
In regards to the duration or frequency of research visits for the STOP-CKD RCT, 
most did not perceive either as barriers for participation. Two of the interviewees felt 
that they had the time to do so whilst another interviewee was reassured that the 
research visit could be fitted around her working hours.  
 
“That didn’t bother me as long as obviously you know you didn’t mind that obviously 
I had to fit it in around work, which was quite OK as the lady said if you know, you’ve 
got to do it through work, around work, that was fine and I was happy with that.” 
Interviewee #4 (attended STOP-CKD RCT screening) 
 
Nonetheless, there was one who preferred to have less frequent visits to avoid 
disrupting his daily routine and another suggested ‘research-fatigue’ might occur with 
studies that have a longer follow-up period.  
 
“Yes, 3 or 4 months (frequency of visit). Well, or even longer if necessary but 
certainly no shorter because I would have to keep planning my life around that 
appointment.” Interviewee #15 (declined to participate in STOP-CKD RCT)  
 
“… I suppose if it goes on for a long, long while you might get a bit tired of it but I 
mean sometimes these things do take time don’t they.” Interviewee #16 (declined to 
participate in STOP-CKD RCT)  
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7.3.6 Future Research Suggestions 
Overall, most of the interviewees who were screened or participated in the STOP-
CKD RCT found the research experience to be acceptable. The majority of the 
interviewees agreed that the patient information sheet for the STOP-CKD RCT was 
informative and helpful. 
 
“Yeah, really informative – it tells you all about what’s going to happen, what you’re 
going to do and there was a number if I wanted to chat to anybody.” Interviewee #4 
(attended STOP-CKD RCT screening) 
 
However, a few of the participants highlighted a few concerns regarding the 
discomfort of the simultaneous blood pressure measurements on both arms and the 
quantity of the blood taken.  
 
“Well, yeah, having both arms at the same time.  It wasn’t a problem standing up but 
you had to have them done stood up.  I mean the blood, it was six syringes of blood, 
but you know, there you go, as long as you can spare it (laughing)!” Interviewee #1 
(attended STOP-CKD RCT screening) 
 
In addition, one of the patients also criticised the repetitive paperwork associated with 
the STOP-CKD study and wondered if such defensive method of research conduct 
were due to the researchers’ fear of potential legal repercussion. 
 
“… There is a lot of repetitiveness in it. Like that sheet (consent form) there I’ve four 
already, four or five of those already. I have sent some back. I have signed during 
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the… and again. That it is why it did not take me long to read it. That doesn’t bother 
me that much; it is just whether you are repeating yourself too many times in certain 
areas.  It is almost as if you are frightened that you don’t get the consent of the 
person, there will be some comeback to you.” Interviewee #10 (attended STOP-CKD 
RCT screening) 
 
A number of interviewees made some other constructive suggestions on how the 
STOP-CKD RCT could potentially improve its design and recruitment. During the 
screening visit for the STOP-CKD RCT, a questionnaire regarding participants’ 
demographics and medical history was completed before the research team proceeded 
to measure their blood pressure. An unexpectedly large proportion of the participants 
were found to be ineligible for the study due to low blood pressure. Hence, an 
interviewee suggested that the blood pressure could be measured first to identify 
eligible participants before completing the questionnaire. 
 
“…It was to the point, asked me the questions and then …… I didn’t need to have 
blood taken because my…. I wonder why they didn’t just take my blood pressure at 
the start, it would have saved a lot of questions, wouldn’t it?  So my god, we’ve given 
him loads of forms to fill in, and now it’s no good.” Interviewee #2 (attended STOP-
CKD RCT screening) 
 
Additionally, the same interviewee also suggested that invitation letters should be 
more reassuringly worded to avoid triggering fear amongst the recipients. In parallel 
with the findings in Chapter 6, as the awareness of mild to moderate CKD diagnosis 
amongst the patients in the community is low (7), many appeared to be taken aback 
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by the suggestion of their diagnosis of reduced kidney function or CKD on the 
research invitation letter. 
 
“I think the wording could be processed better – ‘this is nothing to be alarmed 
about’.” Interviewee #2 (attended STOP-CKD RCT screening) 
 
“I think what really surprised me was the chronic kidney function (failure), I think 
you know nobody has told me that I didn’t know whether there was anything I could 
do to help put it right but nobody had suggested there was a problem and I think that 
is why I thought I didn’t know that.” Interviewee #16 (declined to participate in 
STOP-CKD RCT) 
 
As the STOP-CKD RCT faced issues with poor recruitment, this qualitative study 
also explored interviewees’ views on ways to overcome the problem. Instead of a 
postal invitation, some interviewees felt that a face-to-face approach is more personal 
and might help to alleviate their fear and rectify any misconceptions they might have 
regarding the study. One interviewee proposed contacting individual potential 
participants via telephone but was later concerned regarding the intrusiveness of such 
approach.  
 
“Maybe go out and speak to people, like you’re doing now, before you call them in to 
do blood pressure tests and things like that.  You put people at ease and they know 
what is involved instead of sort of sitting reading a leaflet, it might…. I know it’s time, 
and taking your time, and more doctors going out, but nurses could do it and things 
like that, couldn’t they? You know.  I think, as I say, communication, putting people at 
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ease, because people get frightened when they don’t know what’s what, or what’s 
happening, and information…hmm, seriously, yeah – I think so anyway.” Interviewee 
#9 (attended STOP-CKD RCT screening) 
 
“I think the person to person approach is always better than stuff through the post 
frankly and sort of in between that I suppose is an approach by telephone but then 
that can be intrusive.  I think people don’t like things that are intrusive generally 
speaking.” Interviewee #17 (declined to participate in STOP-CKD RCT) 
 
Another interviewee considered research advertisement to be another method of 
boosting recruitment. Incorporating current participants’ positive comments into 
future research invitation letters was also suggested by another interviewee.  
  
“Well, at the moment you are doing it just through GPs, aren’t you? Yes, there is 
enough GP health centres, isn’t there for people to. I don’t know where else you could 
do it apart from advertising in newspapers I suppose but then it is costly isn’t it?” 
Interviewee #11 (declined to participate in STOP-CKD RCT) 
 
“Perhaps you could get a little leaflet out that you send out for people’s comments of 
those taking part so that they know how little time it takes up and how they’re not 
having any reaction to anything, so they’ve got something to fall back on to say, well, 
it didn’t happen.” Interview #3 (attended STOP-CKD RCT screening) 
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As time constraints were suggested to be one of the barriers for research participation 
for working people, an interviewee proposed conducting the research visit in the 
evening or during weekends.  
 
“I suppose people would have to try and come in the evening… Yes, out of normal 
hours or weekends or something.” Interviewee #8 (participant of STOP-CKD RCT) 
 
Conversely, one of the interviewees appeared sceptical regarding the effectiveness of 
any of such strategies. 
 
“I think it is difficult because people have got to want to and you can’t force people.  
You can lead a horse to water but you can’t make them drink.  It is like everything if 
you want to pack smoking up you will, if you want to stop drinking you will, if you go 
about if half-hearted you won’t and so at the end of the day whatever you do you can 
only advertise it or offer it.  You can’t make people do it and I think it is up here 
(pointed to his head) whether people want to do it or not and I don’t think whatever 
you do will make it any more attractive because it can be as attractive as you like but 
if they don’t want to do it, they won’t do it.” Interviewee #15 (declined to participate 
in STOP-CKD RCT) 
 
7.3.7 Inclusion of Elderly Participants in Clinical Trials 
During the setting up of the STOP-CKD RCT, one of the recruiting sites proposed 
excluding elderly patients (75 years and above) from being invited to participate, 
believing that they might be too frail to take part in such an interventional study. 
Therefore, the interview study took the opportunity to further explore patients’ views 
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on inviting the elderly to participate in research studies. Interestingly, most of the 
interviewees had dissimilar views to those of the GPs. In fact, one of the interviewees, 
who was 77 year-old, clearly appreciated being included in the research study and 
was delighted to have the chance to take part. 
  
“I think it’s very, very good of the doctors that they’re interested, at the ages I am, 
you know, so I think it’s extremely good.” Interviewee #7 (attended STOP-CKD RCT 
screening) 
 
Additionally, many of the interviewees felt that there were several compelling reasons 
to include participants from all ages and found no clear reason to exclude elderly 
populations. They believed that age should not be a limiting factor if research is 
performed for the health benefits of the public and that the condition studied affects 
people from all ages. As biological functions vary with age, another interviewee also 
thought that the results found in the selective group of participants of younger ages 
might therefore not be applicable to those who were older.   
 
“Well, I suppose everybody’s life counts doesn’t it?  You know, whatever age.” 
Interviewee #5 (declined to participate in STOP-CKD RCT) 
 
“I don’t think there is any reason why you shouldn’t do.  I think the thing is every age 
group is going with various studies type thing is going to show up anomalies in line 
with various things. I mean some people say only 20/30 or 40’s type of thing, they are 
probably able to more absorb medication whereas a lot of older people may not be, 
so it could affect them on that basis, so I can’t see why anybody shouldn’t be, you 
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know, should be exempt from a study. To get a cross-section of people, you need to 
get a cross-section of ages.” Interviewee #14 (STOP-CKD RCT participant) 
 
“I can’t see why age should be a barrier really. Otherwise you would be saying 
people above a certain age, there is no point in monitoring people like that because 
they haven’t got long to go or whatever really. I think the condition is universal to age 
really and the treatment you are thinking of are going to be beneficial to all ages, I 
don’t see why it has to be age discriminating.” Interviewee #8 (STOP-CKD RCT 
participant) 
 
One of the interviewees also felt that elderly population might be more willing and 
prepared to help in research, as they might not be as restricted by work or time 
constraints when compared to younger patients.  
 
“I think that is a good idea for elderly people to take part in research, definitely. I 
think the younger generation, they don’t realise. They are so full of what is going on 
in their lives and young mothers becoming pregnant and all that, so the older 
generation, yes, I think they could do quite a bit actually.” Interviewee #11 (declined 
to participate in STOP-CKD RCT) 
 
Likewise, one of the interviewees felt passionately that elderly patients should be 
listened to and believed that their knowledge was valuable for others with similar 
conditions.  
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“I think they should. Absolutely, because I work with the elderly and just because 
they’re elderly, why shouldn’t they have a voice?  As I say, my lady goes, and she’s 
75 I think she is, and she goes and she’s an elderly lady. I mean, we nurse her in bed 
but for 2 hours once every 2 weeks I think it is, she goes, sits and chats to people, 
much, much younger than her, and she gets a lot out of it, so you know, a lot of these 
elderly people, just because they’re frail in body, they’ve got a good mind, do you 
know what I mean.  I think yeah, they should be involved.  And if they’ve had to live 
with it for a long, long time, they’re the best people to ask aren’t they, do you know 
what I mean, they’ve been there before us and they will have a lot of knowledge and 
stuff that I think….. And sometimes they’ll give us coping mechanisms that we 
probably haven’t even thought of.” Interviewee #4 (attended STOP-CKD RCT 
screening) 
 
From a more clinical standpoint, another interviewee felt that by including patients 
from all ages, it might allow certain epidemiological patterns to emerge and help to 
guide further research planning.  
 
“I would have thought it needs to be left open ended really because as you are doing 
your research, you will get a pattern of where the highest proportion of difficulty is, 
won’t you?  So if you say, you may say well after 85, you have got to die of something, 
I am being slightly frivolous, I am serious really, but you know if it throws up that 
kind of pattern, that it’s not really worth doing a great deal say for people from 90 
because they are not going to live very long anyway and you have got to die from 
something but I would think keep it open ended.  I wouldn’t want to say a cut off 
either end really.” Interviewee #17 (declined to participate in STOP-CKD RCT) 
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However, some of the interviewees were less certain and had a more practical 
approach on such matters. They believed that participation of different age groups 
should be decided by the medical professionals, perhaps based on the clinical 
appropriateness of individual research topics. Additionally, an interviewee also 
believed that such a cut-off might be unimportant as all patients would make their 
decisions regarding research participations based on their personal views.  
 
“The cut-off has got to be from the medical profession knowing is it any use to use 
somebody over the age of 75 or something whatever figure you do. We are growing 
older. I think... I mean, I don’t know medically about anything so what I am just 
saying is off the top of my head.” Interviewee #10 (attended STOP-CKD RCT 
screening) 
 
“You’re the doctors, not me. I mean, I wouldn’t know whether…..   I have no idea.  I 
mean surely it is for the benefit of the public, so whatever age you want you deal with. 
I don’t know. I mean I don’t think it matters. If people don’t want to do it, they 
won’t.” Interviewee #12 (declined to participate in STOP-CKD RCT) 
 
 Discussion 7.4
Patients’ willingness to participate in research studies is likely to be influenced not 
only by design of studies but also by their attitude towards research. While several 
factors and various barriers for research participation have already been extensively 
examined by both quantitative and qualitative studies to date (466, 473, 475-478), the 
set-up of the STOP-CKD RCT and the target population were unique. Therefore, its 
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failure to recruit deserved a thorough and more individualised analysis. The principal 
findings emerging from this qualitative study identified the motivators and barriers to 
research participation pertinent to the STOP-CKD RCT and highlighted several 
crucial issues specific to the recruiting of patients with CKD in primary care. 
Additionally, it also gathered suggestions for future research improvement and 
importantly, valuable opinions with regard to inviting the elderly population to 
participate in clinical trials.  
 
Though prior research experience was common amongst the interviewees and the 
majority considered their past experience to be positive, most of the experience was 
limited to participation in observational studies. A survey study of 386 African 
Americans found that those who had previously participated in clinical trials had 
more positive views towards research compared to those without (485). Other 
quantitative surveys also demonstrated that people with prior research experience 
were potentially more willing to participate in future research (486, 487). 
Nevertheless, this interview study appeared to suggest otherwise. Many of those who 
declined to participate in the STOP-CKD RCT had in fact been participants in 
observational research studies. Hence, it seemed that factors other than the general 
positive attitudes towards research were far more influential in governing patients’ 
decisions on their participation in interventional studies. In addition, the issue with the 
research team’s delay in communicating incidental findings to patients’ GPs noted 
within this theme also represented an important learning point for future studies.  
 
In general, altruism (469, 478, 488-491) and self-interest (469, 489-494) are often 
cited to be central in determining their willingness to participate in any research 
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studies. Indeed, within the context of the STOP-CKD RCT, both were found to be the 
recurring factors stated by most of the interviewees during the interview. Their 
altruistic notion appeared to be based on the belief that research studies would 
advance medical knowledge in CKD, improve treatments, ‘find a cure’ and ultimately 
‘benefit others’. Conversely, their self-interest was governed by whether they 
perceived their participation would achieve personal gain by enhancing their 
knowledge of CKD, having additional health monitoring, improving their health 
status or resulting in personal loss as the consequences of trial medications’ side 
effects and the additional demands of the trials on their daily lives. Intriguingly, apart 
from one of the interviewees who expressed her ‘duty of altruism’ as the sole reason, 
others often described these two factors collectively as the reasons for research 
participation. As altruism is supposed to be a selfless notion, one might therefore 
question the ‘pureness’ of such altruism cited by the interviewees. Overall, how 
significant was the role of self-interest, in relation to altruism, in driving such research 
participation? This question is perhaps best assessed in those who declined to 
participate in the STOP-CKD RCT.  
 
Most of those who declined to participate in the STOP-CKD RCT acknowledged the 
importance of CKD research for the public interest. However, despite such 
understanding, their perceived personal loss or the failure to perceive any potential 
personal gain ultimately hindered their participation. This implied that safeguarding 
one’s personal interest is most probably the single decisive factor in this process. It 
also supported the notion that altruism cited as the reason for research participation is 
‘conditional’, requiring not only the absence of personal loss, but also the presence of 
perceived personal gain. This finding of the magnitude of the effect of self-interest on 
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research participation is in agreement with the previously published studies (471, 
493). In a literature review of the ethics of RCTs, Edwards et al noted that self-
interest was expressed more frequently than altruism as the reason for participating in 
trials, irrespective of whether the studies were based on concrete or hypothetical 
scenarios (493). Additionally, a qualitative interview study of patient decisions about 
recruitment to an epilepsy treatment trial also found that participants often applied 
‘weak altruism’ while maintaining their self-interest  (469). Similarly, McCann et al 
used ‘conditional altruism’ to describe the fact that though altruistic tendencies 
encouraged trial participation, it was on the condition that there were perceived 
personal benefits and the absence of overriding concerns in a qualitative study of 
people invited to participate in an RCT comparing medical and surgical interventions 
for gastro-oesophageal reflux disease (468). Hunter et al went one step further and 
concluded that the opportunity to benefit directly was the primary, if not, the only 
motive of research participation (495).  
 
Such motive of personal gain warrants exploration. Given clinical equipoise being the 
fundamental principal of any RCT and that there are in fact genuine clinical 
uncertainties related to the trial intervention, why did some interviewees perceive 
potential significant personal gain from their research participation? Was there any 
‘therapeutic misconception’ (469, 496)? Reassuringly, apart from one interviewee 
(interviewee #6) who might have slightly over-played the benefits of the trial 
intervention, most did not appear to have therapeutic misconceptions with regards to 
the trial intervention of the STOP-CKD RCT. In fact, an overwhelming majority 
agreed to take part in the STOP-CKD RCT in order to improve their personal 
knowledge regarding the condition or to receive additional medical attention and 
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monitoring. It is conceivable that being a silent and less known condition with 
considerably low illness awareness meant that these putative, non-specific trial effects 
become highly-valued benefits. Additionally, as patients have been shown to perceive 
CKD as a severe condition (detailed in Chapter 6), the opportunity to improve their 
understanding of such illness by taking part in research might, therefore, represent a 
significant appeal to their self-interest.  
 
Of particular importance, such perceived gain also appeared to be heavily influenced 
by the perceived relevance of CKD to their health. Recently, Frew et al developed the 
Clinical Research Involvement Scales and demonstrated that the instrument was 
reliable for assessing community attitudes towards clinical trials participation (497). 
Factors included in the scales consist of behavioural belief, outcome evaluation, 
normative belief, motivation to comply, attitudes, subjective norms, organization 
involvement and personal relevance. Amongst which, ‘personal relevance’ was noted 
to have the strongest reliance (497). Indeed, Canvin et al underlined the fact that ‘in 
agreeing to participate in a clinical trial, patients should first accept the clinical 
definitions of disease and the need for treatment, then be willing to entertain the 
possibility of clinical equipoise about which treatment to offer, and the need for 
evidence to resolve it…’ (469). The health belief model, which was initially 
developed to understand the ‘widespread failure of people to accept disease 
prevention or screening tests for the early detection of asymptomatic disease’, (498) 
also appeared to be applicable to the understanding of patients’ decision-making in 
CKD research participation. In the context of early to moderate CKD, where belief in 
the diagnosis is often hindered by low illness awareness as well as the lack of physical 
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symptoms, the health belief model of CKD interestingly appears to be more akin to 
that of the preventative health behaviour than the sick role behaviour.  
 
The striking disparity amongst the interviewees in their acceptance or rejection of a 
diagnostic label of an asymptomatic long-term condition, and therefore resulting in 
either the acknowledgment of or disagreement with the diagnostic significance and 
requirement of intervention was an interesting finding of this study. Whilst 
unawareness of a diagnosis of CKD motivated some of the interviewees to participate 
in the STOP-CKD RCT in order to glean further information to fill in their knowledge 
gap regarding their health, for many others, it represented a barrier as they 
unequivocally rejected the diagnosis and failed to see the relevance of the study or the 
benefit of being involved. A previous quantitative study reported ‘feeling healthy’ 
together with ‘no interest’ and presence of ‘current medical treatment’ as the main 
reasons for non-participation in a lifestyle interventional study in a group of men with 
high CV risk (499). Likewise, a qualitative interview study found that the lack of 
perceived need was one of the most cited reasons for not participating in a telephone 
care management program (480). It seemed that as many of this CKD population ‘feel 
well’, some of the interviewees did not only question the diagnosis of CKD, but also 
the need for intervention. The issues of low illness awareness and asymptomatic 
nature pertinent to early-stage CKD therefore affected not only their perception of 
susceptibility, but also influenced the perceived severity or consequences of CKD. In 
addition, such rejection of the diagnosis of CKD was also likely to be closely linked 
with their misconception of the disease terminology, often dominated by fear, as 
highlighted in Chapter 6. These issues therefore represent crucial barriers pertinent to 
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the recruitment of early CKD patients into interventional research studies especially 
in primary care setting.  
 
A survey in Germany found that even though almost 90% of the public judged 
clinical trials as important, only a quarter were willing to take part in the trials (486). 
Evidently, despite a generally positive attitude towards research, there are multiple 
barriers to research recruitment and such issues have been extensively investigated in 
various populations (478, 494, 500, 501). A systematic review by Ross et al 
summarised from the patients’ perspective reported that the additional trials 
procedures and appointments, travel problems and costs, preferences for no treatment 
or a particular treatment, concerns about information and consent as well as the 
uncertainty associated with the treatment or trials were the main participation barriers 
in RCTs (478). Indeed, this interview study reaffirmed those findings as the impact of 
trials on patients’ daily lives, the increased medication burden and the invasiveness of 
trial procedures were identified as some of the common barriers for participation. 
However, ‘fear or uncertainty’ was the consistent, recurring factor highlighted by the 
majority of the interviewees as the main barrier to research participation. This is in 
agreement with the finding of a survey of 100 cancer outpatients whereby awareness, 
fear and myths about clinical trials participation were noted to be the key issues (502). 
According to the data which emerged from this interview study, this notion of ‘fear’ 
appeared to be driven predominantly by their sense of uncertainty with regards to 
various aspects of trials, including but not limited to the possibilities of incidental 
findings during the screening process, treatment assignment, treatment effects, end-
of-trial arrangement and the perception of being the subject of an experiment. While 
some of these fears might be alleviated by the provision of further information or 
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judicious reassurance by the researchers, it seemed that the fear was also governed by 
the individual’s ability to accept such uncertainty which was unavoidably the nature 
of most RCTs. Indeed, a previous qualitative study demonstrated that while the 
concept of clinical equipoise was understood by the majority of the patients, those 
who found it acceptable were more likely to consent to the randomisation process and 
vice versa (503).  
 
While John Harris argued that everyone should have a positive moral obligation to not 
only pursue research, but also participate in it as a mandatory contribution to the 
public good (504), it was clear that some of the interviewees did not agree with his 
notion. In the face of uncertainty, many often prioritised their personal interest over 
the potential public good. Some of the willing participants of the STOP-CKD RCT 
suggested that there might be a ‘letting somebody else do it’ mentality amongst those 
who declined to participate, akin to the so-called ‘free riding’ behaviour. As 
safeguarding of self-interest was the predominant factor, it was plausible that as the 
risks and uncertainty associated with interventional studies were perceived to be high, 
some logically chose not to participate in the study in order to minimize their 
individual ‘costs’ relative to the potential benefits they might receive from others’ 
collective effort. Interestingly, based on economics models, Sandler et al published 
their mathematical deductions concluding that there was greater tendency for ‘free 
riding’ behaviour with increased uncertainty (505).  
 
With regards to the impact of study characteristics on willingness to participate, a 
Swiss quantitative survey study found that destruction of blood samples at the end of 
a trial, use of placebo controls and a randomisation process were associated with 
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reduced likelihood of participation whilst new drugs without side effects, no 
additional visits and provision of balanced information encouraged participation 
(506). Neither the source of funding or financial reward influenced the decision in the 
same survey (506). During this interview study, it appeared that participants’ trust in 
researchers was central to their acceptance of the trial intervention. The rejection of 
one of the interviewees to be involved in the interventional study might not only 
reflect her aversion towards taking additional medication, but also hint at her slight 
mistrust of the research team in contrast to her faith in her GP. With regard to the trial 
setting, the majority preferred the convenience of a primary care setting compared to 
travelling to secondary care location. Although it appeared that most of the 
interviewees did not seem to mind the duration or frequency of research visits, this 
might be biased by the fact that many of them were retirees. In contrast to the findings 
of a survey by Agoritsas et al (506), there seemed to be diverse views on research 
funding sources amongst the interviewees in this study. Some interviewees expressed 
no bias against or preference for research from different funding sources with the 
understanding that there is limited research budget from non-industry sources. 
Nevertheless, many others were either hesitant towards, or completely opposed, 
research funded by pharmaceutical companies as they were concerned about the 
conflict of interest. With the CV trials funded by for-profit organisations found to be 
more likely to favour newer treatments compared to their counterparts (507), it is 
perhaps justifiable for the interviewees to have such wariness towards industry-
sponsored research. Djulbegovic et al concluded that such bias was attributed to their 
violations of the principle of equipoise in regards to the study design and results 
reporting (508). However, with 92% of the new chemical entities approved by the US 
Food and Drug Administration (FDA) in the 80’s having been developed by 
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pharmaceutical companies (509), it is perhaps unreasonable to disregard industrial-
sponsored research as a whole. Furthermore, as the pharmaceutical industry’s annual 
worldwide budget for drug development exceeds $6 billion (510), the solution to such 
bias and issues related to industry sponsored research might not be as simple as 
demanding that governments increase healthcare research budgets.  
 
In addition to detailing the key factors influencing research participation amongst 
patients with early to moderate CKD, this study also reported on their views on 
inclusion of the elderly in clinical trials. It is a well-known fact that GFR declines 
with advancing age (511). Nevertheless, the reasons for such decline as a normal 
physiological process or a pathological condition remain a heavily debated topic (511, 
512). The proposal by one of the general practices to exclude elderly patients from the 
STOP-CKD RCT invitation during the set-up of the study indicated not only a certain 
scepticism about the definition of CKD in the elderly population amongst some of the 
GPs, but also implied that there are preconception based on patients’ age regarding 
their fitness and willingness to take part in research. Data regarding the influence of 
age on willingness to research participation has been conflicting in the literature to 
date (486, 487, 494, 513). A systematic review found that in general, elderly patients 
did not regard age as the main reason for declining to take part (514). In fact, a survey 
of elderly oncology patients demonstrated that most were willing to consider research 
participation but few were informed of the availability of the clinical trials indicating 
that the barrier to the research recruitment of elderly patients might be physician or 
research-related (515). The findings from this interview study were in agreement with 
those of Townsley’s (515). The majority of the interviewees believed that the elderly 
patients should be invited to participate in research on the grounds that they deserved 
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a voice and importantly, warranted a sufficient representation in the research 
population. In the context of CKD whereby the elderly comprise a substantial 
proportion of the population, it is clearly all the more important to ensure that the 
findings of CKD research are generalisable and applicable to this subgroup of 
patients. Though selection bias cannot be excluded, none of the interviewees objected 
to the inclusion of elderly patients in clinical trials. While some thought that such 
issues should be the decision of healthcare professionals, many were enthusiastic and 
passionate about elderly population being included and felt that this group of patients 
were probably more willing to engage in research studies. 
 
Several suggestions were also made regarding the STOP-CKD RCT trial process, 
which may serve as learning points for further studies. Wording of the invitation 
letter, sequence of screening procedures, discomfort during blood pressure 
measurement, and the quantity of blood taken were some of the concerns mentioned. 
Furthermore, a few of the interviewees also suggested a more personal recruitment 
approach, advertising the research, incorporating enrolled participants’ comments in 
future research invitation letters or extending recruitment hours to aid the recruitment 
rate. Further research in identifying the effectiveness of such recruitment methods in 
CKD research is clearly warranted.  
 
7.4.1 Limitations 
This interview study has several limitations. As only the latest recorded eGFRs was 
used to short-list eligible patients for the STOP-CKD research invitation, it is 
plausible that not all interviewees have a confirmed diagnosis of CKD. In addition, 
there was a preponderance of patients with older age and white ethnicity. As the 
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majority of the patients were above the age of 65 years and not in work or had retired, 
this might influence their views regarding research participation especially in regards 
to study duration and frequency of visits. As advancing age is known to be associated 
with increasing disease prevalence and medication use (516), their views on 
participation in clinical trials involving pharmacological intervention could also 
potentially vary from those of the younger age. Furthermore, due to the absence of 
non-whites, the study was unable to explore the issue of potential ethnic differences in 
the perception of both CKD diagnosis and research participation. Although significant 
efforts were put into maximizing the representativeness of interviewees, this study 
was still limited by patients’ self-selection that could lead to bias in the findings. It is 
possible that patients who were willing to taking part in this interview study, despite 
having declined to participate in the STOP-CKD RCT, had dissimilar views on CKD 
or research participation compared with those who declined participation in both the 
RCT and the interview study. In addition, while the interviewer aimed to maintain a 
neutral attitude during the interview study, her role as a nephrology registrar in a 
tertiary hospital as well as an active clinical researcher who was involved in the 
recruitment of both the STOP-CKD RCT and the interview study might have resulted 
in potential biases. As the interview study focused mainly on CKD in primary care in 
the UK, the findings might therefore not be necessary applicable to other illnesses in 
different settings and in different countries.  
 
7.4.2 Conclusions 
Despite these limitations, this study has identified ‘perceived relevance of the 
research topic to personal health’ as a significant prerequisite for patients’ 
participation in CKD research in the primary care. Complementary to the findings of 
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Chapter 6, patients’ perception of the term CKD was found to be influential in 
governing patients’ decisions on research participation via their perception of 
susceptibility and severity of the said condition. Furthermore, this study also 
reaffirmed the importance of self-interest, in relation to altruism, as the primary 
motivator for research participation. Amongst all, improving personal knowledge of 
CKD through research participation appeared to be a highly valued benefit amongst 
this group of patients. While ‘cues to action’ often appear to be the foci of most 
recruitment strategies, it seems unlikely that such cues will result in research 
participation in the absence of ‘perceived susceptibility’, ‘perceived severity’ and 
‘personal gain’. Hence, further CKD research recruitment strategies should aim not 
only at ‘cues to action’, but also consider methods to overcome the much wider issues 
of low illness awareness and knowledge as well as misconception of the term CKD 
amongst the CKD population, all of which ultimately impact on patients’ participation 
in CKD research, especially in primary care. 
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CHAPTER 8 SUMMARY AND CONCLUSIONS 
 
Chronic kidney disease represents the 19
th
 leading cause of global loss of life (1). It is 
a growing and important public health issue, which affects up to 14% of the 
population of the developed world (2-5). While patients with CKD undoubtedly have 
heightened risk of progressing to ESRD, their competing risk of death was far greater 
(6). This significant increase in mortality amongst the CKD population appeared to be 
heavily driven by their excessive CV burden (41). 
 
However, this increased CV burden observed in patients with CKD is not fully 
explained by traditional CV risk factors as the Framingham risk score which is based 
upon age, gender, DM, systolic BP, smoking status and cholesterol profiles has been 
shown to significantly under-estimate CV events in patients with CKD at 5 and 10 
years (60). While patients with CKD are at high risk of developing vasculo-occlusive, 
atheromatous disease including myocardial infarction or peripheral vascular disease, 
they are also at much higher risk of developing non-vasculo-occlusive, arteriosclerotic 
disease leading to heart failure and arrhythmias. Increased arterial stiffness is believed 
to be the key, early mechanistic pathway leading to such CV abnormalities in the 
CKD population (58) which is evident even in the early stages (65, 66) despite 
satisfactory BP control (67). Nevertheless, the reasons for this increased arterial 
stiffness found in patients with CKD are poorly understood (58).  
 
Crucially, there is a significantly lack of RCT data (141) and an over-reliance on post-
hoc or subgroup analyses of studies in the general population (142) in guiding the 
management of this heightened CV risk in the CKD population. Indeed, a recent 
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authoritative and comprehensive systematic review struggled to find large, high 
quality RCTs from which to make strong recommendations on screening, monitoring 
and treatment of early stage CKD (166). Additionally, while majority of the CKD 
studies were conducted in the secondary care settings, patients with stage 3 CKD in 
the U.K. are in fact mostly managed in the primary care setting (395, 396) and are 
often older with less well-defined renal phenotypes than the patients included in the 
hospital-based study. 
 
The works presented in this thesis therefore attempt to address some of the issues 
highlighted above. 
 
1. Could treatment with xanthine oxidase inhibitor be an intervention to be tested in a 
future feasibility RCT aims at lowering arterial stiffness in CKD? (Chapter 2) 
 
Hyperuricaemia is highly prevalent among CKD population (194). Asymptomatic 
hyperuricaemia is associated with increased CV and all-cause mortality in both the 
general population (183-188) and in patients with CKD (194-196, 303-305). To date, 
a small number of studies exploring the use of the xanthine oxidase inhibitors (i.e.: 
allopurinol and febuxostat) in patients with CKD have demonstrated encouraging 
results in improving inflammatory markers, endothelial function, LVH, reduced 
hospitalisations, and lowering risk of CV events (198-201).  
 
 Using the data from a prospective, observational cohort study of CKD patients at 
high risk of renal disease progression, the study found an independent association 
between the use of allopurinol and lower arterial stiffness. Interestingly, there was no 
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direct association between serum uric acid levels and arterial stiffness, suggesting that 
the beneficial effect of allopurinol on arterial stiffness is likely to be attributable to its 
anti-oxidant property rather than its uric acid lowering effect. Although the study was 
limited by its observational nature and therefore does not prove causation, the finding 
nevertheless adds to the accumulating evidence of the favourable effect of allopurinol 
on CV outcomes (200, 213, 517) and indicates one mechanism by which this may 
occur. It also provides further justification for a definitive RCT to fully examine the 
therapeutic potential of xanthine oxidase inhibitor in CKD. Perhaps most importantly, 
this study provides vital information to inform any future RCT by giving some idea of 
the potential effect size expected and thus the number of patients required to 
adequately power a study with arterial stiffness as the outcome measure. 
 
Future Directions 
Although there is an accumulating body of evidence indicating the beneficial effects 
of xanthine oxidase inhibitors on various CV surrogate markers, CV risk and CKD 
progression by small published studies (198-201), a large, multi-centre, randomised, 
hard-end points study would be required before allopurinol is recommended as a CV 
risk reducing intervention in patients with CKD. Allopurinol hypersensitivity 
syndrome is an infrequent but life-threatening adverse effect of allopurinol (518). 
Studies examining the safety of allopurinol use amongst patients with CKD have so 
far reported inconsistent findings (519). It is therefore crucial for further research to 
establish the safe, dosing profile of xanthine oxidase inhibitors for patients with 
different stages of CKD, especially if the indication for such therapy were to be 
broadened beyond the treatment of gout in the future. As such, preliminary feasibility 
and safety studies are currently being planned (520). 
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2. Is there enough evidence to justify the routine use of MRAs to lower CV risk 
associated with CKD? (Chapter 3) 
 
To date, the renal and CV benefits of treatment with ACEi or ARB have been 
demonstrated in multiple large trials (347). They represent the principal therapeutic 
interventions for improving hypertension, proteinuria and CV risk in patients with 
CKD (228-230). However, despite initial reduction, plasma aldosterone levels have 
been found to return to pre-treatment levels in subgroups of patients after prolonged 
exposure to ACEi or ARB, a phenomenon termed ‘aldosterone breakthrough’ (234). 
Aldosterone is implicated in numerous deleterious CV effects (218-221, 227) and the 
use of MRAs which inhibit the action of aldosterone have been reported to attenuate 
some of those consequences (217) leading some commentators to label MRAs such as 
spironolactone as “renal aspirin” (349). 
 
Given the potential theoretical benefits of aldosterone blockade on CV outcomes in 
CKD as well as the potential harm of hyperkalaemia and deterioration in renal 
function, a systematic review and meta-analysis was conducted to examine the CV 
effects of MRAs in patients with CKD. Overall, MRAs were found to effectively 
reduce both the SBP and DBP in patients with CKD, even amongst those who were 
already receiving ACEi and/or ARB. Nevertheless, these beneficial BP-lowering 
effects were counterbalanced by an associated increase of serum potassium and risk 
of hyperkalaemia. The meta-analysis did not demonstrate any significant change in 
serum creatinine or GFR with the use of MRAs. Although a few short-term studies 
reported beneficial effects of aldosterone blockade on several CV surrogate markers, 
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due to the limited quality and quantity of the evidence thus far, it remains unclear if 
MRAs improve long-term CV outcomes in addition to their BP-lowering effect (249, 
357, 375, 376, 379). Encouragingly a recent open-label study of 309 haemodialysis 
patients reported statistically significant reduction in CV morbidity and mortality at 
three years in patients receiving daily spironolactone of 25mg (391). Though the 
findings of this systematic review and meta-analysis do not support the routine use of 
MRAs to lower CV risk in patients with CKD, it does provide further evidence to 
support further RCTs in CKD to establish the risk and benefits associated with such 
an intervention in patients with different stages of CKD. 
 
3. Does low-dose spironolactone safely lower arterial stiffness in patients with CKD 
stage 3 managed in primary care? What is the feasibility of conducting a large and 
appropriately powered future trial examining hard end-points in primary care? 
(Chapter 4 methodology, Chapter 5 results) 
 
In a previous double-blind, placebo-controlled RCT, low-dose spironolactone safely 
lowered arterial stiffness in patients with CKD stage 3 managed in secondary care 
(140). However, most patients with CKD are in fact managed in primary care (395, 
396). Additionally, they are often older and are less likely to be proteinuric than 
patients included in hospital-based studies, factors that could theoretically be 
associated with less benefit and more harm from MRA treatment. Furthermore, 
monitoring of potassium and renal function may be significantly more difficult from 
primary care. Thus, it is not known whether low-dose spironolactone can be used 
safely to lower arterial stiffness in patients with stage 3 CKD managed in primary 
care or whether a future, larger trial examining hard-outcomes would indeed be 
 239 
 
feasible. Hence, the STOP-CKD trial was designed as a pilot study to examine 
whether low dose spironolactone safely lowers arterial stiffness in patients with CKD 
stage 3 managed in primary care. It was also designed to examine potential barriers to 
recruiting a large and appropriately powered future trial examining hard end-points. 
 
Despite attempting to invite and screen for research participants who were 
representative of the ‘real-life’ CKD population in primary care, the STOP-CKD pilot 
RCT was terminated early due to poor recruitment. Although the study failed to 
provide scientific evidence regarding the effectiveness or the safety of the use 
spironolactone on patients with stage 3 CKD in the primary care, several observations 
made from this study are nonetheless valuable in informing and facilitating future 
CKD studies: (1) the distinct characteristics of patients with stage 3 CKD recruited in 
primary care in comparison to those in the secondary care and (2) the barriers and 
recruitment issues pertinent in conducting RCT in CKD population in primary care 
setting.  
 
In contrast to previous CKD studies, patients who were invited, screened and 
eventually randomised for the STOP-CKD RCT were older, with a mean age of 71 
years. This was in keeping with the epidemiological finding of the NEOERICA study 
whereby 50% of patients with stage 3a and more than 80% of those with stage 3b 
CKD were older than 70 years (37). Additionally, the degree of CKD among this 
cohort of patients was also found to be modest with most having no or only a mild 
degree of albuminuria, an unclear cause of CKD and a surprisingly large proportion 
having low SBP which precluded a signification number of patients from participating 
in the STOP-CKD RCT. These unique characteristics of patients recruited to this 
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study are clinically important and challenge our preconceived knowledge on the 
appropriate intervention and management of the non-diabetic CKD population in 
primary care. With the majority of interventional studies in CKD patients thus far 
conducted from secondary and tertiary centres, there is undoubtedly a need to 
reconsider the study design and choices of intervention for future CKD studies in 
order to optimise the generalisability of future CKD research, especially in the early 
stages. 
 
In the course of the STOP-CKD study, numerous barriers pertinent to the recruitment 
of the non-diabetic, stage 3 CKD population in primary care arose and resulted in the 
early termination of the study. The study highlighted the over-estimation of CKD 
prevalence in the literature, the difficulties faced in enrolling general practices as 
recruiting sites as well as the inefficiency of large mailshots as patient recruitment 
strategies for an interventional CKD study, all of which in return necessitated 
significant inflation of the number of the patients needed to be invited in order to 
recruit to the planned sample size. Although research-active practices appeared to 
have a positive influence on patients’ reply to research invitation, it did not appear to 
translate to actual research recruitment. The experience and lessons learnt from this 
study clearly provide important information for all CKD researchers, especially those 
in the UK, to meticulously reflect on their future research aims, study design, choices 
of intervention and most importantly recruiting strategies.  
 
Future Directions 
Overall, the results of the systematic review detailed in Chapter 3 highlighted the 
need for high-quality, definitive research trials in evaluating the CV role of MRAs in 
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CKD. Nevertheless, the STOP-CKD study was terminated early to due to poor 
recruitment. The information gleaned from this study should help inform and assist 
other trials planned in this population to succeed. The finding of the STOP-CKD 
study that patients with CKD in the primary care are older, have more modest 
reduction of eGFR and less prevalence of albuminuria, in comparison to their 
counterparts in the secondary care setting, is in agreement with the previous study 
(521). However, research evidence with regard to the appropriate management of the 
CKD population in the primary care remains scarce. Additionally, the current clinical 
practice often derives from the research outcomes of those from the secondary care 
despite the distinct disparity between the groups. With a recent systematic review 
showing that intensive BP control reduces the risk of renal progression, but only 
amongst those with proteinuria (147), there is clearly a need for further research to 
better characterise the long-term outcomes as well as define the risk modifiers, 
specific to the CKD population managed in the primary care. Such research data will 
be invaluable not only in guiding the day-to-day management, setting the clinical 
guidelines as well as audit standards, but also directing future research questions and 
interventions.  
 
Furthermore, hyperkalaemia is a well-established adverse effect associated with the 
use of MRAs. In particular for the CKD population already receiving ACEi or ARB, 
issues with hyperkalaemia may potentially affect the risk:benefit ratio of MRA 
therapy and limit its clinical applicability. Two new oral agents, Patiromer (522) and 
Zirconium Cyclosilicate (523), have so far shown promising short-term outcomes in 
the treatment of moderate hyperkalaemia, including patients with CKD. Nonetheless, 
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their durability, side effect profiles and potential to permit wider, long-term usage of 
MRA will required further investigations. 
 
Effective and efficient recruitment strategies are indispensable for the success of any 
research study. The STOP-CKD study demonstrated that large mailshot of 
interventional research invitation to CKD population is not a cost-effective method of 
recruitment and is often liable to patients’ self-selection bias. There is clearly room 
for innovative recruitment strategies which require further exploration.  
 
A large prospective, randomised, open blinded end-point trial (BARACK D study) 
aiming to determine the effect of MRA on mortality and CV outcomes in patients 
with stage 3b CKD in primary care is currently ongoing (524). Encompassing stage 
3b CKD population with a minimal SBP of 100 mmHg, and including those with 
Type 2 DM; the participants’ criteria of BARACK D study varies somewhat from that 
of the STOP-CKD. To date, it has recruited 16% of its target sample of 2,910 
participants, however, the recruitment is significantly falling behind schedule and 
rescue proposals have recently been submitted to its funding body (personal 
communication, supervisor). Its findings, assuming the trial successfully recruits, are 
eagerly anticipated.  
 
4. What are patients’ illness perceptions of early or moderate CKD in primary care 
and what are the barriers to patients’ participation in CKD research study? (Chapter 
6 & 7) 
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Although there is an increasing number of a quantitative research study exploring the 
effects of various pharmacological interventions in improving CKD outcomes, issues 
regarding patients’ illness experience and disease perceptions on CKD, especially in 
the early or moderate stage remain under-researched. In addition, despite the potential 
of clinical research to advance medical treatments, poor recruitment, as faced by the 
STOP-CKD RCT, is regrettably a chronic and ubiquitous issue. Understanding 
patients’ illness perception of CKD and exploring their attitudes towards research 
participation are therefore two imperative steps in formulating strategies to enhance 
delivery of healthcare in CKD and improve future CKD research recruitment. 
Characterised by its ability to produce rich, comprehensive and in-depth data, 
qualitative research is therefore an ideal method to address such complex or 
unquantifiable social and healthcare research questions (404).  
 
In agreement with the literature (438, 440, 441), the qualitative interview study 
embedded within the STOP-CKD trial found that the majority were often unaware of 
their CKD diagnosis. Furthermore, the study also reported issues with uncertainty of 
illness identity and negative misconceptions of the term CKD amongst the 
interviewed patients. It highlighted the importance of the disclosure of CKD diagnosis 
by healthcare professionals in order to address patients’ illness perceptions, avoid 
misconception and minimise unnecessary stress amongst the patients.  
 
With regard to CKD research participation, the qualitative study reaffirmed the 
importance of self-interest, in relation to altruism, as the primary motivator. 
Importantly, ‘perceived relevance of the research topic to personal health’ was 
identified as a crucial prerequisite for patients’ participation in CKD research in the 
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primary care. Such perception was found to be closely governed by patients’ 
awareness of CKD diagnosis as well as their views on the term CKD. Further CKD 
research recruitment strategies should therefore consider methods to overcome the 
much wider issues of low illness awareness, uncertainty of illness identity and 
misconception of the illness terminology amongst the CKD population, all of which 
represent major barriers to CKD research recruitment in primary care.  
 
Future Directions  
The findings from the qualitative study suggest that there is a need to improve public 
awareness and knowledge of CKD, encourage healthcare professionals in disclosing 
the CKD diagnosis and ensure shared decision making. Illness identity and CKD 
terminology represent two of the key areas which warrant attentive clarification by 
the healthcare providers during CKD diagnosis disclosure to the patients in the future.  
 
As low awareness of CKD diagnosis amongst the patients appears to be one of the 
key reasons for poor recruitment, future research into the other barriers to disclosure 
of CKD diagnosis by the healthcare professionals will be useful to mitigating the 
issue. Importantly, improving our understanding of patients’ experience of such 
disclosure and the impact on their self-management of health as well as willingness to 
research participation should also be the focus of future CKD research in the primary 
care.  
 
While the chronic issue of poor recruitment and uncertainty of generalisability 
continue to challenge the running of most clinical trials, the future perhaps lies in 
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expanding patients’ involvement not only in their healthcare, but also their 
engagement in research world.  
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APPENDICES 
Appendix 3-1: Data collection form for systematic review and meta-analysis of CV 
effects of mineralocorticoid receptor blockers in patients with chronic kidney disease. 
 
First author/study title: _________________________________________________ 
 
 
 
Method 
 
Country  
Setting (i.e.: multicentre)  
Time Frame  
Randomisation method  
 
 
Blinding Participants: 
Investigators: 
Outcome assessors: 
Data assessors: 
Intention-to-treat: Yes / No 
Duration of follow-up  
Lost to follow-up Treatment group: 
Control group: 
Participants 
 
Inclusion criteria  
 
 
 
Exclusion criteria 
 
 
 
 
 
Treatment group Age:  
Male :           Female: 
Others: 
Control/comparator group Age:  
Male :           Female: 
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Others: 
 
Interventions 
Treatment group  
Control/comparator  group  
Duration of intervention  
Co-interventions  
 
 Treatment group Control group 
Total randomised   
Excluded*   
Observed   
Lost to f/u*   
Reasons for loss/exclusion: 
 
 
Outcomes 
Outcomes Methods of measurement/ Definitions 
  
  
  
  
  
  
  
Notes 
Request for further information: 
Clarification of methods: 
Clarification of results: 
Funding source: 
Others: 
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Appendix 3-2: Risk of Bias Assessment Form 
 
First author/study title: __________________________________________________ 
Study design 
 
Parallel/crossover 
Was the allocation sequence adequately 
generated? 
Yes / No / Unclear 
Comments: 
 
 
Was allocation adequately concealed? Yes / No / Unclear 
Comments: 
 
Was knowledge of the allocated interventions 
adequately prevented during the study? 
Participants: Yes/ No/ Unclear 
 
Investigator: Yes / No / Unclear 
 
Outcomes assessors: Yes / No / Unclear 
 
Data assessors : Yes / No / Unclear 
 
 
Outcomes assessment and measurement 
 
 
 
 
 
 
 
Intention-to-treat analysis 
 
 
 
 
 
 
 
 
 
 250 
 
Appendix 3-3: Risk of bias assessment of all included studies 
      
Study Allocation 
sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of 
outcome 
Incomplete 
outcome data 
Selective reporting  Other bias 
Rossing et al, 2005 (372) Low Unclear Low Unclear Low Low Low 
Schjoedt et al, 2005 (374) Low  Unclear Low Unclear Low Low Low 
Bianchi et al, 2006 (355) Low Unclear High High Low Unclear Low 
Chrysostomou et al, 2006(358) Low Unclear Low Unclear Low Low Low 
Epstein et al, 2006 (359) Unclear Unclear Low Unclear Unclear Unclear Unclear  
Matsumoto et al, 2006 (366) Unclear Unclear High Unclear Unclear Low Unclear 
Meiracker, et al, 2006 (368) Unclear Low Unclear Unclear Unclear Low Unclear 
Takebayashi et al, 2006 (377) Unclear Unclear Unclear Unclear Low Unclear Unclear 
Joffe et al, 2007 (364) Unclear Unclear Low Unclear Unclear Unclear Unclear 
Furumatsu et al, 2008  (361) Unclear Unclear High High Low Low Unclear 
Saklayen et al, 2008 (373) Unclear Unclear Low Low Low Unclear  Unclear 
Tylicki et al, 2008 (378) Low Unclear High High Low Low Low 
Edwards et al, 2009, 2010, 2012 
(140, 248, 249) 
Unclear Unclear Low Unclear Low Low Low 
Guney et al, 2009 (362) Unclear Unclear Unclear Unclear Unclear Low Unclear 
Mehdi et al, 2009 (367) Low Unclear Low Unclear High Low Low 
Morales et al, 2009 (369) Unclear Low Unclear Unclear Low Low Unclear 
Taheri et al, 2009 (375) Unclear Low Low Unclear Unclear Unclear Unclear 
Vukusich et al, 2010 (379) Unclear Low Unclear Low Low Low Unclear 
Abolghasmi et al, 2011 (354) Unclear Unclear Unclear Unclear Low Low Unclear 
Boesby et al, 2011 (356) Unclear Low High High Low Unclear Unclear 
Zheng et al, 2011 (380) Unclear Unclear Unclear  Unclear Low Unclear Unclear 
Nielsen et al, 2012 (370) Low Low Low Unclear Unclear Unclear Unclear 
Taheri et al, 2012 (376) Unclear Unclear Unclear Unclear Low Unclear Unclear 
Boesby et al, 2013 (357) Unclear High High High Low Low Unclear 
Esteghamati et al, 2013 (360) Unclear High High Unclear Low Low Unclear 
Hase et al, 2013 (363) Unclear High High Unclear High Unclear Unclear 
Lizakowski et al, 2013 (365) Unclear Low Low Unclear Unclear Unclear Unclear 
Nielsen et al, 2013 (371) Unclear Low Low Unclear Unclear Unclear Unclear 
Ziaee et al, 2013 (381) Unclear High High  Unclear High  High High 
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Appendix 4-1: STOP-CKD working instruction for general practice electronic records 
search 
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Appendix 4-2: STOP-CKD Patient research invitation letter 
[GP Name, Address and Contact Number] 
 
[Date as postmark] 
 
 
 
 
 
Dear [Title and surname] 
 
Invitation to Participate in Research Study: 
STOP-CKD: Spironolactone to Prevent Cardiovascular Events in Early Stage Chronic Kidney 
Disease: A Pilot Trial 
 
We are working with the Primary Care Clinical Research and Trials Unit at the University of 
Birmingham on a study that aims to look into the possible benefits of the use of a ‘water-
tablet’, called Spironolactone in patients with early stage chronic kidney disease. We are 
writing to people from the practice to ask for their help and you have been selected as you 
have had a blood test in the past indicating you may have a lowered kidney function.  
 
We would be very grateful if you would read the attached information sheet about the study 
and think about whether you would like to take part.  Please indicate on the response slip 
whether or not you are interested in participating in the main study and/or the interview 
study.  A FREEPOST envelope is enclosed for you to return your response directly to the 
research team at the University. 
 
If you have any questions about the study then you can contact the research team directly 
on  
0800 923 0329. 
 
Thank you for your time. 
Yours sincerely, 
 
[Signature] 
 
[Name] 
[Practice Lead GP] 
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Appendix 4-3: STOP-CKD Patient Information Sheet 
 
STOP-CKD 
 
 
  
Spironolactone to Prevent Cardiovascular Events in                                   
Early Stage Chronic Kidney Disease: A Pilot Trial Version 2.2 20/06/2013 
 
Patient Information Sheet 
We would like to invite you to take part in a research study.  Before you decide, we would 
like you to understand why the research is being done and what it would involve for you.  
Please take time to read the following information carefully.  Talk to others about the study 
if you wish.  Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part. 
 
Part 1  
What is the purpose of the study? 
About 1 in 10 people have mild chronic kidney disease (CKD) most commonly because 
kidney function declines with age. Patients with kidney disease are at increased risk of 
hardening of the blood vessels, which can lead to heart disease and stroke. We are 
investigating a medication called Spironolactone which has been used to treat patients with 
high blood pressure, heart disease or liver disease for a long time. In patients with mild 
kidney disease in our specialist hospital kidney clinic, Spironolactone seems to improve 
heart function and reduces hardening of the blood vessels. We want to find out if 
Spironolactone has similar effects on patients with early kidney disease treated in the 
community.  
 
Do I have to take part? 
It is up to you to decide if you wish to join the study.  If you agree to take part, we will then 
ask you to sign a consent form.  You are free to withdraw at any time, without giving a 
reason.  Your medical care will be unaffected whether or not you take part. 
 
Why have I been invited? 
You have been invited to take part in this research study because you have had a previous 
blood test at at your GP surgery that shows you may potentially have reduced kidney 
function.  
 
Who else is taking part? 
We are inviting people like you, from different GP surgeries in Birmingham to take part. We 
need to identify a total of 240 patients with early kidney disease to participate in this 
research study. 
 
What will happen to me if I take part? 
Participation in this study is voluntary.  If you decide that you would like to take part in this 
study, you will be asked to attend a clinic at your own GP surgery run by the research team. 
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A member of the team will explain the study to you and answer any questions you might 
have. They will ask you some questions about your general health and any medication you 
may be taking. You will then be asked to sign a consent form. You should only do this if you 
are happy that you understand the project and want to take part. A urine sample and 30ml 
blood sample (less than 3 tablespoons) will be taken to confirm if you have reduced kidney 
function by a kidney specialist and if you are eligible to take part in this study.  
 
If you are eligible, you will then be contacted by the research team and invited back to 
another clinic, also at your surgery. A member of the team will discuss the study with you 
again and check that there have been no changes to your health or medication. We will 
check your blood pressure, measure your weight, height, waist, hip and thigh circumference 
and measure the stiffness of your blood vessels. You will be asked to complete a 
questionnaire. A computer will then decide at random (like tossing a coin) which type of 
treatment you will have. Half of the people taking part will be prescribed the medication and 
the other half will be prescribed a placebo capsule (A placebo capsule looks similar to the 
active medication but contains no active drug). You will be prescribed the medication the 
computer chooses for you using a prescription that can be collected from one of our 
designated pharmacies. This medication needs to be taken daily for 10 months.  
 
Over the course of the study, you will be seen by the research team at regular intervals (2, 4, 
8, 16, 28 weeks) at your own surgery. They will again take your blood pressure measurements, 
repeat blood samples tests and completion of a Quality of Life questionnaire. At 40 weeks, we will 
repeat the measurement of your blood vessels’ stiffness and collect blood and urine 
samples. You will be informed to stop the trial medication after the 40 week visit. At the end 
of the study (6 weeks after the trial medication is stopped), we will asked you to attend a 
final clinic to have a repeat blood and urine test, as well as repeat measurement of blood 
vessels’ stiffness. So in total, you will be seen at your surgery 8 times. 
 
What will I have to do? 
You will need to take the study medicine regularly during the course of the study (40 weeks) 
and attend all the study visits.  We will ask you to report any missed tablets during the study 
period. You should also continue taking all of your normal tablets.  We will review your 
medication before you start the study to make sure the study medication does not interfere 
with your usual tablets.   
 
We will ask you to tell us if your GP starts you on any new medicines during the study. If 
your Potassium level is found to be high on the blood test during the study period, we might 
ask you to restrict certain foods in your diet to avoid foods high in potassium and provide 
you with an information sheet.  
 
What happens at the end of the research study? 
Once you have completed all of your tests at the final visit, the trial medication 
(Spironolactone or placebo) will be stopped. The results will be studied and analysed.  Your 
usual medical care will continue as before once the study is completed.  All specimens 
collected during the study will be stored for 5 years after the completion of this study. If you 
would like to know the results we will send you a summary. 
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Will I get paid for taking part? 
We are unable to pay you for participating but we will reimburse your travel expenses to 
and from your GP surgery or Queen Elizabeth Hospital Birmingham. 
 
What are the alternatives for treatment? 
There are currently no other medicines licensed for reducing stiffness of the blood vessels in 
patients with early kidney disease. 
 
 
What are the possible risks of taking part? 
With the exception of the blood tests, study procedures should not cause any pain or 
discomfort. There are small risks of increased levels of salts in the blood, reduced kidney 
function or low blood pressure with the use of Spironolactone, requiring the withdrawal of 
the medication. However, the dose of the trial medication is relatively low and you will be 
closely monitored by kidney specialists during the study to ensure that those risks are 
minimised. 
 
Spironolactone should be avoided during pregnancy. If you are a woman of child-bearing 
age, we would ask you for permission to perform a pregnancy test prior to starting the trial 
medication and to agree not to become pregnant whilst taking it. If you do become pregnant 
during the course of the study, you must stop taking the trial medication immediately and 
inform our research team so an appropriate course of action can be taken. 
What are the other side effects of the treatment received when taking part? 
The most common side effects from Spironolactone are diarrhoea, drowsiness, headache, 
nausea, stomach cramping and vomiting. Such effects are usually mild and temporary and 
resolve when the drug is stopped.   
 
Other less common but serious side effects are severe allergic reactions (rash, hives, itching, 
difficulty breathing, tightness in the chest, swelling of the mouth, face, lips, or tongue), 
black, tarry, or bloody stools, change in the amount of urine produced, confusion, dark 
urine, decreased sexual ability, enlarged breasts in men, irregular or missed menstrual 
periods, severe or persistent stomach pain, symptoms of abnormal fluid or electrolyte levels 
(i.e.: fast, slow, or irregular heartbeat, increased thirst, muscle weakness, severe or 
persistent dry mouth, nausea, or vomiting, severe or persistent dizziness or drowsiness, 
unusual fatigue or sluggishness, tingling sensation), yellowing of the skin or eyes. 
 
If you were to experience these serious side effects, you should stop taking the trial 
medication immediately and contact our research team on 0800 9230329. 
What are the benefits of taking part? 
Our previous research study showed that Spironolactone improves heart function and 
reduces hardening of the blood vessels in patients with mild kidney disease in our specialist 
hospital kidney clinic. However, we are unable to guarantee any direct benefit to you as a 
result of taking part in this study. Nonetheless, you will contribute to an improved 
understanding of Spironolactone and its effects on blood vessel and kidney disease.  The 
 264 
 
information gained from this study will also contribute to further studies and may help 
improve the treatment of people with kidney disease in the future. 
 
What if there is a problem? 
Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. The detailed information on this is given in Part 2.  
 
Will my taking part in the study be kept confidential?  
Yes. We will follow ethical and legal practice and all information about you will be handled in 
confidence. The details are included in Part 2.  
 
What will happen if I don’t take part? 
Participation is entirely voluntary.  If you decide not to take part then you will continue to be 
seen as before in outpatient clinics.  A decision not to take part will not affect your routine 
care in any way. 
 
If the information in Part 1 has interested you and you are considering participation, 
please read the additional information in Part 2 before making any decision. 
 
 
Part 2 
 
What if relevant new information becomes available?  
Sometimes we get new information about the treatment being studied.  If this new 
information means that we should stop the study, or change how we are running it, we will 
do this and make sure that you are offered the best treatment.  
 
What will happen if I do not want to carry on with the study? 
You are free to withdraw from the study at any time and this will not affect your care. You 
can either withdraw completely or choose to keep in contact with us to let us know your 
progress. Information collected earlier in the study may still be used. 
 
What if there is a problem? 
If you have concerns about any aspect of this study, you should ask to speak to the research 
coordinator who will do her best to answer your questions (contact numbers below).   
 
If you remain unhappy and wish to complain formally, you can do this through the NHS 
Patient Advisory and Liaison Service (PALS) (Tel: 0800 389 8391; Email: pals@sbpct.nhs.uk). 
In the unlikely event that something does go wrong and you are harmed during the research 
and this is due to someone’s negligence then you may have grounds for compensation 
against the University of Birmingham but you may have to pay your legal costs.  The normal 
National Health Service complaints mechanisms will still be available to you. 
 
Will my taking part in the study be confidential? 
Yes.  We will follow ethical and legal practice and all information about you will be handled 
in confidence.  The study information will only be seen by the research team and will be 
stored in accordance with the Data Protection Act at the University of Birmingham. The 
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study data may also be looked at by representatives of regulatory authorities and by 
authorized people to check that the study is being carried out correctly. All those associated 
with the study will have a duty of confidentiality to you as a research participant. 
 
Will my GP be told that I am in a study? 
Yes, we will inform your GP of your involvement in the study.  
 
What will happen to any samples I give? 
During study visits, extra blood and urine samples will be taken from you. These will be 
labelled with your study number. These samples will be anonymised and kept in a locked 
secure room within the University of Birmingham. Access will be restricted to the study 
researchers only. At the end of the study, these extra samples will be kept for 5 years and 
might be used for other future ethically approved studies.  
 
Will any genetic tests be done? 
No genetic tests will be performed. 
 
What will happen to the results of the research study? 
The results of the research will be published in international, peer-reviewed scientific 
journals.  The results will also be available on the website www.clinicaltrials.gov.  You will 
not be identifiable in any report or publication. 
 
Who is organising and funding the research? 
The study is organised by the Primary Care Clinical Research and Trials Unit (PC-CRTU) at 
the University of Birmingham and is funded by the National Institute for Health Research.   
 
Who has reviewed the study? 
Before deciding whether to fund the study, the National Institute for Health Research asked 
the opinion of independent expert. This study has also been reviewed and approved by 
West Midlands Research Ethics Committee. 
 
What if I have more questions or do not understand something? 
We will be pleased to answer any questions you may have or clarify things you do not 
understand.  You can contact the STOP-CKD team on Tel: 0800 9230329 
If you wish to discuss the study with a doctor who is not directly involved with the study you 
may contact Dr Lukas Foggensteiner on Tel: 0121 371 5841. 
 
What happens now if I decide to take part? 
If you decide that you would like to participate in this study, we ask you to complete the 
attached form with your details and send it back to us in the envelope provided. You may 
also contact us by telephone or e-mail to inform us of your decision to participate.  The 
STOP-CKD research team will then contact you to arrange a convenient day to attend your 
GP surgery. 
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Please return to: 
STOP-CKD Research Team, 
Primary Care Clinical Research and Trial Unit,  
University of Birmingham 
Edgbaston 
Birmingham 
B15 2TT 
 
Dear Dr Ferro  
 
Name:  ……………………………………………………………… Tel: ………………………………………..……… 
Address: ……………………………………………………………… Mobile: .......................................... 
  ……………………………………………………………… 
……………………………………………………………… Postcode: ....................................... 
  
Signature: ……………………………………………………………… Date:        __ __/__ __/__ __ __ __ 
         
 
Please tick if applicable: 
□ I am interested in participating in this study.  I would be happy for a member of the study 
team to contact me to arrange a date to attend. 
 
□ I do NOT wish to be involved in this study. 
If you have decided not to take part in this study, it would be very useful if you could tell us your 
reasons to help us to improve other research studies in the future. We would be grateful if you could 
complete the following voluntary questionnaire and return it in the enclosed prepaid envelope: 
 
I am:  Male  Female   My date of birth is: __ __/__ __/__ __ __ __  
 
I do not wish to take part in this study for the following reason(s): Tick as many as applicable 
□ I do not have time to take part in the study 
□ I do not wish to take a new medication 
□ I do not wish to have further blood tests 
□ I do not wish to be part of a research trial 
□ Kidney problems are of no concern to me 
□ I am unable to attend the surgery 
□ I do not want to give a reason 
□ Other (Please specify): ………………………………… 
 
Please tick if applicable: 
□  I am interested to take part in an INTERVIEW study to discuss my reasons further 
We are carrying out a separate interview study to find out people’s view of research study in kidney disease 
in the community. If you are interested, we will send out further information on the INTERVIEW study to you.  
 
□  I am NOT interested to take part in an INTERVIEW study to discuss my reasons further 
 
If you wish to give further information, please do so below: 
………………………………………………………………………………………………………………………………………………………………
………………………………………………………………………………………………………………………………………………………………
……………… 
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Appendix 4-4: STOP-CKD Part 1 Consent Form 
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Appendix 4-5: STOP-CKD Part 2 Consent Form 
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Appendix 4-6: STOP-CKD medication monitoring questionnaire 
 
Side Effect Yes No 
Nausea   
Vomiting   
Abdominal Discomfort   
Diarrhoea   
Black Discoloured Stool   
Tiredness   
Headache   
Confusion   
Drowsiness   
Dizziness/ Imbalance   
Breast swellings   
Breast pain   
Menstrual (period) disturbance   
Change in libido   
Excessive hair growth   
Unwanted hair growth   
Hair loss   
Leg cramps   
Rash   
Joint pain   
Others: (Please comment)  
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Appendix 4-7: STOP-CKD study abnormal blood pressure working instruction 
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Appendix 4-8: STOP-CKD working instruction on the use of BpTRU blood pressure 
monitor 
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Appendix 4-9: STOP-CKD working instruction on the use of Vicorder system for the 
measurement of PWV and PWA 
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Appendix 4-10: STOP-CKD Trial Steering Committee 
 
 
Name Role 
 
Dr Charles Ferro Chief Investigator 
Consultant Nephrologist and Senior Lecturer, Queen Elizabeth Hospital 
Birmingham  
Dr Robert Cramb  
 
Co-investigator 
Consultant Chemical Pathologist, Director of Pathology Service,  
Queen Elizabeth Hospital Birmingham  
 
Prof Richard McManus  
 
Co-investigator 
Professor of Primary Care Cardiovascular Research , 
Department of Primary Care Health Sciences, University of Oxford  
 
Dr Paramjit Gill  
 
Co-investigator 
Reader in Primary Care Research ,  
Primary Care Clinical Sciences, University of Birmingham  
 
Prof John Townend Co-investigator 
Consultant Cardiologist and Senior Lecturer,  
Cardiology Department, Queen Elizabeth Hospital Birmingham  
 
Prof Nick Freemantle  
 
Co-investigator 
Professor of Clinical Epidemiology & Biostatistics,  
Primary Care Clinical Sciences, University College London  
 
Dr Poorva Jain  
 
Co-investigator 
Renal Medicine Research Fellow/Registrar in Nephrology,  
Primary Care Clinical Science, University of Birmingham  
 
Dr Khai Ping Ng  
 
Research Fellow 
Renal Medicine Registrar , Queen Elizabeth Hospital Birmingham 
 
Dr Odette Chagoury  
 
Senior Trials Manager  
Primary Care Clinical Sciences, University of Birmingham  
 
Mrs Gurdip Heer  Research Nurse  
Primary Care Clinical Sciences, University of Birmingham  
 
Mrs Val Redman Trial Coordinator  
Primary Care Clinical Sciences, University of Birmingham  
 
Mr Nick Flint Lay person 
 
Mr Paul Cornick Lay person 
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Appendix 4-11: STOP-CKD Data Monitoring Committee Charter 
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Appendix 6-1: Patient’s information sheet for the STOP-CKD interview study 
STOP-CKD 
Spironolactone to Prevent Cardiovascular Events in 
Early Stage Chronic Kidney Disease: A Pilot Trial Version 2 24/05/2013 
 
Interview study 
 
You are being invited to take part in an interview as part of a research study.  Before 
you decide if you are willing to be interviewed it is important for you to understand 
why the research is being done and what it will involve.  Please take time to read the 
following information carefully and discuss it with friends and relatives if you wish.  
Ask us if there is anything that is not clear or if you would like more information. 
 
What is the purpose of the interview study? 
This study will explore patients’ and general practitioners’ views on chronic kidney 
disease (reduced kidney function), research in chronic kidney disease in the 
community and the use of a ‘water tablet’, named spironolactone in patients with 
chronic kidney disease. 
 
This study will also explore how the barriers to participating in research and the use 
of spironolactone in patients with reduced kidney function can be addressed. 
 
Why have I been chosen? 
You have previously indicated your interest in taking part in the interview study. 
Our aim is to interview up to 30 patients and 30 general practitioners in this study 
who have previously decided to take part (or not to). 
 
What do I have to do? 
We will make an appointment for you at either your local GP practice/healthcare 
centre or your home.  The researcher will then ask you some questions on your 
views on chronic kidney disease, research in chronic kidney disease and how we can 
encourage more people to be involved with research studies. The interview will be 
tape recorded.  All information is kept confidential and individuals’ details are not 
given to any other person. The interviews should take no more than 60 minutes. Any 
travel costs you may incur will be reimbursed.   
 
Do I have to be interviewed? 
We will telephone you to invite you to take part in an interview.  It is up to you to 
decide whether or not to take part.  If you decide to take part we will ask you to sign a 
consent form.  If you decide to take part, you are still free to withdraw at any time and 
without giving a reason.  This will not affect the care you receive. 
 
What are the possible benefits of taking part? 
Research studies are important in providing useful information for improving 
healthcare. The information we get from this study may help us in improving our 
understanding of chronic kidney disease and identifying any potential barriers that 
may exist to the use of spironolactone. We hope these will facilitate the design of 
further larger-scale research studies in chronic kidney disease in the community in 
the future.   
 
  297 
  
Will my taking part in this study be kept confidential? 
Your name will not be on the tape and we will remove your name from the interview 
transcripts to keep your identity confidential.  Direct quotes may be used in 
publications but these will be numbered and anything which could identify you will be 
removed.  Nothing that you say will be fed back to the doctors and nurses involved in 
your care as coming from you. 
 
Data Protection Act 1998 
The information you give us in the interviews will only be used for the purposes of the 
study.  The information will be kept securely for a period of 5 years after the study 
ends and then will be destroyed. 
 
What happens now if I decide to take part? 
If you decide that you would like to participate in this study, we ask you to complete 
the attached form and send it back to us in the envelope provided. You may also 
contact us by telephone or e-mail to inform us of your decision to participate.   
Dr Khai Ping Ng, STOP-CKD Research Fellow, will then contact you to arrange a 
convenient day to be interviewed.  
 
Who is organising and funding the research? 
The National Institute of Health Research is funding the research project, which is 
being organised by the University of Birmingham.   
 
Who has reviewed the study? 
Both the National Institute of Health Research and the Research Ethics Committee 
have reviewed and approved the study. 
 
Contact for Further Information 
We hope that this leaflet answers some of the questions you may have. If you wish to 
enquire further about the study, please contact: 
 
Dr Khai Ping Ng (email: KXN262@bham.ac.uk) 
Freephone number: 0800 9230329 
STOP-CKD Research Fellow 
Primary Care Clinical Research and Trial Unit, University of Birmingham 
Edgbaston 
Birmingham 
B15 2TT 
 
If you are concerned about any aspect of the study and feel the need for independent 
advice you are recommended to approach your GP or other health professional. 
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Please return to: 
 
STOP-CKD 
Primary Care Clinical Sciences 
University of Birmingham 
Edgbaston 
Birmingham 
B15 2TT 
 
Dear Dr Ferro,  
 
 
Name:  ………………………………………………………………… 
 
Address: ………………………………………………………………… 
  ………………………………………………………………… 
  ………………………………………………………………… 
  ………………………………………………………………… 
  ………………………………………………………………… 
  ………………………………………………………………… 
 
Telephone Number: ………………………………………………………… 
 
   
 
 
 I am interested in participating in this INTERVIEW study.  I would be happy 
for a member of the study team to contact me to arrange a date to be 
interviewed. 
 
 I do not wish to be involved in this study. 
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Appendix 6-2: Consent form for the STOP-CKD interview study 
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Appendix 6-3: Topic guide for the STOP-CKD interview study 
 
Patients Interview Topic Prompts  
 
Interview Informed consent obtained?   
 
Opening 
 
My name is …………… I am a researcher from the University of Birmingham. Thank you 
very much for agreeing to take part in this interview study. I would like to ask you some 
questions on your views on kidney disease as well as research in kidney disease. The 
information we get from this interview study may help to improve our understanding in 
people living with kidney disease, which is important in helping us to improve the healthcare 
provided for people with kidney disease. This study will also help to improve the design of 
future research studies in kidney disease. The interview should take no longer than an hour. Is 
that ok with you?  
 
Everything you say will be confidential. We will make sure that you will not be identified 
from any comments taken from this interview. This interview will be tape recorded. During 
the interview, I will also be taking notes, this is for two reasons, firstly as a backup in case 
something goes wrong with the recorder and secondly to act as a prompt for me to follow up 
on things you may say. I hope you don’t find this too distracting. Do you have any question 
before we start? 
 
Understanding of Chronic Kidney Disease 
 Could you talk me through how your kidney condition was first diagnosed? 
 Has your GP discussed your kidney condition with you? 
 (If yes), what did your GP say? 
 (If no), what is your understanding of your kidney condition? 
 What do think are the location and functions of kidneys? 
 What do you think are the effects of reduced kidney function? 
 What do you think are the long-term effects/complications of reduced kidney 
function? 
 Is there anything you would like to know about your kidney condition but has not 
been explained to you? 
 Perception of CKD term 
 Family reaction to diagnosis 
 
 
Experience of Chronic Kidney Disease 
 Does your kidney condition affect your life?  
 (If yes,), how does your kidney condition affect your life? 
 When did you become aware of it? 
 How did you seek help? 
 What treatment have you received so far regarding your kidney condition? 
 What do you think about the treatment/care you have received regarding your kidney 
condition? 
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Research in Chronic Kidney Disease 
 Do you have any experience in taking part in medical research study? 
 (If yes), could you tell me more about the experience? 
 When you decided to/ not to take part in the main research study, what influenced 
your decision? 
 Do you have any views about medical research in patients with reduced kidney 
function? 
 (If yes), what are your views? 
 What do you think are the advantage(s) of taking part in medical research? 
 What do you think are the disadvantage(s) of taking part in medical research? 
 What do you think are the barriers of taking part in research study? 
 How do you think we can overcome the barriers? 
 If we were going to repeat this study in the future, what do you think we could 
change to encourage more people to take part? 
 Elderly population in research invitation 
 
Ending 
Thank you. I really appreciate the time you took for this interview. Is there anything else you 
would like to add or is there anything I have missed?  
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